2. Search Result
Search Result
Results for "

anti-tumor

" in MCE Product Catalog:

1512

Inhibitors & Agonists

5

Screening Libraries

3

Fluorescent Dye

2

Biochemical Assay Reagents

35

Peptides

28

Inhibitory Antibodies

309

Natural
Products

48

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas
  • HY-115948
    Antitumor agent-46

    		Others Cancer
    Antitumor agent-46 (Compound 2h) is an anti-tumor agent. Antitumor agent-46 demonstrates markedly higher antiproliferative activity on MCF-7 cells with an IC50 value of 2.08 µM.
  • HY-146416
    Antitumor photosensitizer-2

    		Others Cancer
    Antitumor photosensitizer-2 (Compound 11) is a potent photosensitizer. Antitumor photosensitizer-2 has outstanding photodynamic anti-tumor effects without obvious skin photo-toxicity, and can act as new drug candidates for photodynamic research.
  • HY-146414
    Antitumor photosensitizer-1

    		Others Cancer
    Antitumor photosensitizer-1 (Compound 8) is a potent photosensitizer. Antitumor photosensitizer-1 has outstanding photodynamic anti-tumor effects without obvious skin photo-toxicity, and can act as new drug candidates for photodynamic research.
  • HY-145908
    Antitumor agent-49

    		Others Cancer
    Antitumor agent-49 (Compound 10) is a Harmine derivative-furoxan hybrids containing NO donor, with antitumor activities. Antitumor agent-49 shows cytotoxic activity against HepG2 cells with an IC50 of 1.79 µM. Antitumor agent-49 produces high levels of NO in vitro.
  • HY-146743
    Antitumor agent-53

    		Apoptosis Cancer
    Antitumor agent-53 is a potent antitumor agent. Antitumor agent-53 induces cell cycle arrest at the G2/M phase. Antitumor agent-53 inhibits the PI3K/AKT pathway to induce the apoptosis of HGC-27 cells. Antitumor agent-53 has the potential for the research of gastrointestinal tumors.
  • HY-139735
    Antitumor agent-29

    		Others Cancer
    Antitumor agent-29 is a novel hepatocyte-targeting antitumor prodrug, which exhibits good antitumor activity and low toxic side effects.
  • HY-146046
    Antitumor agent-56

    		Apoptosis Cancer Inflammation/Immunology
    Antitumor agent-56 (Compound 33) is a triptolide derivative with antitumor, anti-inflammatory and NO release activities. Antitumor agent-56 significantly inhibits the growth of melanoma. Antitumor agent-56 is orally active.
  • HY-149019
    Antitumor agent-70

    		c-Kit Apoptosis Cancer
    Antitumor agent-70 (compound 8b) has anti-tumor activity and can induce cell apoptosis. Antitumor agent-70 inhibits multiple myeloma with an IC50 value of 0.12 μM. Antitumor agent-70 is a potential multi-targeted kinase inhibitor especially for c-Kit.
  • HY-139975
    Antitumor agent-31

    		Others Cancer
    Antitumor agent-31 is a nanosized chelates of anchoring bisazo dye. Antitumor agent-31 can be used for an antioxidant and antitumor agent.
  • HY-146250
    Antitumor agent-71

    		Microtubule/Tubulin Cancer
    Antitumor Agent-71 is an antiproliferative activity antitumor agent and against tumor cell lines with IC50 values ranging from 3.98-15.70 μM. Antitumor Agent-71 is an antitumor agent that can inhibit tubulin polymerization.
  • HY-151620
    Antitumor agent-80

    		Apoptosis Cancer
    Antitumor agent-80 (compound 11) is an orally active and potent antitumor agent. Antitumor agent-80 induces apoptosis in tumor cells.
  • HY-115995
    Antitumor agent-50

    		Others Cancer
    Antitumor agent-50 (compound 1a), a thiazolidinone, is a potent antitumor agent. Antitumor agent-50 has the potential for osteosarcoma (OS) research.
  • HY-146323
    Antitumor agent-58

    		Apoptosis Cancer
    Antitumor agent-58 (Compound C18) is an anti-tumor agent. Antitumor agent-58 effectively inhibits colony formation and cell migration of MGC-803 cells. Antitumor agent-58 induces apoptosis of MGC-803 cells through activation of the p38 and JNK signaling pathways. Antitumor agent-58 induces mitochondrial dysfunction of MGC-803 cells. Antitumor agent-58 effectively inhibits tumor growth of xenograft model bearing MGC-803 cells.
  • HY-151295
    Antitumor agent-75

    		Others Cancer
    Antitumor agent-75 is a novel potent antitumor agent. Antitumor agent-75 has cytotoxic effects on cancer and normal human cell lines. Antitumor agent-75 shows a highly selective cytotoxic effect against human lung adenocarcinoma (cell line A549) when combined with Antitumor agent-74 (HY-151292), the IC50 value of 2.8 μM. Antitumor agent-75 can be used for the research of cancer.
  • HY-144361
    Antitumor agent-44

    		Apoptosis Cancer
    Antitumor agent-44 (Compound 5n) disrupts the mitochondrial homeostasis, induces cell cycle arrest and apoptosis in human adenocarcinoma cells. Antitumor agent-44 (Compound 5n) possesses good anti-tumor activity in a lung-cancer-cell xenograft mice model.
  • HY-146038
    Antitumor agent-55

    		Apoptosis ROS Kinase MDM-2/p53 Bcl-2 Family Cancer
    Antitumor agent-55 (compound 5q) is a potent antitumor agent. Antitumor agent-55 effectively inhibits PC3, with an IC50 of 0.91 μM. Antitumor agent-55 effectively inhibits the colony formation, suppresses the cell migration in PC3. Antitumor agent-55 induces G1/S phase arrest and apoptosis in PC3.
  • HY-145438
    Antitumor agent-38

    		Others Cancer
    Antitumor agent-38 is a potent antitumor agents. Antitumor agent-38 shows antiproliferative activity for cancer cells. Antitumor agent-38 induces cell cycle arrest at the late S and G2/M phase without interfering with microtubule formation or cell morphology[1].
  • HY-146409
    Antitumor agent-59

    		Apoptosis Cancer
    Antitumor agent-59 (Compound 13b) is a potent antitumor agent. Antitumor agent-59 effectively inhibits the proliferation and migration of HCT116 cells. Antitumor agent-59 induces HCT116 cell apoptosis and arrests the cell cycle at the G2/M phase.
  • HY-146093
    Antitumor agent-62

    		Apoptosis Cancer
    Antitumor agent-62 (Compound 47) is a NO-releasing antitumor agent. Antitumor agent-62 shows antiproliferative activity against four cancer cell lines. Antitumor agent-62 activates mitochondrial apoptosis pathway and arrests cell cycle at G2/M phase.
  • HY-146114
    Antitumor agent-67

    		Others Cancer
    Antitumor agent-67 (compound 3) is a potent antitumor agent. Antitumor agent-67 has highly selective toxicity to cancer cells and lower damage to normal cells. Antitumor agent-67 can be activated by NQO1 and effectively liberate podophyllotoxin and kill tumor cells. Antitumor agent-67 significantly suppresses cancer growth in HepG2 xenograft models without obvious toxicity.
  • HY-146432
    Antitumor agent-60

    		Apoptosis Raf Ras ROS Kinase MDM-2/p53
    Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to CRAF with a Kd value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model.
  • HY-151618
    Antitumor agent-79

    		Apoptosis Cancer
    Antitumor agent-79 shows good antiproliferative activities against hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM. Antitumor agent-79 induces cancer cells apoptosis and shows in vivo antitumor effects. Antitumor agent-79 can be used for the research of cancer.
  • HY-146048
    Antitumor agent-57

    		Apoptosis Reactive Oxygen Species Cancer
    Antitumor agent-57 (Compound 3o) is an NQO1-directed antitumor agent. Antitumor agent-57 inhibits tumor cell growth, triggers ROS generation and induces cell apoptosis.
  • HY-15961
    Antitumor agent-3

    		Others Cancer
    Antitumor agent-3 is a potent compound which comprises a new imidazopyridine having excellent antitumor activity as an active ingredient.
  • HY-151286
    Antitumor agent-73

    		STAT Cancer
    Antitumor agent-73 is a Diosgenin (HY-N0177) derivative, which inhibits STAT3 signaling and activates Pdia3/ERp57 exogenously. Antitumor agent-73 shows potent anti-tumor activity against various cancer cell lines, 7.9-341.7-fold stronger than Diosgenin.
  • HY-151429
    Antitumor agent-77

    		Apoptosis Ferroptosis Bcl-2 Family COX Cancer
    Antitumor agent-77 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-77 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-77 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells.
  • HY-151428
    Antitumor agent-78

    		Ferroptosis Apoptosis Bcl-2 Family COX Cancer
    Antitumor agent-78 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-78 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-78 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells.
  • HY-144125
    Antitumor agent-41

    		Apoptosis Cancer
    Antitumor agent-41 (compound N-12), a potent antitumor agent, enhibits excellent antimigration and anti-invasion activity. Antitumor agent-41 (compound N-12) induces tumor inhibition via tumor necrosis and inflammatory response.
  • HY-150696
    Antitumor agent-72

    		Apoptosis Caspase PARP Cancer
    Antitumor agent-72 (compound 6w) is a potent anticancer agent. Antitumor agent-72 has anticancer activity and induces apoptosis through activation of caspase-3 and cleavage of PARP. Antitumor agent-72 can be used for cancer research.
  • HY-147540
    Antitumor agent-66

    		Others Cancer
    Antitumor agent-66 (Compound 4) is an analogue/derivative of (-)-cleistenolide. Antitumor agent-66 has the potential for the research of cancer diseases.
  • HY-147539
    Antitumor agent-65

    		Others Cancer
    Antitumor agent-65 (Compound 5) is an analogue/derivative of (-)-cleistenolide. Antitumor agent-65 has the potential for the research of cancer diseases.
  • HY-147538
    Antitumor agent-64

    		Apoptosis Cancer
    Antitumor agent-64 (Compound 8d) is a diosgenin derivative. Antitumor agent-64 exhibits potent cytotoxic activity against A549 cell line. Antitumor agent-64 induces A549 cells apoptosis via the mitochondria-related pathway.
  • HY-115949
    Antitumor agent-47

    		Others Cancer
    Antitumor agent-47 (Compound 3e) is a silibinin derivative with an antitumor activity. Antitumor agent-47 shows cytotoxic activity against NCI-H1299 and HT29 cells with IC50 values of 8.07 µM and 6.27 µM, respectively.
  • HY-146094
    Antitumor agent-63

    		Topoisomerase Cancer
    Antitumor agent-63 (Compound 40), a 20 (S)-O-linked camptothecin (CPT) glycoconjugate, is an antitumor agent without toxicity towards normal cells. Antitumor agent-63 shows high stability and very weak direct topoisomerase I (Topo I) inhibition.
  • HY-128934
    Antitumor agent-2

    		Others Cancer Inflammation/Immunology
    Antitumor agent-2 is sourced from patent CN102250203, compound 6a-r, has antitumor action and anti-inflammatory action.
  • HY-144340
    Antitumor agent-43

    		DNA/RNA Synthesis Apoptosis Cancer
    Antitumor agent-43 (Compound 4B) is a potent antitumor agent, with an IC50of 0.5 µM for (T-24 cell). Antitumor agent-43 (Compound 4B) induces cell cycle arrest at G2/M phase.
  • HY-147521
    Antitumor photosensitizer-3

    		Others Cancer
    Antitumor photosensitizer-3 (Compound I) is a chlorin derivative. Antitumor photosensitizer-3 induces tumor cells apoptosis and necrosis under 650 nm laser irradiation. Antitumor photosensitizer-3 exhibits lower skin photo-toxicity than positive reference m-THPC in vivo.
  • HY-151292
    Antitumor agent-74

    		DNA/RNA Synthesis Cancer
    Antitumor agent-74 (compound 13da) is a quinoxalines derivative, an antitumor agent. Antitumor agent-74 exhibits more potent efficacy on tumor inhibition, mixed with regioisomer Antitumor agent-75 (HY-151295, compound 14 da) (mriBIQ 13da/14da). mriBIQ 13da/14da attests cell cycle at S phase, inhibits DNA synthesis, and induces mithochondrial apoptosis.
  • HY-146025
    Antitumor agent-F10

    		Others Cancer
    Antitumor agent-F10 (Compound F10) is a camptothecin derivative. Antitumor agent-F10 is an orally–bioavailable and potent antitumor agent. Antitumor agent-F10 displays lower acute toxicity than SN-38 does and the solubility of F10 reached 9.86 μg/mL.
  • HY-151404
    Antitumor agent-76

    		Apoptosis Cancer
    Antitumor agent-76 (Compound TP-P1) is an orally active, rapid-release and water-soluble Triptolide (HY-32735) prodrug with antitumor activity.
  • HY-146169
    Antitumor agent-68

    		Reactive Oxygen Species Microtubule/Tubulin Cancer
    Antitumor agent-68 is a potent tubulin inhibitor. Antitumor agent-68 shows potent anticancer activity with IC50s of 3.6 and 3.8 µM for HeLa and MCF-7 cells, respectively. Antitumor agent-68 exhibits good scavenging activity of ROS and DPPH radical in a dose-dependent manner.
  • HY-141478
    Antitumor agent-28

    		ATM/ATR Cancer
    Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity.
  • HY-115996
    Antitumor agent-51

    		Others Cancer
    Antitumor agent-51 possesses potent and selective inhibitory for osteosarcoma cell growth and migration with IC50 of 21.9 nM in MNNG/HOS cells. Antitumor agent-51 has a considerable bioavailability and a low toxicity.
  • HY-115950
    Antitumor agent-48

    		Others Cancer
    Antitumor agent-48 (Compound 4a) is a 2,3-dehydrosilybin derivative with an antitumor activity. Antitumor agent-48 shows cytotoxic activity against MCF-7, NCI-H1299, HepG2 and HT29 cells with IC50 values of 8.06 µM, 13.1 µM, 16.51 µM and 12.44 µM, respectively.
  • HY-146302
    Antitumor agent-54

    		Apoptosis Cancer
    Antitumor agent-54 (Compound C11) is a 14-3-3η protein inhibitor with a KD of 35 µM. Antitumor agent-54 shows inhibitory activities against several typical human liver cancer cell lines. Antitumor agent-54 induces cell apoptosis and G1-S cell cycle arrest with good metabolic stability.
  • HY-146080
    Antitumor agent-61

    		Apoptosis Cancer
    Antitumor agent-61 (Compound 9b), Irinotecan (Ir) derivative, is a potential antitumor agent. Antitumor agent-61 displays potent activity with IC50s of 0.92, 1.39, 1.75, 2.20, 3.05 and 3.23 μM against five human cancer cells SK-OV-3, SK-OV-3/CDDP, U2OS, MCF-7, A549 and MG-63, respectively. Antitumor agent-61 induces SK-OV-3 cells apoptosis through mitochondrion pathways.
  • HY-145289
    Antitumor agent-37

    		Apoptosis Cancer
    Antitumor agent-37 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-37 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-37 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-37 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues.
  • HY-145288
    Antitumor agent-36

    		Apoptosis Cancer
    Antitumor agent-36 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-36 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-36 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-36 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues.
  • HY-151799
    Antitumor agent-81

    		E1/E2/E3 Enzyme Cancer
    Antitumor agent-81 (compound 5a) is a low cytotoxic P62-RNF168 agonist that promotes the interaction of P62 with RNF168. Antitumor agent-81 induces a decrease in RNF168-mediated H2A ubiquitination and impairs homologous recombination-mediated DNA repair. Antitumor agent-81 also inhibits mice xenograft tumor growth in a dose-dependent manner.
  • HY-U00414
    Antitumor agent-4

    		Others Cancer
    Antitumor agent-4, a butenylphenyl phosphate derivative, is a drug for mammary cancer and anovulatory sterility.
  • HY-128776
    Antitumor agent-19

    		Others Cancer
    Antitumor agent-19 is an antitomor agent targeting tumor-associated macrophages (TAMs) to serve as an effective TAMs modulator. The EC50 values of Antitumor agent-19 in the RAW 264.7 cells and the BMDM cells are 17.18 μM and 18.87 μM, respectively.
  • HY-146187
    Antitumor agent-69

    		Histone Methyltransferase Cancer
    Antitumor agent-69 (compound 12) is a potent inhibitor of protein-protein interaction between DOT1L and MLL-AF9/MLL-ENL, with Kis of 9 nM and 109 nM for AF9 and ENL, respectively. Antitumor agent-69 exhibits anticancer cellular activitiy.
  • HY-144394
    Antitumor agent-45

    		Apoptosis c-Met/HGFR Cancer
    Antitumor agent-45 (Compound 21) could induce and stimulate A549 cells apoptosis in G0/G1 and G2/M phase. Antitumor agent-45 (Compound 21) inhibits c-Met expression to regulate the growth of tumor cells.
  • HY-107470
    Antitumor agent-21

    		Others Cancer Inflammation/Immunology
    Antitumor agent-21 is an aryl-quinolin derivative, with potential anticancer, anti-inflammatory, anti-proliferative, anti-hormonal effects and inhibition of vasculogenic mimicry .
  • HY-144331
    Antitumor agent-42

    		Microtubule/Tubulin Apoptosis Cancer
    Antitumor agent-42 (Compound 15h) is a bifunctional agent exhibiting both tubulin polymerized inhibition and NO-releasing activities, resulting in potent anti-angiogenesis, colony formation inhibition, cell cycle arrest and apoptosis induction effects.
  • HY-136342
    Antitumor agent-23

    		Others Cancer
    Antitumor agent-23 is a potent anti-cancer agent with GI50s of 38, 48, 5, 27, 80, and 28 nM for lymphoma cell line GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI, respectively. Antitumoral activity.
  • HY-13538
    Gemcitabine elaidate

    CP-4126; CO-101; Gemcitabine 5'-elaidate

    		 Nucleoside Antimetabolite/Analog Autophagy Apoptosis Cancer
    Gemcitabine elaidate (CP-4126) is lipophilic pro-drug of Gemcitabine. Gemcitabine elaidate is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate exhibits anti-tumor activity.
  • HY-13538A
    Gemcitabine elaidate hydrochloride

    CP-4126 hydrochloride; CO-101 hydrochloride; Gemcitabine 5'-elaidate hydrochloride

    		 Nucleoside Antimetabolite/Analog Autophagy Apoptosis Cancer
    Gemcitabine elaidate (CP-4126) hydrochloride is lipophilic pro-drug of Gemcitabine. Gemcitabine elaidate hydrochloride is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate hydrochloride exhibits anti-tumor activity.
  • HY-117260
    Coformycin

    		Adenosine Deaminase Bacterial Antibiotic Cancer Infection
    Coformycin, a nucleoside antibiotic, is a potent inhibitor of adenosine deaminase (ADA) from Streptomyces species. Coformycin possesses anti-tumor and anti-bacterial activity.
  • HY-N10602
    Caryatin

    		Others Cancer
    Caryatin is a natural product found in Rhododendron simiarum, and Aeonium decorum. Caryatin shows anti-tumor activity.
  • HY-N1128
    Trichorabdal A

    (-)-Trichorabdal A

    		 Others Cancer
    Trichorabdal A is a diterpenoid compound isolated from Rabdosia trichocarpa. Trichorabdal A has potent anti-tumor activity.
  • HY-N2596
    Isoscabertopin

    		Others Cancer Inflammation/Immunology
    Isoscabertopin is a sesquiterpene lactone isolated from Elephantopus scaber L and shows anti-tumor activities.
  • HY-16212
    FR901464

    		Others Cancer
    FR901464 is a potent spliceosome inhibitor with prominent anti-tumor and anti-cancer effects.
  • HY-137301
    Mycophenolic acid glucuronide

    		Others Cancer
    Mycophenolic acid glucuronide is a metabolite of the immunosuppressant mycophenolic acid (MPA). Mycophenolic acid glucuronide shows anti-tumor activity and can be used in adenocarcinoma research.
  • HY-N2542
    Tubeimoside III

    		Others Cancer Inflammation/Immunology
    Tubeimoside III, a triterpenoid saponin, shows anti-inflammatory, anti-tumor, anti-tumorigenic activities, and acute toxicity in vivo.
  • HY-144188
    PRMT5-IN-17

    		Histone Methyltransferase Cancer
    PRMT5-IN-17 (Compound 6) is a PRMT5 inhibitor with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification.
  • HY-144187
    PRMT5-IN-16

    		Histone Methyltransferase Cancer
    PRMT5-IN-16 (Compound 20) is a PRMT5 inhibitor with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification.
  • HY-111213
    PRMT5-IN-20

    		Histone Methyltransferase Cancer
    PRMT5-IN-20 is a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with anti-tumor activity.
  • HY-N10539
    Shishijimicin C

    		Others Cancer
    Shishijimicin C is a novel antitumor agent found from the Ascidian Didemnum proliferum. Shishijimicin C shows anti-tumor activity with highly potent cytotoxicities.
  • HY-136640
    BCL6-IN-4

    		Bcl-2 Family Cancer
    BCL6-IN-4 is a potent B-cell lymphoma 6 (BCL6) inhibitor with an IC50 of 97 nM. BCL6-IN-4 has anti-tumor activities.
  • HY-N8091
    Lehmannine

    		Bacterial Cancer Infection
    Lehmannine is a quinolizidine bioalkaloid isolated from S. alopecuroides L, has antibacterial, anti-inflammatory and anti-tumor activities.
  • HY-N8131
    Pangelin

    		Bacterial Cancer Infection
    Pangelin is a coumarin that can be found in Ducrosia anethifolia. Pangelin exhibits anti-mycobacterial and anti-tumor activities.
  • HY-13727A
    Pixantrone

    BBR 2778

    		 Topoisomerase Cancer
    Pixantrone (BBR 2778) dimaleate is a topoisomerase II inhibitor and DNA intercalator, with anti-tumor activity.
  • HY-114244
    USL311

    		CXCR Cancer Endocrinology
    USL311 is a potent and selective CXCR4 antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4.
  • HY-129407A
    AAF-CMK

    		Ser/Thr Protease Apoptosis Cancer
    AAF-CMK is a TPPII (tripeptidylpeptidase II) inhibitor, shows anti-tumor activity and induces apoptosis. AAF-CMK can be used in leukemia research.
  • HY-147316
    TP-5801

    		Others Cancer
    TP-5801 is an orally active TNK1 (non-receptor tyrosine kinase) inhibitor (IC50=1.40 nM), and shows anti-tumor activity.
  • HY-151590
    DKFZ-748

    		HDAC Cancer
    DKFZ-748 is a selective HDAC10 inhibitor (pIC50=7.66), and shows anti-tumor activity.
  • HY-A0128
    Buclizine

    		Histamine Receptor Cancer Inflammation/Immunology
    Buclizine is an orally active antihistamine antiallergic compound. Buclizine is a potent teratogen in the rat and shows anti-tumor activity.
  • HY-A0128A
    Buclizine dihydrochloride

    		Histamine Receptor Cancer Inflammation/Immunology
    Buclizine dihydrochloride is an orally active antihistamine antiallergic compound. Buclizine dihydrochloride is a potent teratogen in the rat and shows anti-tumor activity.
  • HY-N7225
    Yuanhuacine

    Gnidilatidin

    		 Others Cancer
    Yuanhuacine (Gnidilatidin), a daphnane diterpenoid from the flowers of Daphne genkwa with extensive anti-tumor activity. Yuanhuacine is a DNA-damaging agent with orally active.
  • HY-148067
    XMT-1519 conjugate-1

    		ADC Linker Cancer
    ΧΜΤ-1519 conjugate-1 (compound 31) is a linker for the HER-2 monoclonal antibody XMT-1519, which can be used to synthesize ADC and increase anti-tumor activity.
  • HY-13727
    Pixantrone free base

    BBR 2778 free base

    		 Topoisomerase Cancer
    Pixantrone (BBR 2778 (free base)), a mitoxantrone analog, is a topoisomerase II inhibitor and DNA intercalator, with anti-tumor activity.
  • HY-P1009
    Z-YVAD-FMK

    		Caspase Cancer
    Z-YVAD-FMK is a cell-permeable caspase-1 and -4 inhibitor with anti-inflammatory and anti-tumor activities.
  • HY-114535
    Jaceidin

    		EGFR Cancer
    Jaceidin is a promising lead molecule for potent VEGFR inhibitor with excellent membrane permeability and oral bioavailability. Jaceidin exhibits anti-tumor activities.
  • HY-14934
    Rosabulin

    STA 5312

    		 Microtubule/Tubulin Cancer
    Rosabulin (STA 5312) is a potent and orally active microtubule inhibitor that inhibits microtubule assembly. Rosabulin has broad-spectrum anti-tumor activity.
  • HY-N2104
    Daurinoline

    		Others Cancer
    Daurinoline is an alkaloid that can be isolated from the roots of Menispermum dauricum. Daurinoline may be a potential anti-tumor agent or chemosensitizer for chemo-resistant NSCLC research.
  • HY-N10537
    Shishijimicin A

    		Others Cancer
    Shishijimicin A is a novel antitumor agent found from the Ascidian Didemnum proliferum. Shishijimicin A shows anti-tumor activity with highly potent cytotoxicities.
  • HY-13727B
    Pixantrone hydrochloride

    BBR 2778 hydrochloride

    		 Topoisomerase Cancer
    Pixantrone (BBR 2778 (free base)) hydrochloride, a mitoxantrone analog, is a topoisomerase II inhibitor and DNA intercalator, with anti-tumor activity.
  • HY-P99057
    Varlilumab

    CDX-1127

    		 TNF Receptor Cancer
    Varlilumab (CDX-1127) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity.
  • HY-145598
    Sovleplenib

    HMPL-523

    		 Syk Cancer
    Sovleplenib (HMPL-523) is a highly potent, orally available and selective SYK inhibitor with an IC50 of 25 nM. Anti-tumor activity. Sovleplenib can be used for the research of immune thrombocytopenia (ITP).
  • HY-B0109
    Dorzolamide

    L671152; MK507

    		 Carbonic Anhydrase Cancer
    Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
  • HY-B0109A
    Dorzolamide hydrochloride

    L671152 hydrochloride; MK507 hydrochloride

    		 Carbonic Anhydrase Others
    Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
  • HY-151163
    GLS1 Inhibitor-5

    		Glutaminase Apoptosis Cancer
    GLS1 Inhibitor-5 (compound 24y) is an orally active selective glutaminase 1 (GLS1) inhibitor with an IC50 value of 68 nM. GLS1 Inhibitor-5 induces apoptosis and has anti-tumor activity.
  • HY-N1451
    Betulonic acid

    Betunolic acid; Liquidambaric acid; (+)-Betulonic acid

    		 Parasite HSV Cancer Infection Inflammation/Immunology
    Betulonic acid (Betunolic acid), a naturally occurring triterpene, is found in many plants. Betulonic acid has anti-tumor, anti-inflammatory, antiparasitic and anti-viral (HSV-1) activities.
  • HY-120149
    Inotodiol

    		Others Cancer
    Inotodiol (compound 3) is a lanostane-type triterpenoid compound isolated from the sclerotia of Inonotus obliquus. Inotodiol exhibits the potent anti-tumor promoting activity in the in vivo carcinogenesis test.
  • HY-P99039
    Oleclumab

    MEDI9447

    		 CD73 Cancer
    Oleclumab (MEDI9447) is a human IgG1λ anti-CD73 monoclonal antibody that inhibits CD73 function. Oleclumab has an anti-tumor activity.
  • HY-14153
    Tegaserod

    		5-HT Receptor Cancer Metabolic Disease
    Tegaserod is a serotonin receptor 4 agonist (HTR4) used in the treatment of irritable bowel syndrome (IBS). Anti-tumor activity.
  • HY-148228
    ROS kinases-IN-1

    		ROS Kinase Cancer
    ROS kinases-IN-1 (pag 98) is a ROS tyrosine kinase inhibitor with IC50 value of 1.22 μM. ROS kinases-IN-1 shows anti-tumor activity.
  • HY-147389
    Enpp-1-IN-14

    		Phosphodiesterase (PDE) Cancer
    ENPP1-IN-2 is a potent Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) inhibitor with an IC50 value of 32.38 nM for recombinant human ENPP-1. ENPP1-IN-2 has anti-tumor activity.
  • HY-18981
    Decursin

    (+)-Decursin

    		 PKC Apoptosis CXCR Cancer Inflammation/Immunology Neurological Disease
    Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities.
  • HY-77554
    Cephalomannine

    		Microtubule/Tubulin Cancer
    Cephalomannine is a Paclitaxel (HY-B0015) alkaloidal analog and isolated from most Cephalotaxus species. Cephalomannine is an orally active anti-tumor agent and can be used as a chemotherapy agent for cancer research.
  • HY-143250
    Tubulin inhibitor 12

    		Microtubule/Tubulin Cancer
    Tubulin inhibitor 12 (Hit 9) is a novel tubulin inhibitor (IC50=25.3 μM). Tubulin inhibitor 12 shows anti-tumor activity and anti-proliferative activity.
  • HY-P99040
    Onvatilimab

    JNJ-61610588

    		 PD-1/PD-L1 Cancer
    Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity.
  • HY-130628
    PAK4-IN-1

    		PAK Cancer
    PAK4-IN-1 (Compound 19) is a potent, selective, orally active PAK4 inhibitor with robust anti-tumor efficacy in vivo. PAK4-IN-1 is stable under both acidic and neutral conditions.
  • HY-101150
    DGN462

    		DNA Alkylator/Crosslinker ADC Cytotoxin Cancer
    DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs).
  • HY-16062
    ARQ 621

    		Kinesin Cancer
    ARQ 621 is an allosteric, potent and selective inhibitor of Eg5, a microtubule-based ATPase motor protein involved in cell division. Anti-tumor activity. ARQ 621 is a kinesin inhibitor.
  • HY-W013032A
    Oxamic acid sodium

    Sodium oxamate

    		 Lactate Dehydrogenase Apoptosis Cancer
    Oxamic acid (oxamate) sodium salt is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid sodium salt shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis.
  • HY-N7766
    Rubropunctatin

    		Apoptosis Cancer Inflammation/Immunology
    Rubropunctatin, an orange azaphilone pigment, is isolated from the extracts of Monascus pilosus-fermented rice (red-mold rice). Rubropunctatin has anti-inflammatory, immunosuppressive and antioxidative effects, and also exhibits anti-tumor activity.
  • HY-148203
    Mcl-1 inhibitor 9

    		Bcl-2 Family Cancer
    Mcl-1 inhibitor 9 (example 2) is a myeloid cell leukemia 1 (Mcl-1) inhibitor with IC50 value of 0.21889 nM. Mcl-1 inhibitor 9 shows anti-tumor activity.
  • HY-120697
    MSAB

    		Wnt β-catenin Cancer
    MSAB is a potent and selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB exhibits potent anti-tumor effects selectively on Wnt-dependent cancer cells.
  • HY-15031
    l-Naproxen

    (R)-Naproxen

    		 Others Cancer
    l-Naproxen ((R)-Naproxen) is an enantiomer of (S)-Naproxen. l-Naproxen can inhibit Cdc42 and Rac1 (EC50=96 μM and 212 μM, respectively), and show anti-tumor activity. l-Naproxen is a nonsteroidal antiinflammatory drug (NSAID).
  • HY-123055
    Adenosine dialdehyde

    		Nucleoside Antimetabolite/Analog Cancer
    Adenosine dialdehyde, a purine nucleoside analogue, is a potent inhibitor of S-Adenosylhomocysteine hydrolase (SAHH) (Ki=3.3 nM). Adenosine Dialdehyde exhibits potent anti-tumor activity in vivo and can be used for the cancer research.
  • HY-151434
    GLS1 Inhibitor-6

    		Glutaminase Apoptosis Cancer
    GLS1 Inhibitor-6 (Compound 24y) is an orally active, potent and selective glutaminase 1 (GLS1) inhibitor (IC50=68 nM), shows 220-fold selectivity for GLS2. GLS1 Inhibitor-6 shows good anti-tumor activity, antitumor cell proliferation activity and induces apoptosis.
  • HY-P3586
    HKPao

    Hunter-killer peptide ao

    		 Apoptosis Cancer
    HKPao (Hunter-killer peptide ao) is a biologically active peptide. HKPao (Hunter-killer peptide ao) has anti-obesity and anti-tumor pro-apoptotic activity to cause release of cytochrome c from vesicles.
  • HY-N6722
    Swainsonine

    Tridolgosir

    		 Apoptosis Antibiotic Cancer Infection
    Swainsonine (Tridolgosir) is an natural indolizidine alkaloid, a potent and reversible α-mannosidase inhibitor. Swainsonine induces apoptosis and cell cycle arrest at G2/M phase. Swainsonine shows anti-tumor activity.
  • HY-108986
    JFD00244

    		Sirtuin SARS-CoV Cancer
    JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2.
  • HY-13566
    Belotecan

    CKD-602 free base

    		 Topoisomerase Apoptosis Cancer
    Belotecan (CKD-602 free base) is a DNA topoisomerase I inhibitor. Belotecan induces cell apoptosis and cell-cycle arrest. Belotecan is a camptothecin analogue with anti-tumor effects, it can be used for the research of cancer.
  • HY-125286A
    AB-680 ammonium

    		CD73 Cancer
    AB-680 ammonium is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.
  • HY-109176
    Giredestrant

    GDC-9545

    		 Estrogen Receptor/ERR Cancer
    Giredestrant (GDC-9545), a non-steroidal estrogen receptor (ER) ligand, is an orally active and selective ER antagonist. Giredestrant potently competes with Estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity.
  • HY-151460
    GCN2-IN-7

    		Others Cancer
    GCN2-IN-7 (compound 39) is an orally active and selective general control nonderepressible 2 (GCN2) inhibitor (IC50=5 nM). GCN2-IN-7 shows anti-tumor activity in vivo.
  • HY-N10536
    Halichondrin B

    		Others Cancer
    Halichondrin B is found from the sponge Halichondria okadai. Halichondrin B is a noncompetitive inhibitor of Vinca-alkaloid binding to tubulin (IC50 for tubulin polymerization of 1.2-1.4 μM). Halichondrin B shows anti-tumor activity.
  • HY-N3085
    Phellamurin

    		P-glycoprotein Apoptosis Cancer Metabolic Disease
    Phellamurin is a plant flavonone glycoside from the leaves of Phellodendron amurense and inhibits intestinal P-glycoprotein. Phellamurin also inhibits egg laying by Papilio protenor. Phellamurin induces cells apoptosis and has anti-tumor activity.
  • HY-N10578
    Genkwadaphnin

    		Others Cancer
    Genkwadaphnin is a daphnane diterpenoid, targeting of importin-β1 to reduce the nuclear accumulation of key CRPC drivers, and shut down their downstream oncogenic signaling. Genkwadaphnin shows potent anti-tumor activity and inhibits castration-resistant prostate cancer (CRPC) in vivo in mice.
  • HY-N5112
    (Rac)-Arnebin 1

    (Rac)-β,β-Dimethylacrylalkannin; (Rac)-β,β-​Dimethylacrylshikonin

    		 HIF/HIF Prolyl-Hydroxylase Others
    (Rac)-Arnebin 1 ((Rac)-β,β-Dimethylacrylalkannin) is the racemate of β,β-Dimethylacrylalkannin and/or β,β-Dimethylacrylshikonin. β,β-Dimethylacrylalkannin and β,β-Dimethylacrylshikonin are napthoquinones isolated from Arnebia nobilis. β,β-Dimethylacrylshikonin has anti-tumor activity.
  • HY-151513
    Iso5-2DC18

    		Others Cancer
    Iso5-2DC18 is a lipid that can be used for the synthesis of amine containing lipids. These amine containing lipids can be used for mRNA delivery, activate the stimulator of interferon genes (STING) pathway, and exhibit anti-tumor immunity.
  • HY-150591
    20S Proteasome-IN-3

    		Proteasome Cancer
    20S Proteasome-IN-3 is a 20S proteasome β5 subunit inhibitor (IC50=1.64 μM). 20S Proteasome-IN-3 shows anti-tumor proliferation activity.
  • HY-N8213
    Rapanone

    		Apoptosis Phospholipase Bacterial Parasite Cancer Infection Inflammation/Immunology
    Rapanone is a natural benzoquinone. Rapanone exhibits a broad spectrum of biological actions, including anti-tumor, antioxidant, anti-inflammatory, antibacterial and antiparasitic. Rapanone also is a potent and selective human synovial PLA2 inhibitor, with an IC50 of 2.6 μM.
  • HY-111183
    Neocarzinostatin

    Zinostatin; Vinostatin

    		 DNA/RNA Synthesis Bacterial Apoptosis Antibiotic Cancer Infection
    Neocarzinostatin, a potent DNA-damaging, anti-tumor antibiotic, recognizes double-stranded DNA bulge and induces DNA double strand breaks (DSBs). Neocarzinostatin induces apoptosis. Neocarzinostatin has potential for EpCAM-positive cancers treatment .
  • HY-149035
    PAA4

    		Others Cancer
    PAA4 is a methide carbon-centered polynuclear Au(I) clusters. PAA4 shows antiproliferative activity. PAA4 increases the expression of pH2AX in a time dependent manner. PAA4 shows anti-tumor effect in orthotopic bladder cancer mouse model.
  • HY-N0452
    Hyperoside

    		Influenza Virus Fungal NF-κB Apoptosis Cancer Infection Inflammation/Immunology
    Hyperoside is a NF-κB inhibitor, found from Hypericum monogynum. Hyperoside shows anti-tumor, antifungal, anti-inflammatory, anti-viral, and anti-oxidative activities, and can induce apoptosis.
  • HY-N0889
    Ginkgetin

    		Wnt Apoptosis Autophagy Inflammation/Immunology Cancer
    Ginkgetin, a biflavone, is isolated from Ginkgo biloba leaves. Ginkgetin exhibit anti-tumor, anti-inflammatory, neuroprotective, anti-fungal activities. Ginkgetin is also a potent inhibitor of Wnt signaling, with an IC50 of 5.92 μΜ.
  • HY-10619B
    Niraparib tosylate

    MK-4827 tosylate

    		 PARP Apoptosis Cancer
    Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with an IC50 of 3.8 and 2.1 nM, respectively. Niraparib tosylate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
  • HY-P9978
    Toripalimab

    		PD-1/PD-L1 Cancer
    Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma.
  • HY-N8432
    Dipyrithione

    		Apoptosis Bacterial Fungal Cancer Infection Inflammation/Immunology
    Dipyrithione is a potent antimicrobial agent. Dipyrithione shows antifungal activity and antiproliferative activity. Dipyrithione induces apoptosis and cycle arrest at G1 phase. Dipyrithione shows anti-inflammatory activity in vivo. Dipyrithione shows anti-tumor activity. Dipyrithione has the potential for the research of dermatophytosis.
  • HY-P99041
    Panitumumab

    ABX-EGF

    		 EGFR Cancer
    Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer.
  • HY-135903
    Giredestrant tartrate

    GDC-9545 tartrate

    		 Estrogen Receptor/ERR Cancer
    Giredestrant tartrate (GDC-9545 tartrate), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant tartrate potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Anti-tumor activity.
  • HY-150082
    CP681301

    		CDK Cancer
    CP681301 is a potent CDK5 inhibitor. CP681301 shows antiproliferative activity. CP681301 decreases the expression of CD133, OLIG2, SOX2, KI67, pCDK5 protein level in GSCs (Glioma stem cells). CP681301 reduces self-renewal in mouse glioma xenografts. CP681301 shows anti-tumor activity in Drosophila.
  • HY-131724
    4-(Dodecylamino)phenol

    p-DDAP; p-Dodecylaminophenol

    		 Apoptosis Cancer
    4-(Dodecylamino)phenol (p-DDAP) is an anticancer agent. 4-(Dodecylamino)phenol has anti-tumor activity and can suppress proliferation, arrest the cell cycle and induce apoptotic cell death. 4-(Dodecylamino)phenol can be used for the research of cancer, such as prostate cancer.
  • HY-150076
    BLU2864

    		Others Cancer Metabolic Disease
    BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor (IC50=0.3 nM). BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research.
  • HY-10619E
    Niraparib tosylate hydrate

    MK-4827 tosylate hydrate

    		 PARP Apoptosis Cancer
    Niraparib (MK-4827) tosylate hydrate is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib tosylate hydrate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
  • HY-10619
    Niraparib

    MK-4827

    		 PARP Apoptosis Cancer
    Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
  • HY-10619A
    Niraparib hydrochloride

    MK-4827 hydrochloride

    		 PARP Apoptosis Cancer
    Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib hydrochloride leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
  • HY-146674
    IDO1/TDO-IN-3

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1/TDO-IN-3 is a potent inhibitor of IDO1/TDO. IDO1/TDO-IN-3 exhibits significant activities against IDO1 (IC50: 0.005 μM) and TDO (IC50: 0.004 μM). IDO1/TDO-IN-3 shows considerable in vivo anti-tumor activity and no obvious toxicity is observed.
  • HY-10524
    GSK1904529A

    		IGF-1R Insulin Receptor Apoptosis Cancer Endocrinology
    GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC50s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity.
  • HY-N2959
    Brevilin A

    		JAK STAT Apoptosis Autophagy Cancer
    Brevilin A is an orally active STAT3/JAK inhibitor (STAT3 IC50= 10.6 µM). Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy.
  • HY-115581
    Thymidine 3',5'-disphosphate

    Deoxythymidine 3′,5′-diphosphate; pdTp

    		 Others Cancer
    Thymidine 3',5'-disphosphate (Deoxythymidine 3′,5′-diphosphate; pdTp) is a selective small molecule inhibitor of SND1 (the miRNA regulatory complex RISC subunit) and inhibits SND1 activity. Thymidine 3',5'-disphosphate is an anti-HCC agent and exhibits anti-tumor efficacy in vivo.
  • HY-151512
    A12-Iso5-4DC19

    		Others Cancer Inflammation/Immunology
    A12-Iso5-4DC19 is a linked lipid and exhibits anti-tumor immunity. A12-Iso5-4DC19 can facilitate mRNA delivery and be used for the research of RNA vaccines.
  • HY-P99218
    Robatumumab

    Sch 717454; 19D12

    		 IGF-1R Cancer
    Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research.
  • HY-P2268
    RAGE antagonist peptide

    		Amyloid-β Cancer Inflammation/Immunology
    RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities.
  • HY-B0919
    Azaserine

    CI-337; O-Diazoacetyl-L-serine; P-165

    		 Bacterial Antibiotic DNA/RNA Synthesis Cancer Infection
    Azazerine (CI-337) is a competitive inhibitor of glutamine amidotransferase. Azaserine is an antibiotic, it shows antibacterial activities. Azazerine shows anti-tumor activities and it may also act as a tumor inducer. Azazerine can be used for the research of cancer and infection.
  • HY-15255
    Zosuquidar

    RS 33295-198; LY-335979

    		 P-glycoprotein Cancer
    Zosuquidar (LY335979) is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM). Zosuquidar shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research.
  • HY-50671
    Zosuquidar trihydrochloride

    RS 33295-198 trihydrochloride; LY-335979 trihydrochloride

    		 P-glycoprotein Cancer
    Zosuquidar (LY335979) trihydrochloride is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM). Zosuquidar trihydrochloride shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research.
  • HY-146684
    HDAC-IN-36

    		HDAC Autophagy Apoptosis Cancer
    HDAC-IN-36 (compound 23 g) is an orally active and potent HDAC (histone deacetylase) inhibitor, with an IC50 of 11.68 nM (HDAC6). HDAC-IN-36 promotes apoptosis, autophagy and suppresses migration. HDAC-IN-36 shows anti-tumor and anti-metastatic activity, and can be used for breast cancer research.
  • HY-100950
    ABC1183

    		GSK-3 CDK Cancer Inflammation/Immunology
    ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities.
  • HY-P99041A
    Panitumumab (anti-EGFR)

    		EGFR Cancer
    Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer.
  • HY-121993
    Combretastatin A-1

    		Microtubule/Tubulin Cancer
    Combretastatin A-1 is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin. Combretastatin A-1 inhibits the Wnt/β-catenin pathway through tubulin depolymerization mediated AKT deactivation. Combretastatin A-1 exhibits anti-tumor and anti-vascular effects.
  • HY-P2268A
    RAGE antagonist peptide TFA

    		Amyloid-β Cancer Inflammation/Immunology
    RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities.
  • HY-N0126
    Xanthone

    		Bacterial Influenza Virus Fungal Apoptosis Cancer Infection Inflammation/Immunology
    Xanthone is isolated from Mangosteen and is known to control cell division and growth, apoptosis, inflammation, and metastasis in different stages of carcinogenesis. Xanthone has anti-oxidant, anti-tumor, anti-allergic, anti-inflammatory, anti-bacterial, anti-fungal, and anti-viral activities.
  • HY-139108
    DCH36_06

    		Histone Acetyltransferase Apoptosis Cancer
    DCH36_06 is a potent and selective p300/CBP inhibitor with IC50s of 0.6 μM and 3.2 μM for p300 and CBP, respectively. DCH36_06 mediated p300/CBP inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity.
  • HY-15505
    RWJ-67657

    JNJ 3026582

    		 p38 MAPK Cancer Inflammation/Immunology Cardiovascular Disease
    RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity.
  • HY-104066
    Theliatinib

    Xiliertinib; HMPL-309

    		 EGFR Cancer
    Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a Ki of 0.05 nM and an IC50 of 3 nM. Theliatinib has an IC50 of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for EGFR than other kinases. Anti-tumor activity.
  • HY-144881
    (S)-HH2853

    		Histone Methyltransferase Cancer Inflammation/Immunology
    (S)-HH2853 (compound 200), a PYRIDINO five membered aromatic ring compound, is a potent EZH1/2 dual inhibitor with an IC50 of <100 nM for EZH2_Y641F. (S)-HH2853 has the potential to be used in the research of anti-tumor or autoimmune diseases.
  • HY-143617
    photoCORM-1

    		Others Cancer
    photoCORM-1 (compound 8) is a combinatorial carbon monoxide releasing molecule (CORM). photoCORM-1 exhibits good cellular uptake and real-time monitoring ability of CO uncaging by a color change approach. photoCORM-1 has anti-tumor antivity.
  • HY-143618
    photoCORM-2

    		Others Cancer
    photoCORM-2 (compound 3) is a single carbon monoxide releasing molecule (CORM). photoCORM-2 exhibits good cellular uptake and real-time monitoring ability of CO uncaging by a color change approach. photoCORM-2 has anti-tumor activity.
  • HY-N8211
    Gypenoside L

    		p38 MAPK ERK NF-κB Cancer Inflammation/Immunology
    Gypenoside L is a saponin that can be found in Gynostemma pentaphyllum. Gypenoside L increases the SA-β-galactosidase activity, promotes the production of senescence-associated secretory cytokines. Gypenoside L also can activate p38 and ERK MAPK pathways and NF-κB pathway to induce senescence. Gypenoside L exhibits anti-tumor and anti-inflammatory activities.
  • HY-W005130
    2,4,6-Trihydroxybenzaldehyde

    		NF-κB Metabolic Disease
    2,4,6-Trihydroxybenzaldehyde is an orally active NF-ĸB inhibitor. 2,4,6-Trihydroxybenzaldehyde shows anti-tumor activity, anti-cancer cell proliferative activity and anti-obesity activity.
  • HY-16986
    EPZ011989

    		Histone Methyltransferase Cancer
    EPZ011989 is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor with metabolic stability. EPZ011989 has inhibitory inhibition for EZH2 with a Ki value of <3 nM. EPZ011989 shows robust methyl mark inhibition and anti-tumor activity. EPZ011989 can be used for the research of various cancers.
  • HY-N0156
    Oleanolic Acid

    Oleanic acid; Caryophyllin

    		 Autophagy Endogenous Metabolite HIV Cancer
    Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.
  • HY-145389
    SZ-015268

    		CDK Cancer
    SZ-015268 is a CDK7 inhibitor with an IC50 of 23.56 nM. SZ-015268 has extremely significant anti-tumor advantages. SZ-015268 inhibits HCC70, OVCAR-3, HCT116 and HCC1806 cells proliferation with IC50s of 33, 80.56, 12.53, and 61.55 nM, respectively.
  • HY-12203
    PFK-158

    		Autophagy Apoptosis Cancer
    PFK-158 is a potent and selective PFKFB3 inhibitor with an IC50 value 137 nM. PFK-158 reduces glucose uptake, ATP production, lactate release, and induces apoptosis and autophagy in cancer cells. PFK-158 has broad anti-tumor activity. PFK-158 can also enhance Colistin's resistance to bacteria.
  • HY-147281
    BAY 1135626

    		ADC Cytotoxin Others Cancer
    BAY 1135626 is used to synthesize BAY 1129980, and use to anti-tumor research. BAY 1129980 is a Auristatin-based anti-C4.4A (LYPD3) antibody–drug conjugate (ADC), is used to non–small cell lung cancer (NSCLC) research.
  • HY-147414
    Vamotinib

    PF-114

    		 Bcr-Abl Cancer
    Vamotinib (PF-114) is a potent, selective and orally active tyrosine kinase inhibitor. Vamotinib inhibits the autophosphorylation of BCR/ABL and BCR/ABL-T315I. Vamotinib induces apoptosis. Vamotinib shows anti-proliferative and anti-tumor activity. Vamotinib has the potential for the research of resistant philadelphia chromosome-positive (Ph+) leukemia.
  • HY-112328
    Fascaplysin

    		Apoptosis Autophagy Reactive Oxygen Species Cancer Infection
    Fascaplysin is an antimicrobial and cytotoxic red pigment, that can come from the marine sponge (Fascaplysinopsis sp.). Fascaplysin has been synthesized in seven steps from indole (65% yield). Fascaplysin can induces apoptosis and autophagy in human leukemia HL-60 cells. Fascaplysin shows anti-tumor activity.
  • HY-147328
    LCS3

    		Apoptosis Cancer
    LCS3 is a reversible and uncompetitive glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) inhibitor (IC50=3.3 µM and 3.8 µM, respectively). LCS3 shows anti-tumor activity, and induces apoptosis. LCS3 can be used in lung adenocarcinoma (LUAD) research.
  • HY-19828
    Herboxidiene

    GEX1A

    		 DNA/RNA Synthesis Cancer
    Herboxidiene (GEX1A) is a potent phytotoxic polyketide from Streptomyces sp. A7847 with a diverse range of activities, including herbicidal, anti-cholesterol, anti-tumor effects. Herboxidiene inhibits the pre-mRNA splicing process by binding to spliceosome-associated protein (SAP) 155, a subunit of SF3b, in the splicesome.
  • HY-N7526
    Naphthazarin

    DHNQ; 5,8-Dihydroxy-1,4-naphthoquinone

    		 Apoptosis Cancer Neurological Disease
    Naphthazarin (DHNQ) is a naturally occurring compound. Naphthazarin is effective by various cellular mechanisms including oxidative stress, activation of mitochondrial apoptosis-inducing factor (AIF), depolymerization of microtubules, interference with lysosomal function and p53-dependent p21 activation. Naphthazarin triggers apoptosis and has anti-tumor effects.
  • HY-105237
    Eesperamicin A1

    		Antibiotic DNA/RNA Synthesis Cancer
    Esperamicin A1, as an extremely potent antitumor antibiotic, is isolated from cultures of Actinomadura verrucosospora. Esperamicin A1 can be used for the research of antitumor.
  • HY-15721
    FH535

    		PPAR Wnt β-catenin Cancer
    FH535 is an inhibitor of Wnt/β-catenin and PPAR, with anti-tumor activities.
  • HY-16509
    UNBS5162

    		CXCR Autophagy Cancer Endocrinology
    UNBS5162 is a pan-antagonist of CXCL chemokine expression, with anti-tumor activity.
  • HY-U00337
    Datelliptium chloride

    		DNA/RNA Synthesis Cancer
    Datelliptium chloride is a DNA-intercalating agent derived from ellipticine, with anti-tumor activities.
  • HY-105226
    CI-988

    PD134308

    		 Cholecystokinin Receptor Cancer Neurological Disease
    CI-988 (PD134308) is a potent, selective and orally active CCK2R (cholecystokinin 2 receptor) antagonist with an IC50 of 1.7 nM for mouse cortex CCK2. CI-988 shows >1600-fold selectivity for CCK2 over CCK1 receptor. CI-988 has anxiolytic and anti-tumor effects.
  • HY-151576
    PRMT5:MEP50 PPI

    		Others Cancer
    PRMT5:MEP50 PPI is a novel PRMT5:MEP50 protein-protein interaction (PRMT5:MEP50 PPI) inhibitor, shows anti-tumor activity and anti-proliferative activity of lung and prostate cancer cells.
  • HY-144436
    ATR-IN-12

    		ATM/ATR Cancer
    ATR-IN-12 (Compound 5g) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with an IC50 value of 0.007 μM. ATR-IN-12 displays good anti-tumor activity and significantly reduces the phosphorylation level of ATR and its downstream signaling protein. ATR-IN-12 is a promising lead compound for subsequent drug discovery targeting ATR kinase.
  • HY-16986A
    EPZ011989 trifluoroacetate

    EPZ-011989 trifluoroacetate

    		 Histone Methyltransferase Cancer
    EPZ-011989 trifluoroacetate is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor with metabolic stability. EPZ-011989 trifluoroacetate has inhibitory inhibition for EZH2 with a Ki value of <3 nM. EPZ-011989 trifluoroacetate shows robust methyl mark inhibition and anti-tumor activity. EPZ-011989 trifluoroacetate can be used for the research of various cancers.
  • HY-10249A
    AKT Kinase Inhibitor

    		Akt Cancer
    AKT Kinase Inhibitor is an Akt kinase inhibitor with anti-tumor activity.
  • HY-10249D
    AKT Kinase Inhibitor hydrochloride

    		Akt Cancer
    AKT Kinase Inhibitor hydrochloride is an Akt kinase inhibitor with anti-tumor activity.
  • HY-N0235
    Bakuchiol

    (S)-(+)-Bakuchiol

    		 p38 MAPK Autophagy Cancer
    Bakuchiol is a phytoestrogen isolated from the seeds of Psoralea corylifolia L; has anti-tumor effects.
  • HY-N1977
    Podophyllotoxin glucoside

    		Others Cancer
    Podophyllotoxin glucoside is a podophyllotoxin derivative, has anti-tumor effects.
  • HY-113450
    10Z-Nonadecenoic acid

    		Endogenous Metabolite Metabolic Disease Cancer
    10Z-Nonadecenoic acid is a kind of long-chain fatty acid with anti-tumor activity.
  • HY-N0214A
    Peimisine hydrochloride

    Ebeiensine hydrochloride

    		 mAChR Angiotensin-converting Enzyme (ACE) Apoptosis Cancer Inflammation/Immunology Cardiovascular Disease
    Peimisine (Ebeiensine) hydrochloride is a muscarinic M receptor antagonist and angiotensin converting enzyme (ACE) inhibitor. Peimisine hydrochloride shows anti-tumor, anti-inflammatory, antihypertensive activities. Peimisine can induce apoptosis and be used in cough and asthma research.
  • HY-N0214
    Peimisine

    Ebeiensine

    		 mAChR Angiotensin-converting Enzyme (ACE) Apoptosis Cancer Inflammation/Immunology Cardiovascular Disease
    Peimisine (Ebeiensine) is a muscarinic M receptor antagonist and angiotensin converting enzyme (ACE) inhibitor. Peimisine shows anti-tumor, anti-inflammatory, antihypertensive activities. Peimisine can induce apoptosis and be used in cough and asthma research.
  • HY-N4042
    Hirsutenone

    		PI3K ERK Cancer Inflammation/Immunology
    Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone attenuates adipogenesis by binding directly to PI3K and ERK1 in a non-ATP competitive manner. Hirsutenone can be used for the study of obesity.
  • HY-147308
    PCLX-001

    		Others Cancer
    PCLX-001 is an orally acitve, small-molecule, dual N-myristoyltransferase (NMT) inhibitor, with IC50s of 5 nM (NMT1) and 8 nM (NMT2), respectively. PCLX-001 exhibits anti-tumor activity and inhibits early B-cell receptor (BCR) signaling, can be used to B-cell malignancies research.
  • HY-143265
    Topoisomerase I inhibitor 2

    		Topoisomerase Apoptosis Caspase Cancer
    Topoisomerase I inhibitor 2 (ZML-8) is a highly selective inhibitor of DNA topoisomerase I (Top1). Topoisomerase I inhibitor 2 inhibits Top1 activity and results DNA damage. Topoisomerase I inhibitor 2 blocks G2/M phase and induces apoptosis, exhibits anti-tumor effect.
  • HY-14947
    Balamapimod

    MKI 833

    		 MEK Cancer
    Balamapimod (MKI 833) is a reversible Ras/Raf/MEK inhibitor with potential anti-tumor activity.
  • HY-16496
    Thiarabine

    OSI-7836

    		 DNA/RNA Synthesis Cancer Inflammation/Immunology
    Thiarabine (OSI-7836) shows potent anti-tumor activity and inhibition of DNA synthesis.
  • HY-147081
    AS 1411

    AGRO-100

    		 Others Cancer
    AS1411 is a quadruplex-forming oligonucleotide aptamer that targets nucleolin. It has anti-tumor activity.
  • HY-N10353
    4-Methyl withaferin A

    		Others Cancer Inflammation/Immunology
    4-Methyl withaferin A is a withaferin A-analogue with anti-tumor activity.
  • HY-N8197
    Epigambogic acid

    		Others Cancer
    Epigambogic acid is a natural anti-tumor, antitussive, expectorant and anti-inflammatory compound.
  • HY-U00379
    LM985

    		Others Cancer
    LM985 is one of a series of compounds based on the flavone ring structure, with anti-tumor activities.
  • HY-N4124
    Poricoic acid B

    		Others Cancer
    Poricoic acid B, isolated from Poria cocos, possesses anti-tumor activity.
  • HY-N9400
    Lucidenic acid F

    		Others Cancer Inflammation/Immunology
    Lucidenic acid F, a natural triterpenoid, possesses anti-Inflammatory and anti-tumor activity.
  • HY-N6988
    Cimigenol

    		Others Cancer
    Cimigenol is an active compound isolated from Cimicifuga, with potent anti-tumor activity.
  • HY-134472
    PI3Kδ-IN-8

    		PI3K Cancer
    PI3Kδ-IN-8 is a potent, selective and orally active PI3Kδ inhibitor, with an IC50 of 3.3 nM. PI3Kδ-IN-8 shows selectivity for PI3Kδ over PI3Kα, PI3Kβ, and PI3Kγ (IC50=377.2, 241.6, 17.9 nM, respectively). PI3Kδ-IN-8 has anti-tumor activity.
  • HY-148101
    BT5528

    		Ephrin Receptor Cancer
    BT5528 is a bicyclic peptide toxin conjugate, an EphA2 activator. BT5528, made up of a bicyclic peptide and Auristatin E (HY-15582), is derivated from BCY6099. BT5528 shows potent anti-tumor activity without bleeding or coagulation toxicity in rats model.
  • HY-N0184
    Glycyrrhizic acid

    Glycyrrhizin

    		 Virus Protease Cancer Metabolic Disease
    Glycyrrhizic acid is a triterpenoid saponinl, acting as a direct HMGB1 antagonist, with anti-tumor, anti-diabetic activities.
  • HY-128937
    EC1454

    		Others Cancer
    EC1454 is an anti-tumor compound, extracted from US20170348376A1.
  • HY-B1436
    Nifuroxazide

    		STAT Bacterial Antibiotic Cancer Infection
    Nifuroxazide is an effective inhibitor of STAT3, also exerts potent anti-tumor and anti-metastasis activity.
  • HY-N0428
    Obacunone

    		Apoptosis Cancer
    Obacunone, isolated from Citrus fruits, exhibits anti-tumor activity by the induction of apoptosis.
  • HY-N9390
    Wilforlide B

    		Others Cancer
    Wilforlide B, a natural norditerpenoid, possesses anti-tumor activity in human cancer cells.
  • HY-N7255
    Cycloartenol

    		p38 MAPK Apoptosis Cancer
    Cycloartenol, a phytosterol compound, is one of the key precusor substances for biosynthesis of numerous sterol compounds. Cycloartenol inhibits the migration of glioma cells and suppresses the phosphorylation of the p38 MAP kinase. Cycloartenol has a variety of pharmacological activities such as anti-inflammatory, anti-tumor, antioxidant, antibiosis and anti-alzheimer's disease. Cycloartenol also plays an important role in the process of plant growth and development.
  • HY-N5077
    Sinapine

    		Cholinesterase (ChE) P-glycoprotein Cancer Inflammation/Immunology Neurological Disease
    Sinapine is an alkaloid isolated from seeds of the cruciferous species. Sinapine exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease.
  • HY-16146
    Combretastatin A-1 phosphate tetrasodium

    OXi-4503 tetrasodium

    		 Microtubule/Tubulin Cancer
    Combretastatin A-1 phosphate (OXi-4503) tetrasodium, a prodrug of Combretastatin A-1, is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin. Combretastatin A-1 phosphate tetrasodium inhibits the Wnt/β-catenin pathway through tubulin depolymerization mediated AKT deactivation. Combretastatin A-1 phosphate tetrasodium exhibits anti-tumor and anti-vascular effects.
  • HY-112243
    Cimpuciclib

    		CDK Cancer Inflammation/Immunology
    Cimpuciclib is a selective CDK4 inhibitor (IC50: 0.49 nM) that has anti-tumor activity.
  • HY-N1550
    Przewalskin

    Norsalvioxide

    		 Others Cancer
    Przewalskin (Norsalvioxide) is a natural product found in Salvia yunnanensis. Przewalskin shows anti-tumor activity.
  • HY-112243A
    Cimpuciclib tosylate

    		CDK Cancer Inflammation/Immunology
    Cimpuciclib tosylate is a selective CDK4 inhibitor (IC50: 0.49 nM) that has anti-tumor activity.
  • HY-N0370
    Bergapten

    5-Methoxypsoralen

    		 Cytochrome P450 Autophagy Cancer
    Bergapten is a natural anti-inflammatory and anti-tumor agent. Bergapten is inhibitory towards mouse and human CYP isoforms.
  • HY-128939
    EC0488

    		Antifolate Cancer
    EC0488 is used to synthesize EC0531 with folate receptor (FR)-specific and anti-tumor activities.
  • HY-N4255
    Resibufagin

    		Others Cancer
    Resibufagin is a kind of bufadienolide isolated from the venom of Bufo bufo gargarizans, has anti-tumor activities.
  • HY-N0140
    Ursolic acid

    Prunol; Urson; Malol

    		 Autophagy Endogenous Metabolite Cancer
    Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.
  • HY-111458
    GSK2643943A

    		Deubiquitinase Cancer
    GSK2643943A is a deubiquitinating enzyme (DUB) inhibitor targeting USP20. GSK2643943A has affinity with an IC50 of 160 nM for USP20/Ub-Rho. GSK2643943A has anti-tumor efficacy and can be used for the research of oral squamous cell carcinoma (OSCC) .
  • HY-N5077B
    Sinapine hydroxide

    		Cholinesterase (ChE) P-glycoprotein Cancer Inflammation/Immunology Neurological Disease
    Sinapine hydroxide is an alkaloid isolated from seeds of the cruciferous species. Sinapine hydroxide exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine hydroxide is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease.
  • HY-N0450
    Sinapine thiocyanate

    		P-glycoprotein Cholinesterase (ChE) Cancer
    Sinapine thiocyanate is an alkaloid isolated from seeds of the cruciferous species. Sinapine thiocyanate exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine thiocyanate is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease.
  • HY-N8204
    Siaresinolic acid 28-O-β-D-glucopyranosyl ester

    		Others Cancer Metabolic Disease
    Siaresinolic acid 28-O-β-D-glucopyranosyl ester possesses anti-tumor and antidiabetic effect activity.
  • HY-N0743
    Senkyunolide A

    		Others Cancer
    Senkyunolide A, isolated from Ligusticum chuanxiong Hort, has cytoprotective and antiproliferative activities. Anti-tumor activity.
  • HY-15866
    FR901465

    		Others Cancer
    FR901465 is a potent anti-cancer and anti-tumor agent. FR901465 can be used for cancer research.
  • HY-16674
    10-Oxo Docetaxel

    Docetaxel Impurity 1

    		 Microtubule/Tubulin Cancer
    10-Oxo Docetaxel (Docetaxel Impurity 1) is a novel taxoid having remarkable anti-tumor properties and a Docetaxel intermediate.
  • HY-N2242
    Hosenkoside G

    		Others Cancer
    Hosenkoside G, a baccharane glycoside isolated from the seeds of Impatiens Balsamina L., possesses anti-tumor activity.
  • HY-N0891
    Tubeimoside II

    Tubeimoside-B

    		 Others Cancer
    Tubeimoside II(Tubeimoside-B) is a natural analogue of oleanane type of triterpenoid saponin; show anti-inflammatory, antitumor, and antitumor-promoting effects.
  • HY-N2604
    Loureirin C

    		Bacterial Cancer Infection Metabolic Disease Inflammation/Immunology Neurological Disease
    Loureirin C has anti-bacterial, anti-spasmodic, anti-inflammatory, analgesic, anti-diabetic, and anti-tumor activities.
  • HY-N6075
    Specneuzhenide

    Nuezhenide

    		 Others Cancer
    Specneuzhenide (Nuezhenide) is a phenol glycoside isolated from Ligustrum sinense. Specneuzhenide (Nuezhenide) possesses anti-tumor activity.
  • HY-N0400
    Wogonin

    		CDK Wnt Autophagy Apoptosis Cancer Inflammation/Immunology
    Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.
  • HY-N0271
    Echinocystic acid

    		Reactive Oxygen Species Apoptosis Inflammation/Immunology Cancer
    Echinocystic acid a pentacyclic triterpene isolated from the fruits of Gleditsia sinensis Lam, has potent antioxidant, anti-inflammatory and anti-tumor properties.
  • HY-103712
    Samuraciclib

    CT7001; ICEC0942

    		 CDK Apoptosis Cancer
    Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib has anti-tumor effects.
  • HY-103712A
    Samuraciclib hydrochloride

    CT7001 hydrochloride; ICEC0942 hydrochloride

    		 CDK Apoptosis Cancer
    Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects.
  • HY-103712C
    Samuraciclib hydrochloride hydrate

    CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate

    		 CDK Apoptosis Cancer
    Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib hydrochloride hydrate has anti-tumor effects.
  • HY-103712B
    Samuraciclib hydrochloride hydrate

    CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate

    		 CDK Apoptosis Cancer
    Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib hydrochloride hydrate has anti-tumor effects.
  • HY-A0020
    Eldecalcitol

    ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3

    		 VD/VDR Apoptosis Cancer Metabolic Disease Inflammation/Immunology
    Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1.
  • HY-N0834
    Pulsatilla saponin D

    SB365; Hederacolchiside A

    		 Apoptosis Cancer
    Pulsatilla saponin D (SB365), isolated from the root of Pulsatilla chinensis, is an anti-tumor agent.
  • HY-135317
    Emavusertib

    CA-4948

    		 IRAK FLT3 Cancer Inflammation/Immunology
    Emavusertib (CA-4948) is a potent IRAK4/FLT3 inhibtor with anti-tumor activity.
  • HY-13062A
    Daunorubicin

    Daunomycin; RP 13057; Rubidomycin

    		 Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Autophagy Bacterial Antibiotic Apoptosis Cancer Infection Neurological Disease
    Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.
  • HY-13062
    Daunorubicin hydrochloride

    Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride

    		 Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Bacterial Autophagy Apoptosis Antibiotic Cancer Infection Neurological Disease
    Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.
  • HY-N4189
    Isocucurbitacin B

    		Others Cancer
    Isocucurbitacin B is a potent cytotoxic compound isolated from Helicteres rswa L. (Sterculiaceae). Isocucurbitacin B possesses anti-tumor acticity.
  • HY-132979
    KRAS G12C inhibitor 18

    		Ras Cancer
    KRAS G12C inhibitor 18 is a potent and orally active KRAS G12C inhibitor. Anti-tumor activities.
  • HY-126330
    SS-208

    		HDAC Cancer
    SS-208 is a selective HDAC6 inhibitor, with an IC50 of 12 nM. SS-208 possesses anti-tumor activity in melanoma.
  • HY-N8207
    Gypenoside LI

    		Apoptosis MicroRNA Cancer
    Gypenoside LI, a gypenoside monomer, possesses anti-tumor activity. Gypenoside LI induces cell apoptosis, cell cycle and migration.
  • HY-147317
    Epothilone E

    		Microtubule/Tubulin Cancer
    Epothilone E is a related compound of epothilone, which inhibits microtubule protein function and blocks cell division, and has anti-tumor activity.
  • HY-N4109
    Decursinol

    		Others Cancer Inflammation/Immunology
    Decursinol, isolated from the roots of Angelica gigas, possesses antinociceptive effect with orally bioavailability. Decursinol possesses anti-tumor and anti-metastasis activity.
  • HY-N2997
    Ganoderic acid LM2

    		Others Cancer
    Ganoderic acid LM2 is a natural terpenoid isolated from the Fungus Ganoderma lucidum. Ganoderic acid LM2 possesses potential anti-tumor activity.
  • HY-137442
    Inupadenant

    EOS-850

    		 Adenosine Receptor Cancer
    Inupadenant is an orally active, highly selective A2A receptor antagonist. Inupadenant is not brain-penetrant. Inupadenant has potent anti-tumor activity.
  • HY-143655
    QW24

    		Autophagy Cancer
    QW24 exerts potent anti-tumor activity by down-regulating BMI-1 and is used as an effective therapeutic agent for clinical colorectal cancer treatment.
  • HY-B1436S
    Nifuroxazide-d4

    		STAT Bacterial Antibiotic Cancer Infection
    Nifuroxazide-d4 is the deuterium labeled Nifuroxazide. Nifuroxazide is an effective inhibitor of STAT3, also exerts potent anti-tumor and anti-metastasis activity.
  • HY-N6004
    (Rac)-Shikonin

    Shikalkin

    		 Others Cancer
    (Rac)-Shikonin (Shikonin) possesses anti-tumor activity. (Rac)-Shikonin (Shikonin) circumvents cancer drug resistance by induction of a necroptotic death.
  • HY-N0429
    Diosbulbin B

    		Endogenous Metabolite Cancer
    Diosbulbin B is a diterpene lactone isolated from D. bulbifera L., with anti-tumor activity. Diosbulbin B can induce liver injury.
  • HY-N0714
    Berbamine

    		NF-κB Autophagy Cancer
    Berbamine is a natural compound extracted from traditional Chinese medicine Phellodendron amurense Rupr. with anti-tumor, immunomodulatory and cardiovascular effects. Berbamine is a calcium channel blocker.
  • HY-147670
    TPB15

    		Hedgehog Smo Gli Apoptosis Cancer
    TPB15 is an orally active and potent Hh (Hedgehog) signaling inhibitor. TPB15 markedly induces cell cycle arrest and apoptosis in MDA-MB-468 cells. TPB15 blocks Smo (Smoothened) translocation into the cilia and reduced Smo protein and mRNA expression. TPB15 inhibits the expression of the downstream regulatory factor glioma-associated oncogene 1 (Gli1). TPB15 shows good anti-tumor activity with low toxicity.
  • HY-130116A
    IACS-8779 disodium

    		STING Cancer
    IACS-8779 disodium is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy. IACS-8779 disodium shows robust activation of the STING pathway in vitro and a superior systemic anti-tumor response in the B16 murine model of melanoma.
  • HY-135805
    JBJ-04-125-02

    		EGFR Cancer
    JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC50 of 0.26 nM for EGFR L858R/T790M. JBJ-04-125-02 can inhibit cancer cell proliferation and EGFR L858R/T790M/C797S signaling. JBJ-04-125-02 has anti-tumor activities.
  • HY-N3442
    Juglanin

    		JNK Apoptosis Autophagy Cancer Inflammation/Immunology
    Juglanin, a natural occurring flavonoid, is a JNK acticator, with inflammation and anti-tumor activities. Juglanin can induce apoptosis and autophagy on human breast cancer cells.
  • HY-125711
    Capsanthin

    		ROS Kinase Cancer Inflammation/Immunology
    Capsanthin is a carotenoid that has been found in C. annuum. Capsanthin has antioxidant、antitumor and anti-inflammatory effects.
  • HY-N0370S
    Bergapten-d3

    5-Methoxypsoralen-d3

    		 Cytochrome P450 Autophagy Cancer
    Bergapten-d3 is deuterium labeled Bergapten. Bergapten is a natural anti-inflammatory and anti-tumor agent. Bergapten is inhibitory towards mouse and human CYP isoforms.
  • HY-108876
    Daunorubicin citrate

    Daunomycin(citrate); RP 13057(citrate); Rubidomycin(citrate)

    		 Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Autophagy Bacterial Antibiotic Apoptosis Cancer Infection Neurological Disease
    Daunorubicin (Daunomycin) citrate is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin citrate inhibits DNA and RNA synthesis. Daunorubicin citrate is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin citrate is also an anthracycline antibiotic. Daunorubicin citrate can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.
  • HY-107691
    GR 159897

    		Neurokinin Receptor Cancer Endocrinology Neurological Disease
    GR 159897 is a highly potent, selective, competitive, brain-penetrated non-peptide neurokinin 2 (NK2) receptor antagonist. GR 159897 has little or no affinity for NK1 and NK3 receptors. GR 159897 inhibits binding of [ 3H]GR100679 to human NK2 (hNK2)-CHO cells and rat colon membranes with pKis of 9.51 and 10, respectively. Antagonizes bronchoconstriction. Anxiolytic-like and anti-tumor effects.
  • HY-121618
    α-Thujone

    		GABA Receptor Reactive Oxygen Species Parasite Apoptosis Autophagy Cancer Infection Neurological Disease
    α-Thujone is a monoterpene isolated from Thuja occidentalis essential oil with potent anti-tumor activities. α-Thujone is a reversible modulator of the GABA type A receptor and the IC50 for α-Thujone is 21 μM in suppressing the GABA-induced currents. α-Thujone induces ROS accumulation-dependent cytotoxicity, also induces cell apoptosis and autophagy. α-Thujone has antinociceptive, insecticidal, and anthelmintic activity, and easily penetrates the blood-brain barrier.
  • HY-N4116
    Xanthyletin

    		Fungal Cancer Infection
    Xanthyletin is a coumarin isolated from Stauranthus perforatus, with anti-tumor and anti-bacterial activities. Xanthyletin also inhibits symbiotic fungus cultivated by leaf-cutting ants.
  • HY-N4322
    Decursinol angelate

    		PKC Cancer Inflammation/Immunology
    Decursinol angelate, a cytotoxic and protein kinase C (PKC) activating agent from the root of Angelica gigas, possesses anti-tumor and anti-inflammatory activities.
  • HY-103088
    E7046

    		Prostaglandin Receptor Cancer Endocrinology
    E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM. E7046 exhibits anti-tumor activities.
  • HY-144434
    RSK-IN-1

    		Ribosomal S6 Kinase (RSK) Cancer
    RSK-IN-1 (compound 7d) is a RSK inhibitor that inhibits the YB-1 phosphorylation. RSK-IN-1 has anti-tumor effects.
  • HY-128599
    NMS-P515

    		PARP Cancer
    NMS-P515 is a potent, orally active and stereospecific PARP-1 inhibitor, with a Kd of 16 nM and an IC50 of 27 nM (in Hela cells). Anti-tumor activity.
  • HY-N0011
    Baohuoside I

    Icariin-II; Icariside-II

    		 CXCR Apoptosis Cancer Inflammation/Immunology Endocrinology
    Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of CXCR4, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.
  • HY-129181
    FGFR4-IN-4

    		FGFR Cancer
    FGFR4-IN-4 (compound 693) is a FGFR4 inhibitor with anti-tumor activity, extracted from patent WO2018113584A1.
  • HY-N0344
    Farrerol

    		Others Cancer Inflammation/Immunology Neurological Disease
    Farrerol is a bioactive constituent of Rhododendron, with broad activities such as anti-oxidative, anti-inflammatory, anti-tumor, neuroprotective and hepatoprotective effects.
  • HY-12460
    SPDB-DM4

    		Drug-Linker Conjugates for ADC Cancer
    SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.
  • HY-W005629
    Leelamine

    		Cannabinoid Receptor PDHK Cancer
    Leelamine is a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine also inhibits pyruvate dehydrogenase kinases (PDKs). Leelamine exhibits anti-tumor activity.
  • HY-N2432
    Paederoside

    		HBV Cancer Infection
    Paederoside is a monoterpene S-methyl thiocarbonate isolated from Paederia pertomentosa. Paederoside shows a high anti-tumor promoting activity against the Epstein-Barr virus activation.
  • HY-N0205
    Pulchinenoside C

    Anemoside B4

    		 Others Cancer
    Pulchinenoside C (Anemoside B4) is Pulsatilla koreana Nakai that have many numerous biological effects in vitro, including enhancing hypoglycemic, anti-tumor, neuroprotective and anti-angiogenic activity.
  • HY-129467
    (Rac)-Idroxioleic acid

    2-Hydroxyoleic acid; 2-OHOA

    		 Apoptosis Cancer
    (Rac)-Idroxioleic acid (2-Hydroxyoleic acid) is a synthetic oleic acid (OA) derivative that binds to the plasma membrane and alters lipid organization. (Rac)-Idroxioleic acid has anti-tumor effect.
  • HY-117737A
    RRD-251

    		Raf Apoptosis Cancer
    RRD-251 is an inhibitor of retinoblastoma tumor suppressor protein (Rb)-Raf-1 interaction, with potent anti-proliferative, anti-angiogenic and anti-tumor activities.
  • HY-N6892
    3'-​O-​Acetylhamaudol

    		Others Cancer
    3'-O-Acetylhamaudol, isolated from Angelica polymorpha, exhibits anti-tumor activity through dual actions, anti-angiogenesis and intestinal intraepithelial lymphocyte activation.
  • HY-15496
    E6201

    ER-806201

    		 MEK FLT3 Cancer
    E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of MEK1 and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC50 value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC50 value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC50 value of 19 nM. Anti-tumor and anti-psoriasis efficacy.
  • HY-144050
    EGFR-IN-33

    		EGFR Cancer
    EGFR-IN-33 is a potent inhibitor of EGFR. EGFR-IN-33 is an anti-tumor drug with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 13).
  • HY-144052
    EGFR-IN-35

    		EGFR Cancer
    EGFR-IN-35 is a potent inhibitor of EGFR. EGFR-IN-35 is an anti-tumor drug with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-35 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 11).
  • HY-144051
    EGFR-IN-34

    		EGFR Cancer
    EGFR-IN-34 is a potent inhibitor of EGFR. EGFR-IN-34 is an anti-tumor drug with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-34 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 12).
  • HY-144056
    EGFR-IN-39

    		EGFR Cancer
    EGFR-IN-39 is a potent inhibitor of EGFR. EGFR-IN-39 is an anti-tumor drug with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-39 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 2).
  • HY-144054
    EGFR-IN-37

    		EGFR Cancer
    EGFR-IN-37 is a potent inhibitor of EGFR. EGFR-IN-37 is an anti-tumor drug with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-37 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 7).
  • HY-144055
    EGFR-IN-38

    		EGFR Cancer
    EGFR-IN-38 is a potent inhibitor of EGFR. EGFR-IN-38 is an anti-tumor drug with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-38 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 4).
  • HY-N0102
    Isoliquiritigenin

    GU17; ISL; Isoliquiritigen; SJ000286237

    		 Aldose Reductase Influenza Virus Autophagy Apoptosis Cancer Infection Inflammation/Immunology
    Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza uralensis Fisch., which inhibits aldose reductase with an IC50 of 320 nM. Isoliquiritigenin is a potent inhibitor of influenza virus replication with an EC50 of 24.7 μM.
  • HY-N6049
    Lup-20(29)-en-28-oic acid

    		Others Cancer Inflammation/Immunology
    Lup-20(29)-en-28-oic acid, a triterpenoid saponins of Pulsatilla koreana Root, possesses anti-inflammatory and anti-tumor effect.
  • HY-146863
    Tubulin polymerization-IN-10

    		Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-10 is a potent tubulin polymerization inhibitor with an IC50 of 4.25±0.75 μM. Tubulin polymerization-IN-10 has anti-tumor effects.
  • HY-N2198
    Podocarpusflavone A

    		Topoisomerase Apoptosis Cancer
    Podocarpusflavone A is a DNA topoisomerase I inhibitor. Podocarpusflavone A has moderated anti-proliferative activity and induces cell apoptosis in MCF-7. Podocarpusflavone A is developing anti-tumor drugs.
  • HY-131096
    L-Proline 4-methoxy-β-naphthylamide hydrochloride

    H-Pro-4MβNA hydrochloride

    		 Others Cancer
    L-Proline 4-methoxy-β-naphthylamide hydrochloride (H-Pro-4MβNA hydrochloride) can be used for Fap-activated anti-tumor compounds preparaction.
  • HY-132995
    DP-1

    		Drug Metabolite Others
    DP-1, a degradation product of SDC-TRAP-0063, is a fragment of Ganetespib. Ganetespib is a heat shock protein 90 (HSP90) inhibitor with anti-tumor activity.
  • HY-18295
    Erteberel

    LY500307

    		 Estrogen Receptor/ERR Neurological Disease
    Erteberel (LY500307) is a potent and selective estrogen receptor beta (ERβ) agonist with Ki and EC50 of 1.54 nM and 3.61 nM, respectively. Anti-tumor activities.
  • HY-114277A
    Sotorasib racemate

    AMG-510 racemate

    		 Ras Cancer
    Sotorasib (AMG-510) racemate is the racemate of Sotorasib (AMG-510). AMG-510 is a potent, orally bioavailable, and selective KRAS G12C covalent inhibitor with anti-tumor activity.
  • HY-151443
    HDAC-IN-47

    		HDAC Cancer
    HDAC-IN-47 is an orally active inhibitor of histone deacetylase (HDAC), with IC50s of 19.75 nM (HDAC1), 5.63 nM (HDAC2), 40.27 nM (HDAC3), 57.8 nM (HDAC2), 302.73 nM (HDAC8), respectively. HDAC-IN-47 inhibits autophagy and induces apoptosis via the Bax/Bcl-2 and caspase-3 pathways. HDAC-IN-47 arrests cell cycle at G2/M phase, and shows anti-tumor efficacy in vivo.
  • HY-143246
    EGFR kinase inhibitor 1

    		EGFR Apoptosis Cancer
    EGFR kinase inhibitor 1 is a potent EGFR inhibitor with IC50s of 37, 1.7, >300 nM for WT, l885R/T790M, L858R/T790M/C797S, respectively. EGFR kinase inhibitor 1 induces apoptosis and cell cycle arrest at G0/G1-phase. EGFR kinase inhibitor 1 inhibits the cell motility. EGFR kinase inhibitor 1 shows antiproliferative and anti-tumor activity.
  • HY-17576
    Satraplatin

    BMS182751; BMY45594; JM216

    		 DNA Alkylator/Crosslinker Cancer
    Satraplatin is an alkylating agent, with potent antitumor effect.
  • HY-148150
    Cyclocreatine phosphate

    		Others Cancer
    Cyclocreatine phosphate is an anti-tumor agent. Cyclocreatine phosphate is the proposed active form of cyclocreatine (CCr), a substrate analogue of creatine kinase. Cyclocreatine phosphate has anti-tumour activity and can be used for the research of cancer.
  • HY-N3737
    Derrone

    		Aurora Kinase PERK Reactive Oxygen Species Cancer
    Derrone, a prenylated isoflavones, is an Aurora kinase inhibitor, with IC50 values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity.
  • HY-129180
    XY028-133

    		PROTACs CDK Cancer
    XY028-133 (example 14) is a PROTAC-based CDK4/6 degrader with anti-tumor activity, which consists of ligands for von Hippel-Lindau and CDK.
  • HY-109963
    PR5-LL-CM01

    		Histone Methyltransferase Cancer
    PR5-LL-CM01 is a potent protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50= 7.5 μM). Anti-tumor activies.
  • HY-N6958
    2-O-β-D-Glucopyranosyl-L-ascorbic acid

    AA-2βG

    		 Others Cancer Metabolic Disease
    2-O-β-D-Glucopyranosyl-L-ascorbic acid (AA-2βG), isolated from Lycium chinense, is a stable vitamin C analog with anti-tumor activity.
  • HY-B1436S1
    Nifuroxazide-13C6

    		STAT Bacterial Antibiotic Cancer Infection
    Nifuroxazide-13C6 is the 13C6 labeled Nifuroxazide. Nifuroxazide is an effective inhibitor of STAT3, also exerts potent anti-tumor and anti-metastasis activity.
  • HY-131088
    N3-PEG8-Phe-Lys-PABC-Gefitinib

    		Drug-Linker Conjugates for ADC Cancer
    N3-PEG8-Phe-Lys-PABC-Gefitinib is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC.
  • HY-101150A
    sulfo-DGN462 sodium

    		DNA Alkylator/Crosslinker ADC Cytotoxin Cancer
    sulfo-DGN462 sodium is degraded to DGN462 in culture medium and plasma. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML).
  • HY-16126
    Carboxyamidotriazole

    L-651582; CAI

    		 Calcium Channel Cancer Inflammation/Immunology
    Carboxyamidotriazole (L-651582) is a cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole shows anti-tumor, anti-inflammatory and antiangiogenic effects.
  • HY-129188
    CCT369260

    		Bcl-2 Family Cancer
    CCT369260 (compound 1) is an orally avtive B-cell lymphoma 6 (BCL6) inhibitor with anti-tumor activity. CCT369260 (compound 1) exhibits an IC50 of 520 nM.
  • HY-P1599
    Valorphin

    		Opioid Receptor Cancer Neurological Disease
    Valorphin is an endogenous hemoglobin β-chain (33-39) fragment with opioid analgesic activity, binds to rat mu-opioid receptor, with an IC50 of 14 nM; Valorphin also shows anti-tumor activity.
  • HY-N7994
    Hellebrigenol

    		Others Cancer
    Hellebrigenol is a metabolite of bufadienolides with antitumor activity.
  • HY-17574
    Thio-TEPA

    		DNA Alkylator/Crosslinker Bacterial Antibiotic Cancer Infection
    Thio-TEPA is a DNA alkylating agent, with antitumor activity.
  • HY-12202
    MEK inhibitor

    		MEK Cancer
    MEK inhibitor is a potent MEK inhibitor with antitumor potency.
  • HY-19791
    N-Acetyl-Calicheamicin

    N-Acetyl-Calicheamicin γ; N-Acetyl-γ-calicheamicin

    		 Bacterial Cancer Infection
    N-Acetyl-Calicheamicin is a potent enediyne antitumor antibiotic.
  • HY-N0865
    Ingenol

    (-)-Ingenol

    		 PKC Cancer
    Ingenol is a PKC activator, with a Ki of 30 μM, with antitumor activity.
  • HY-14821
    Namitecan

    ST-1968

    		 Topoisomerase Cancer
    Namitecan is a potent topoisomerase I inhibitor, with antitumor property.
  • HY-N10332
    Leptosphaerodione

    		Proteasome Cancer
    Leptosphaerodione, isolated from Remotididymella sp. Fungus, is a potent ubiquitin-proteasome system (UPS) inhibitor. Leptosphaerodione exhibits cytotoxicity in HeLa cells with IC50 value of 3.2 μM. Anti-tumor agent.
  • HY-107271
    Imperialine 3-β-D-glucoside

    		Others Cancer
    Imperialine 3-β-D-glucoside is the glycoside of Imperialine. Imperialine 3-β-D-glucoside may exhibit anti-tumor properties against multi-drug resistant tumor cells.
  • HY-122493
    Illudin M

    		DNA Alkylator/Crosslinker Apoptosis Cancer
    Illudin M is a cytotoxic fungal sesquiterpene that can be isolated from the culture medium of Omphalotus olearius mushrooms. Illudin M can alkylate DNA. Illudin M has anti-tumor activities.
  • HY-13603
    Crolibulin

    EPC2407

    		 Microtubule/Tubulin Apoptosis Cancer
    Crolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicity.
  • HY-N2490
    Dehydrotrametenolic acid

    		Caspase Apoptosis Cancer Inflammation/Immunology
    Dehydrotrametenolic acid is a sterol isolated from the sclerotium of Poria cocos. Dehydrotrametenolic acid induces apoptosis through caspase-3 pathway. Dehydrotrametenolic acid has anti-tumor activity, anti-inflammatory, anti-diabetic effects.
  • HY-101021
    Ascochlorin

    Ilicicolin D

    		 STAT Apoptosis Antibiotic Cancer Inflammation/Immunology
    Ascochlorin (Ilicicolin D), an isoprenoid antibiotic, mediates its anti-tumor effects predominantly through the suppression of STAT3 signaling cascade. Ascochlorin induces apoptosis. Anti-inflammatory activity.
  • HY-B2230
    Hinokitiol

    β-Thujaplicin

    		 Keap1-Nrf2 DNA Methyltransferase Virus Protease Cancer Infection
    Hinokitiol is a component of essential oils isolated from Chymacyparis obtusa, reduces Nrf2 expression, and decreases DNMT1 and UHRF1 mRNA and protein expression, with anti-infective, anti-oxidative, and anti-tumor activities.
  • HY-10529
    Betulinic acid

    Lupatic acid; Betulic acid

    		 Apoptosis Topoisomerase HIV Autophagy Mitophagy NF-κB Endogenous Metabolite Parasite Cancer Infection Inflammation/Immunology
    Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic topoisomerase I inhibitor, with an IC50 of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties.
  • HY-N0103A
    Sophocarpine monohydrate

    		Autophagy Apoptosis PI3K Akt Influenza Virus Cancer Infection Inflammation/Immunology
    Sophocarpine (monohydrate) is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory. Sophocarpine (monohydrate) significantly inhibits the growth of gastric cancer (GC) cells through multiple mechanisms such as induction of autophagy, activation of cell apoptosis and down-regulation of cell survival PI3K/AKT signaling pathway. Sophocarpine (monohydrate) has been demonstrated to have anti-tumor activity in various cancer cells, including hepatocellular carcinoma, prostate cancer and colorectal cancer.
  • HY-N0103
    Sophocarpine

    		Autophagy Apoptosis PI3K Akt Influenza Virus Cancer Infection Inflammation/Immunology
    Sophocarpine is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory. Sophocarpine significantly inhibits the growth of gastric cancer (GC) cells through multiple mechanisms such as induction of autophagy, activation of cell apoptosis and down-regulation of cell survival PI3K/AKT signaling pathway. Sophocarpine has been demonstrated to have anti-tumor activity in various cancer cells, including hepatocellular carcinoma, prostate cancer and colorectal cancer.
  • HY-101566A
    Elimusertib hydrochloride

    BAY 1895344 hydrochloride

    		 ATM/ATR Cancer
    Elimusertib (BAY 1895344) hydrochloride is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib hydrochloride has anti-tumor activity. Elimusertib hydrochloride can be used for the research of solid tumors and lymphomas.
  • HY-12628
    GNE-618

    		NAMPT Cancer
    GNE-618 is a potent, orally active nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with an IC50 of 6 nM. GNE-618 depletes NAD levels and induces tumor cell death. Anti-tumor activity.
  • HY-135145
    CB-103

    		Notch Cancer
    CB-103 is a first-in-class, orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex. CB-103 has anti-tumor activity.
  • HY-N6990
    Anhydrosecoisolariciresinol

    		Others Cancer
    Anhydrosecoisolariciresinol is from the flower of Wedelia biflora, has anti-tumor activities. Anhydrosecoisolariciresinol decreases the growth of human breast cancer MCF-7 and MDA-MB-231 cell lines.
  • HY-N0250
    Saikosaponin D

    		STAT NF-κB Estrogen Receptor/ERR Bacterial Cancer Infection Inflammation/Immunology
    Saikosaponin D is a triterpene saponin isolated from Bupleurum, with anti-inflammatory, anti-bacterial, anti-tumor, and anti-allergic activities; Saikosaponin D inhibits selectin, STAT3 and NF-kB and activates estrogen receptor-β.
  • HY-N2357
    Eudesmin

    (-)-Eudesmin; Eudesmine; (-)-Eudesmine

    		 Ribosomal S6 Kinase (RSK) Cancer Infection Metabolic Disease Inflammation/Immunology
    Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.
  • HY-N0405
    Orientin

    		Others Cancer Neurological Disease
    Orientin is a naturally occurring bioactive flavonoid that possesses diverse biological properties, including anti-inflammation, anti-oxidative, anti-tumor, and cardio protection. Orientin is a promising neuroprotective agent suitable for therapy for neuropathic pain.
  • HY-111192
    IPR-803

    		Ser/Thr Protease Cancer
    IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction (PPI). IPR-803 binds directly to uPAR with sub-micromolar affinity. IPR-803 displays anti-tumor activity.
  • HY-P1404
    R8-T198wt

    		Pim Cancer
    R8-T198wt is a cell-permeable carboxyl-terminal p27 Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.
  • HY-108472
    Loxoribine

    7-Allyl-8-oxoguanosine; RWJ 21757

    		 Toll-like Receptor (TLR) Influenza Virus Cancer Infection
    Loxoribine (7-Allyl-8-oxoguanosine) is a guanosine analog with anti-viral and anti-tumor activities. Loxoribine is an orally bioavailable and selective Toll-like receptor (TLR) 7 agonist.
  • HY-101566
    Elimusertib

    BAY 1895344

    		 ATM/ATR Cancer
    Elimusertib (BAY-1895344) is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib has anti-tumor activity. Elimusertib can be used for the research of solid tumors and lymphomas.
  • HY-N1984
    Artemisic acid

    Qing Hao acid; Artemisinic acid; Arteannuic acid

    		 Bacterial Cancer Infection Metabolic Disease Inflammation/Immunology
    Artemisinic acid (Qing Hao acid), an amorphane sesquiterpene isolated from Artemisia annua L., possesses a variety of pharmacological activity, such as antimalarial activity, anti-tumor activity, antipyretic effect, antibacterial activity, allelopathy effect and anti-adipogenesis effect.
  • HY-U00447
    PK11000

    		MDM-2/p53 DNA Alkylator/Crosslinker Cancer
    PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 proteins by covalent cysteine modification without compromising DNA binding. PK11000 has anti-tumor activities.
  • HY-100763
    Mcl1-IN-12

    		Bcl-2 Family Cancer
    Mcl1-IN-12 (Compound F) is a selective Mcl-1 inhibitor, less potent at Bcl-2, with Kis of 0.29 and 3.1 μM, respectively. Anti-tumor activity.
  • HY-150782
    UNC-CA359

    		EGFR Cancer
    UNC-CA359 is a potent epidermal growth factor receptor (EGFR) inhibitor, with an IC50 value of 18 nM. UNC-CA359 exhibits strong anti-tumor activity, can be used to Chordoma research.
  • HY-P1687
    Siomycin A

    		Bacterial Apoptosis Cancer
    Siomycin A is a thiopeptide antibiotic and is a Forkhead box M1(FOXM1) selective inhibitor without affecting other members of the Forkhead box family. Siomycin A has anti-tumor and promotes apoptosis.
  • HY-143256
    Enpp-1-IN-12

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-12 (compound 43) is a potent and orally active ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor, with a Ki of 41 nM. Enpp-1-IN-12 exhibits anti-tumor activity.
  • HY-N2135
    Puerarin 6''-O-Xyloside

    		Apoptosis Cancer Inflammation/Immunology
    Puerarin 6''-O-Xyloside, isolated from radix of Pueraria lobata (Willd.), possesses snti-osteoporotic and anti-tumor activity. Puerarin 6''-O-Xyloside induces the mitochondria-mediated apoptosis pathway..
  • HY-100846
    JQEZ5

    		Histone Methyltransferase Cancer
    JQEZ5 is a potent and selective EZH2 lysine methyltransferase inhibitor. JQEZ5 SAM-competitive inhibition of polycomb repressive complex 2 (PRC2) with an IC50 of 80 nM. JQEZ5 has anti-tumor effects.
  • HY-P3707
    Tumor targeted pro-apoptotic peptide

    		Apoptosis Cancer
    Tumor targeted pro-apoptotic peptide (CNGRC-GG-D(KLAKLAK)2) is an anti-tumor peptide. Tumor targeted pro-apoptotic peptide disrupts mitochondrial membranes and promotes apoptosis, showing anticancer activity in mice.
  • HY-136065
    bpV(phen)

    		PTEN Phosphatase Parasite Apoptosis Cancer Infection Metabolic Disease Inflammation/Immunology
    bpV(phen), a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC50s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity.
  • HY-N1366
    Herniarin

    7-Methoxycoumarin; Methyl umbelliferyl ether

    		 Others Cancer
    Herniarin is a natural coumarin occurs in some flowering plants, with antitumor effect.
  • HY-136486
    Lasiocarpine N-oxide

    		Others Cancer
    Lasiocarpine N-oxide is a natural compound with antitumor activity.
  • HY-13669
    Lomustine

    CCNU; NSC 79037

    		 DNA Alkylator/Crosslinker Autophagy Apoptosis Cancer
    Lomustine (CCNU; NSC 79037) is a DNA alkylating agent, with antitumor activity.
  • HY-101604
    Atrimustine

    Bestrabucil; KM2210

    		 Others Cancer
    Atrimustine is a conjugate of chlorambucil and β-estradiol benzoate with the antitumor activity.
  • HY-N7685
    Podophyllol

    		Others Cancer
    Podophyllol, a derivative of podophyllotoxin esters, has antitumor activity.
  • HY-14798
    Palifosfamide

    Isophosphoramide mustard; IPM; ZIO-201

    		 DNA Alkylator/Crosslinker Drug Metabolite Cancer
    Palifosfamide is a novel DNA alkylator and the active metabolite of ifosfamide, with antitumor activity.
  • HY-13585
    Carmustine

    		DNA Alkylator/Crosslinker Cancer
    Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA.
  • HY-N2420
    Flavokawain A

    		Apoptosis Cancer
    Flavokawain A, a proming anticarcinogenic agent, is a chalcone from kava extract with anti-tumor activity. Flavokawain A induces cell apoptosis by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway. Flavokawain A has the potential for the study of bladder cancer.
  • HY-N1333
    Rubioncolin C

    		NF-κB Cancer
    Rubioncolin C exerts anti-tumor activity by inducing apoptotic and autophagic Cell Death and inhibiting the NF-κB and Akt/mTOR/P70S6K Pathway in Human Cancer Cells.
  • HY-124711
    TBOPP

    		Others Cancer
    TBOPP is a selective inhibitor of DOCK1 with an IC50 of 8.4 μM. TBOPP binds to the DOCK1 DHR-2 domain with high affinity (Kd of 7.1 μM), has anti-tumor activity for broader types of tumors.
  • HY-107981
    LSN 3213128

    		Antifolate Cancer
    LSN 3213128 is a selective, nonclassical, orally bioavailable antifolate with potent and specific inhibitory activity for aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFT), with IC50 of 16 nM for AICARFT enzyme inhibiton and 19 nM in cells. Anti-tumor activity.
  • HY-129055
    Isoeleutherin

    		Fungal Inflammation/Immunology
    Isoeleutherin is a naphthopyran derivative isolated from E. americana Merr. Et Heyne with anti-fungal, anti-viral, and anti-tumor activities. Isoeleutherin plays an important role in selective modulation of T helper cell-mediated immune responses.
  • HY-112607
    Tubulin inhibitor 1

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin inhibitor 1 is a tubulin inhibitor, inhibits tubulin polymerization. Tubulin inhibitor 1 shows potent anti-tumor activity, casues cellular mitotic arrest in the G2/M phase, and induces cellular apoptosis.
  • HY-N7046
    Silybin B

    		Amyloid-β Cancer Neurological Disease
    Silybin B, a flavonolignan separated from Silybum marianum, has anti-tumor activity. Silybin B is the most potent antifibrillogenic and anti-oligomeric component of silymarin and proposes it as a promising anti Alzheimer’s disease drug candidate.
  • HY-128920
    Phortress free base

    		Cytochrome P450 Cancer
    Phortress free base (NSC 710305) is a P450 CYP1A1-activated antitumor prodrug with antitumor activity. Phortress free base leads to DNA damage and cell cycle arrest.
  • HY-100219
    CB1151

    		VD/VDR Cancer
    CB1151 is a 20-epi analogue of 1,25 dihydroxyvitamin D3 (VD) with potent anti-tumor effects. CB1151 inhibits MCF-7 cell growth with an IC50 value of 0.82 nM.
  • HY-147322
    YAP/TAZ inhibitor-2

    		YAP Cancer
    YAP/TAZ inhibitor-2 is a potent and orally active TEAD-YAP/TAZ inhibitor with an EC50 value of 3 nM. YAP/TAZ inhibitor-2 shows anti-proliferative activity. YAP/TAZ inhibitor-2 shows antitumor activity.
  • HY-N4121
    Isocurcumenol

    		Estrogen Receptor/ERR Apoptosis Cancer
    Isocurcumenol, an estrogen receptor alpha (ERα) inhibitor isolated from Curcuma zedoaria Rhizomes, possesses anti-tumor acticity, with IC50 values of 99.1µg/mL and 178.2 µg/mL in DLA and KB cells, respectively.
  • HY-N2463
    Kushenol E

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    Kushenol E is a class of flavonoids isolated from Sophora flavescens and is a non-competitive indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an IC50 of 7.7 µM and a Ki of 9.5 µM, has anti-tumor activity.
  • HY-N6674
    Diazepinomicin

    ECO-4601; TLN-4601; BU 4664L

    		 Ras Apoptosis Cancer
    Diazepinomicin (TLN-4601) is a secondary metabolite produced by Micromonospora sp. Diazepinomicin (TLN-4601) inhibits the EGF-induced Ras-ERK MAPK signaling pathway and induces apoptosis. An anti-tumor agent for K-Ras mutant models.
  • HY-128766
    CHK1-IN-4

    		Checkpoint Kinase (Chk) Cancer
    CHK1-IN-4 (Compound 3) is a potent checkpoint kinase 1 (chk1) inhibitor, and potently inhibits chk1 phosphorylation in the tumor cells. CHK1-IN-4 has anti-tumor activity.
  • HY-131704
    FGFR4-IN-5

    		FGFR Cancer
    FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research.
  • HY-N6884
    Bixin

    		Reactive Oxygen Species Cancer Inflammation/Immunology Cardiovascular Disease
    Bixin (BX), isolated from the seeds of Bixa orellana, is a carotenoid, possessing anti-inflammatory, anti-tumor and anti-oxidant activities. Bixin treatment ameliorated cardiac dysfunction through inhibiting fibrosis, inflammation and reactive oxygen species (ROS) generation.
  • HY-145034
    KIF18A-IN-1

    		Microtubule/Tubulin Cancer Inflammation/Immunology
    KIF18A-IN-1 is a mitotic kinesin KIF18A inhibitor extracted from patent WO2021026098A1 example 100-13. KIF18A-IN-1 exhibits anti-tumor activity.
  • HY-N2995
    Poricoic acid A

    Poricoic acid A(F)

    		 NF-κB Keap1-Nrf2 Cancer
    Poricoic acid A, isolated from Poria cocos, possesses anti-tumor activity. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis.
  • HY-19542
    C6 Ceramide

    C6-Cer; N-Hexanoylsphingosine

    		 Apoptosis Cancer
    C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects.
  • HY-17411
    Limonin

    Limonoic acid 3,19:16,17 dilactone

    		 HIV Apoptosis Endogenous Metabolite Infection Cancer
    Limonin is a triterpenoid enriched in citrus fruits, which has antivirus and antitumor ability.
  • HY-32364
    3-arylisoquinolinamine derivative

    		Others Cancer
    3-arylisoquinolinamine derivative is a 3-arylisoquinolinamine derivative with antitumor activity.
  • HY-13644A
    Gusperimus trihydrochloride

    Spanidin; NKT-01; BMS181173

    		 Antibiotic Cancer Inflammation/Immunology
    Gusperimus trihydrochloride (Spanidin) is a derivative of the antitumor antibiotic spergualin with immunosuppressant activity.
  • HY-B1960
    Canthaxanthin

    E 161g; all-trans-Canthaxanthin

    		 Reactive Oxygen Species Endogenous Metabolite Cancer Inflammation/Immunology
    Canthaxanthin is a red-orange carotenoid with various biological activities, such as antioxidant, antitumor properties.
  • HY-N0827
    Perillene

    		Bacterial Cancer Infection
    Perillene is a component of the essential oil, has antibacterial and antitumor effects.
  • HY-10940
    Pifithrin-μ

    PFTμ; 2-Phenylethynesulfonamide

    		 MDM-2/p53 HSP Autophagy Cancer Neurological Disease
    Pifithrin-μ is an inhibitor of p53 and HSP70, with antitumor and neuroprotective activity.
  • HY-N4304
    Gambogellic acid

    		Others Cancer
    Gambogellic acid is an xanthone isolated from the processed gamboge, with antitumor activity.
  • HY-N2040
    (20R)-Protopanaxadiol

    		Bacterial Cancer Infection
    (20R)-Protopanaxadiol is a triterpenoid saponin metabolite of 20(R)-ginsenoside Rg3 in black ginseng. (20R)-Protopanaxadiol exhibits anti-tumor activity and cytotoxicity, and potently inhibits the growth of Helicobacter pylori.
  • HY-144793
    Deac-SS-Biotin

    		Others Cancer
    Deac-SS-Biotin is a potent antitumor agent. Deac-SS-Biotin uptakes into the cells through biotin-mediated internalization. Deac-SS-Biotin combined with DTT (Glutathione mimetic) can effectively inhibit microtubule assembly and displays greater antitumor activity.
  • HY-130518
    AS-0141

    Cdc7-IN-6

    		 CDK Cancer
    AS-0141 (Cdc7-IN-6) is a potent Cdc7 kinase inhibitor (IC50=4 nM), extracted from patent WO2019165473A1, compound I- D, has anti-tumor activity.
  • HY-135967
    MTH1-IN-2

    		DNA/RNA Synthesis Cancer
    MTH1-IN-2 is a MutT homolog 1 (MTH1) inhibitor extracted from patent WO2016135138A1, Compound (6), MTH1-IN-2 can be used for the research of cancer. Anti-tumor activity.
  • HY-P1728
    Super-TDU (1-31)

    		YAP Cancer
    Super-TDU (1-31) is a peptide fragment of Super-TDU. Super-TDU (1-31) is an inhibitor of YAP-TEAD complex. Super-TDU shows potent anti-tumor activity and suppresses tumor growth in gastric cancer mouse model.
  • HY-N0222
    Avicularin

    		COX NF-κB PPAR ERK GLUT Apoptosis Cancer Infection Inflammation/Immunology Neurological Disease
    Avicularin is an orally active flavonoid. Avicularin inhibits NF-κB (p65), COX-2 and PPAR-γ activities. Avicularin has anti-inflammatory, anti-infectious anti-allergic, anti-oxidant, hepatoprotective, and anti-tumor activities.
  • HY-124036
    DS-7423

    		PI3K mTOR Cancer
    DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity.
  • HY-106381
    Aurothiomalate sodium

    		PKC Cancer Inflammation/Immunology
    Aurothiomalate sodium is a potent and selective oncogenic PKCι signaling inhibitor. Aurothiomalate sodium inhibits tumor cell proliferation and not cell apoptosis. Aurothiomalate sodium is a potent thioredoxin reductase (TrxR) inhibitor. Aurothiomalate sodium, an anti-rheumatoid agent, exhibits potent anti-tumor activity.
  • HY-N0004
    Oridonin

    NSC-250682; Isodonol

    		 Akt Bacterial Cancer Infection Inflammation/Immunology
    Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.
  • HY-N0211
    Cyasterone

    		EGFR Apoptosis Cancer
    Cyasterone, a natural EGFR inhibitor, mainly isolated from Ajuga decumbens Thunb (Labiatae). Cyasterone manifests anti-proliferation effect by induced apoptosis and cell cycle arrests. Cyasterone may serves as a therapeutic anti-tumor agent against human tumors.
  • HY-125286
    AB-680

    		CD73 Cancer
    AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.
  • HY-129179
    Lisaftoclax

    APG-2575; Bcl-2/Bcl-xl inhibitor 1

    		 Bcl-2 Family Cancer
    Lisaftoclax (compound 6) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively.
  • HY-144064
    Adenosine receptor antagonist 2

    		Adenosine Receptor Cancer
    Adenosine receptor antagonist 2 is an orally active A2a/A2b adenosine receptor antagonist with IC50s of 1 nM and 3 nM, respectively. Adenosine receptor antagonist 2 has anti-tumor activity.
  • HY-P99217
    Rilotumumab

    AMG 102

    		 c-Met/HGFR Cancer
    Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.
  • HY-147570
    ATR-IN-18

    		ATM/ATR Cancer
    ATR-IN-18 (compound 2) is an orally active and potent ATR kinase inhibitor, with an IC50 of 0.69 nM. ATR-IN-18 shows antiproliferative activity in LoVo cells, with an IC50 of 37.34 nM. ATR-IN-18 has anti-tumor activity.
  • HY-151137
    HSP90/mTOR-IN-1

    		mTOR HSP Apoptosis Autophagy Cancer
    HSP90/mTOR-IN-1 is a potent and orally active Hsp90 and mTOR inhibitor with IC50 values of 69 nM and 29 nM, respectively. HSP90/mTOR-IN-1 suppresses the proliferation of SW780 cells through the over-activation of the PI3K/AKT/mTOR pathway. HSP90/mTOR-IN-1 induces apoptosis and autophagy via selective Hsp90 and mTOR inhibition. HSP90/mTOR-IN-1 also has considerable in vivo anti-tumor activity. HSP90/mTOR-IN-1 can be used for researching bladder cancer.
  • HY-115677
    ILK-IN-3

    		Integrin Cancer
    ILK-IN-3 is an integrin linked kinase inhibitor with antitumor activity.
  • HY-112570
    CC-90003

    		ERK Cancer
    CC-90003 is an irreversible and selective inhibitor of ERK 1/2 with antitumor activity.
  • HY-N0351
    p-Coumaric acid

    trans-4-Hydroxycinnamic acid

    		 Endogenous Metabolite Cancer
    p-Coumaric acid is the abundant isomer of cinnamic acid which has antitumor and anti-mutagenic activities.
  • HY-W012352
    2-Hydroxyanthraquinone

    		Others Cancer
    2-Hydroxyanthraquinone, a natural compound, possesses antitumor and immunosuppressive activity.
  • HY-N4257
    Yadanzioside A

    		Others Cancer
    Yadanziolide A, a quassinoid glycoside from Brucea javanica, has antitumor activity.
  • HY-16568
    Irinotecan hydrochloride trihydrate

    (+)-Irinotecan hydrochloride trihydrate; CPT-11 hydrochloride trihydrate

    		 Topoisomerase Autophagy Cancer
    Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity.
  • HY-N6623
    Malvidin-3-galactoside chloride

    		Apoptosis Endogenous Metabolite Reactive Oxygen Species Cancer
    Malvidin-3-galactoside chloride, an anthocyanin monomer, induces hepatocellular carcinoma (HCC) cells cycle arrest and apoptosis. Malvidin-3-galactoside chloride inhibits the production and accumulation of ROS. Malvidin-3-galactoside chloride has anti-tumor function.
  • HY-122312
    BAY-8002

    		Monocarboxylate Transporter Cancer
    BAY-8002 is a potent, selective, orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM in the MCT1-expressing DLD-1 cells, displays excellent selectivity against MCT4. Anti-tumor activity.
  • HY-143280
    Topoisomerase II inhibitor 4

    		Topoisomerase Cancer
    Topoisomerase II inhibitor 4 (compound E17) is a potent Topoisomerase II inhibitor. Topoisomerase II inhibitor 4 triggers G2/M cell cycle arrest and shows anti-tumor activity with strong cytotoxic and anti-proliferative effect.
  • HY-112642
    9-Methoxycanthin-6-one

    		Others Cancer
    9-Methoxycanthin-6-one, a canthin-6-one alkaloid, is present in intact plant parts and in callus tissues of different explants. 9-Methoxycanthin-6-one shows anti-tumor activity.
  • HY-151508
    Diamino lipid DAL4

    		Others Cancer
    Diamino lipid DAL4 is novel lipid nanoparticles (LNPs) encapsulated with mRNAs encoding cytokines including IL-12, IL-27 and GM-CSF. Diamino lipid DAL4 delivers mRNA to tumor cells to exert anti-tumor activity.
  • HY-100492
    Fisogatinib

    BLU-554

    		 FGFR Cancer
    Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling.
  • HY-128587
    Mevociclib

    SY-1365

    		 CDK Cancer
    Mevociclib (SY-1365) is a potent and first-in-class selective CDK7 inhibitor, with a Ki of 17.4 nM. Mevociclib exhibits anti-proliferative and apoptotic effects in solid tumor cell lines. Mevociclib possesses anti-tumor activity in hematological and multiple aggressive solid tumors.
  • HY-P1728A
    Super-TDU (1-31) (TFA)

    		YAP Cancer
    Super-TDU (1-31) TFA is a peptide fragment of Super-TDU. Super-TDU (1-31) TFA is an inhibitor of YAP-TEAD complex. Super-TDU TFA shows potent anti-tumor activity and suppresses tumor growth in gastric cancer mouse model.
  • HY-100544
    FLLL32

    		STAT JAK Apoptosis Cancer
    FLLL32, a synthetic analog of curcumina, is a JAK2/STAT3 dual inhibitor with anti-tumor activity. FLLL32 can inhibit the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.
  • HY-N1231
    Sophoraflavanone G

    Kushenol F

    		 Apoptosis Cancer
    Sophoraflavanone G (Kushenol F) is iaolated from Sophora flavescens and shows anti-tumor and anti-inflammatory properties.  Sophoraflavanone G (Kushenol F) induces MDA-MB-231 and HL-60 cells apoptosis through suppression of MAPK-related pathways.
  • HY-16513
    VAL-083

    Dianhydrodulcitol; Dianhydrogalactitol

    		 DNA Alkylator/Crosslinker Cancer
    VAL-083 is an alkylating agent that creates N7 methylation on DNA, with antitumor activity.
  • HY-N1944
    Nerolidol

    		Bacterial Fungal Parasite Endogenous Metabolite Cancer Infection
    Nerolidol is a natural membrane-active sesquiterpene, with antitumor, antibacterial, antifungal and antiparasitic activity.
  • HY-147359
    Boanmycin

    		Antibiotic Apoptosis Cancer
    Boanmycin is an antibiotic with antitumor activity that induces cellular senescence and apoptosis.
  • HY-100453
    HO-3867

    		STAT Apoptosis Cancer
    HO-3867 is a selective and potent STAT3 inhibitor and shows good antitumor activity.
  • HY-100033
    NSC5844

    RE-640

    		 Parasite Cancer Infection
    NSC5844 (RE-640) is a 4-aminoquinoline derivative, with antitumor and antimalarial activity.
  • HY-N0123
    Aloin

    Aloin-A; Barbaloin-A

    		 Others Cancer
    Aloin(Aloin-A; Barbaloin-A) is a natural antitumor anthraquinone glycoside with iron chelating and non-atherogenic activities.
  • HY-111411
    IZCZ-3

    		c-Myc Autophagy Cancer
    IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity.
  • HY-N0368
    Linalool

    		iGluR Apoptosis Endogenous Metabolite Cancer Cardiovascular Disease
    Linalool is natural monoterpene in essential olis of coriander, acts as a competitive antagonist of Nmethyl d-aspartate (NMDA) receptor, with anti-tumor, anti-cardiotoxicity activity.Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome.
  • HY-131194
    JAK2/STAT3-IN-1

    		Interleukin Related Cancer
    JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC50 of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity.
  • HY-16059
    Arglabin

    (+)-Arglabin

    		 NOD-like Receptor (NLR) Farnesyl Transferase Autophagy Cancer Inflammation/Immunology
    Arglabin ((+)-Arglabin), a natural product isolated from Artemisia glabella, is a NLRP3 inflammasome inhibitor. Arglabin shows anti-inflammatory and antitumor activities. The antitumor activity of Arglabin proceeds through its inhibition of farnesyl transferase which leads to the activation of RAS proto-oncogene.
  • HY-N7507
    Sempervirine

    		Others Cancer
    Sempervirine is an indole alkaloid isolated from Gelsemium sempervirens with anti-tumor activities. Sempervirine is against sempervirine-sensitive tumor cells with EC50 values of 2.7 μM, 1.77 μM, and 1.96 μM for Raji, MDA-MB-231 and HeLa cells, respectively.
  • HY-126297
    c-Fms-IN-10

    		c-Fms Cancer Inflammation/Immunology
    c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC50 of 2 nM. c-Fms-IN-10 has anti-tumor activity.
  • HY-135147
    ONC206

    		Dopamine Receptor Cancer Neurological Disease
    ONC206 is an analogue of TRAIL inducer ONC201. ONC206 is a selective antagonist of the D2-like dopamine receptors (DRD2/3/4) at nanomolar concentrations. ONC206 has broad-spectrum anti-tumor activity.
  • HY-150613
    PARP1/BRD4-IN-2

    		Epigenetic Reader Domain PARP Apoptosis Cancer
    PARP1/BRD4-IN-2 is a potent and selective PARP1 and BRD4 inhibitor with IC50 values of 197 nM and 238 nM, respectively. PARP1/BRD4-IN-2 inhibits DNA damage repair, arrests G0/G1 transition and induces apoptosis. PARP1/BRD4-IN-2 has anti-tumor activity in MDA-MB-468 xenograft mouse model. PARP1/BRD4-IN-2 can be used for researching triple-negative breast cancer (TNBC).
  • HY-N0289
    Lycorine hydrochloride

    		Autophagy Bacterial Virus Protease Cancer Inflammation/Immunology
    Lycorine hydrochloride is the main active ingredient of the herbal medicine derived from Lycoris radiata (L’Her.) Herb. and is also a melanoma vasculogenic inhibitor and has anti-tumor activity. Lycorine hydrochloride effectively inhibits mitotic proliferation of Hey1B cells (IC50 of 1.2 μM).
  • HY-P2316
    Epinecidin-1 TFA

    		Bacterial Antibiotic Infection
    Epinecidin-1 TFA is a multi-functional antimicrobial peptide (AMP) from Orange-spotted grouper (Epinephelus coioides). Epinecidin-1 TFA has antibacterial, antifungal, antiviral, anti-tumor, and immunomodulatory effects. Epinecidin-1 TFA has the potential to be an alternative for current antibiotics.
  • HY-N10447
    Kurzipene D

    		Apoptosis Cancer
    Kurzipene D (compound 4) is a potent anticancer agent. Kurzipene D induces the apoptosis and arrested the HepG2 cell cycle at S stage. Kurzipene D shows anti-tumor effects using in vivo zebrafish model. Kurzipene D has the property of inhibiting tumor proliferation and migration.
  • HY-N0462
    Corilagin

    		Reverse Transcriptase Bacterial Cancer Infection Inflammation/Immunology
    Corilagin, a gallotannin, inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows good anti-tumor activity on hepatocellular carcinoma and ovarian cancer. Corilagin shows a low level of toxicity toward normal cells and tissues.
  • HY-16590
    X-376

    		Anaplastic lymphoma kinase (ALK) c-Met/HGFR Cancer
    X-376 is a potent and highly specific ALK tyrosine kinase inhibitor (TKI) (IC50=0.61 nM). X-376 is a less potent inhibitor of MET (IC50=0.69 nM). X-376 displays potent anti-tumor activity.
  • HY-N5020
    Carabrone

    		Bacterial Infection
    Carabrone is isolated from the fruits of Carpesium abrotanoides , is a well-known sesquiterpene and exhibits significant anti-bacterial and anti-tumor activities. Carabrone exhibits antifungal activities in vitro and in vivo against Botrytis cinerea, Colletotrichum lagenarium(EC50=7.10 μg/mL) and Erysiphe graminis.
  • HY-N7422
    Kauran-16,17-diol

    ent-Kauran-16β,17-diol

    		 Apoptosis Cancer Inflammation/Immunology
    Kauran-16,17-diol (ent-Kauran-16β,17-diol), a natural diterpene, posseses anti-tumor and inducing-apoptosis activity, with a IC50 of 17 μM on inhibiting NO production in LPS-stimulated RAW 264.7 macrophages.
  • HY-117244
    AZD7507

    		c-Fms Cancer
    AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.
  • HY-143659
    QW30

    		Others Cancer
    QW30 (Compound 19) shows potent antitumor activity with an IC50 value of 0.33 μM.
  • HY-N8038
    Isoanthricin

    (Rac)-Deoxypodophyllotoxin

    		 Others Others
    Isoanthricin ((Rac)-Deoxypodophyllotoxin) is the racemate of Deoxypodophyllotoxin. Deoxypodophyllotoxin is a potent antitumor and anti-inflammatory agent.
  • HY-N7595
    Microhelenin C

    		Others Cancer
    Microhelenin C is a sesquiterpene lactone that can be isolated from Helenium microcephalum, with antitumor activity.
  • HY-14944
    Homoharringtonine

    Omacetaxine mepesuccinate; HHT

    		 STAT Cancer
    Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting translation elongation.
  • HY-124916
    Lycopsamine

    		Others Cancer
    Lycopsamine, a pyrrolizidine alkaloid, is a potential antitumor agent isolated from Eupatorium maculatum L..
  • HY-17565A
    Bleomycin hydrochloride

    		DNA/RNA Synthesis Antibiotic Cancer
    Bleomycin hydrochloride is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin hydrochloride is an antitumor antibiotic.
  • HY-N3125
    Osajin

    CID 95168; NSC 21565

    		 Apoptosis Cancer Metabolic Disease Inflammation/Immunology Cardiovascular Disease
    Osajin is the major bioactive isoflavone present in the fruit of Maclura pomifera with antitumor, antioxidant and anti-inflammatory activities.
  • HY-101275
    EMT inhibitor-1

    		Hippo (MST) TGF-beta/Smad Wnt Cancer
    EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities.
  • HY-10818
    LY309887

    		Antifolate Cancer
    LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), with a Ki of 6.5 nM, and has antitumor activity.
  • HY-144028
    Pan-Trk-IN-2

    		Trk Receptor Cancer
    Compound cpd-1 is a small molecule Trks inhibitor with good antitumor activity.
  • HY-139570
    Ecubectedin

    		Bacterial Infection Inflammation/Immunology
    Ecubectedin is a derivative. Ecteinascidins is a family of tetrahydroisoquinoline alkaloids with wide range of antitumor and antimicrobial activities.
  • HY-N10174
    Tomaymycin

    		Antibiotic Infection
    Tomaymycin is an antitumor antibiotic. Tomaymycin has antimicrobial activity against Grampositive bacteria.
  • HY-N0189
    Aloe emodin

    Rhabarberone; 3-Hydroxymethylchrysazine

    		 Autophagy Cancer
    Aloe emodin is a hydroxyanthraquinone present in Aloe vera leaves, has a specific in vitro and in vivo antitumor activity.
  • HY-N1517
    Ganoderic acid C2

    		Others Cancer
    Ganoderic acid C2 is a bioactive triterpenoid in Ganoderma lucidum. Ganoderic acid C2 possesses the potential anti-tumor bioactivity, antihistamine, anti-aging and cytotoxic effects. Ganoderic acid C2 exhibits high inhibitory activity against the rat lens aldose reductase (RLAR) with an IC50 of 3.8 µM.
  • HY-N9398
    3β,6α,12β-Dammar-E-20(22)-ene-3,6,12,25-tetraol

    		Sirtuin Cancer
    3β,6α,12β-Dammar-E-20(22)-ene-3,6,12,25-tetraol, a SIRT1 activator, exhibits significant stimulation of SIRT1 activity. Anti-tumor activity.
  • HY-115400
    1V209

    TLR7 agonist T7

    		 Toll-like Receptor (TLR) Cancer
    1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity.
  • HY-W009156
    Hydroxycitric acid tripotassium hydrate

    Potassium citrate monohydrate

    		 ATP Citrate Lyase HIF/HIF Prolyl-Hydroxylase Bacterial Endogenous Metabolite Cancer Infection Metabolic Disease Inflammation/Immunology
    Hydroxycitric acid tripotassium hydrate (Potassium citrate monohydrate) is the major active ingredient of Garcinia cambogia. Hydroxycitric acid tripotassium hydrate competitively inhibits ATP citrate lyase with weight loss benefits. Hydroxycitric acid tripotassium hydrate effective inhibits stones formation and also inhibits HIF, and has antioxidation, anti-inflammation and anti-tumor effects.
  • HY-119272
    EF24

    		ERK Caspase Cancer
    EF24 is a curcumin analogue with greater anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK.
  • HY-147368
    PKM2 activator 2

    		Pyruvate Kinase Cancer
    PKM2 activator 2 is a pyruvate kinase M2 (PKM2) activitor with an AC50 value of 66 nM. PKM2 activator 2 may show anti-tumor proliferation effect and relieve the Warburg effect, while PKM2 activation can restore normal glycolytic metabolism in cells.
  • HY-N0790
    Lupeol

    Clerodol; Monogynol B; Fagarasterol

    		 Androgen Receptor Apoptosis Cancer
    Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen receptor (AR) inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC).
  • HY-N0662
    Amentoflavone

    Didemethyl-ginkgetin

    		 Reactive Oxygen Species Apoptosis Bacterial Fungal RSV GABA Receptor Cancer Infection Inflammation/Immunology Neurological Disease
    Amentoflavone (Didemethyl-ginkgetin) is a potent and orally active GABA(A) negative modulator. Amentoflavone also shows anti-inflammatory, antioxidative, anti-viral, anti-tumor, anti-radiation, anti-fungal, antibacterial activity. Amentoflavone induces apoptosis and cell cycle arrest at sub-G1 phase.
  • HY-129467S
    (Rac)-Idroxioleic acid-d17

    2-Hydroxyoleic acid-d17; 2-OHOA-d17

    		 Apoptosis Cancer
    (Rac)-Idroxioleic acid-d17 (2-Hydroxyoleic acid-d17) is the deuterium labeled (Rac)-Idroxioleic acid. (Rac)-Idroxioleic acid (2-Hydroxyoleic acid) is a synthetic oleic acid (OA) derivative that binds to the plasma membrane and alters lipid organization. (Rac)-Idroxioleic acid has anti-tumor effect.
  • HY-106218
    Flurocitabine

    5-Fluorocyclocytidine; 5'-Fluorocyclocytidine

    		 Nucleoside Antimetabolite/Analog Cancer
    Flurocitabine (5-Fluorocyclocytidine) is a fluorinated anlydride analog of cytosine arabinoside, partially hydrolysecl in vivo into two active antitumor substances (arabinosyl-tluorocytosine (ara-FC) and arabinosyl-fluorouracil (ara-FU)). Flurocitabine (5-Fluorocyclocytidine) has antitumor activity during phase I studies in acute leukemia and solid tumors.
  • HY-16125
    Carboxyamidotriazole Orotate

    L-651582 Orotate; CAI Orotate

    		 Calcium Channel Cancer Inflammation/Immunology
    Carboxyamidotriazole Orotate (L-651582 Orotate) is the orotate salt form of Carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor. Carboxyamidotriazole Orotate is a cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole Orotate shows anti-tumor, anti-inflammatory and antiangiogenic effects.
  • HY-147215
    UC-1V150

    		Toll-like Receptor (TLR) Inflammation/Immunology
    UC-1V150 is a specific TLR7 (Toll-like receptor) agonist that stimulates cellular immune responses and has anti-tumor activity. UC-1V150 can be used to synthesize ISAC (Immune-Stimulating Antibody Conjugates) molecule.
  • HY-143658
    SH498

    		Autophagy Cancer
    SH498, a novel Bmi-1-mediated antitumor agent, shows potent antiproliferative activity.
  • HY-14846
    Litronesib

    LY2523355

    		 Kinesin Cancer
    Litronesib (LY2523355) is a selective mitosis-specific kinesin Eg5 inhibitor, with antitumor activity.
  • HY-146970
    Lankacyclinone C

    		Antibiotic Cancer
    Lankacyclinone C is a lankacidin C congener lacking the δ-lactone moiety, with antitumor activity.
  • HY-145623
    Mulnitorsen

    		DNA/RNA Synthesis Cancer
    Mulnitorsen is an antisense non-coding mitochondrial RNA (ASncmtRNA) synthesis reducer. Mulnitorsen is an antitumor agent.
  • HY-132900
    RORγ agonist 1

    		ROR Cancer
    RORγ agonist 1 is a potent and orally bioavailable RORγ agonist (EC50 = 21 nM) with antitumor activity.
  • HY-142681
    EGFR-IN-28

    		EGFR Cancer
    EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity.
  • HY-P99108
    Penpulimab

    		PD-1/PD-L1 Cancer Inflammation/Immunology
    Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities.
  • HY-16111
    BMS-214662

    		Farnesyl Transferase Cancer
    BMS-214662 is a potent and selective farnesyl transferase inhibitor with potent antitumor activity with an IC50 of 1.35 nM.
  • HY-13565
    Becatecarin

    NSC 655649; BMS 181176; BMY 27557

    		 Topoisomerase Cancer
    Becatecarin is a rebeccamycin analog with antitumor effects. Becatecarin intercalates into DNA and inhibites the catalytic activity of topoisomerases I/II.
  • HY-131790
    3'-Amino-3'-deoxyadenosine

    		Others Cancer
    3'-Amino-3'-deoxyadenosine is an antitumor agent extracted from Helminthosporium.
  • HY-N0706
    Gracillin

    		Apoptosis Cancer
    Gracillin is a kind of steroidal saponin isolated from the root bark of wild yam Dioscorea nipponica with antitumor agent.
  • HY-19994
    ML264

    		KLF Cancer
    ML264 is an antitumor agent that potently and selectively inhibits Krüppel-like factor five (KLF5) expression.
  • HY-117280
    GN25

    		MDM-2/p53 Cancer
    GN25 is a specific p53-Snail binding inhibitor with antitumor effects.
  • HY-B1295
    Lithium citrate tetrahydrate

    Litarex tetrahydrate

    		 ATP Citrate Lyase Bacterial HIF/HIF Prolyl-Hydroxylase Endogenous Metabolite Cancer Infection Metabolic Disease Inflammation/Immunology
    Lithium citrate (Litarex) tetrahydrate is the major active ingredient of Garcinia cambogia. Lithium citrate tetrahydrate competitively inhibits ATP citrate lyase with weight loss benefits. Lithium citrate tetrahydrate effective inhibits stones formation and also inhibits HIF, and has antioxidation, anti-inflammation and anti-tumor effects.
  • HY-B1334
    Perhexiline

    		Mitochondrial Metabolism Apoptosis Cancer Cardiovascular Disease
    Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina.
  • HY-136291
    Sulfo-SPDB-DGN462

    		Drug-Linker Conjugates for ADC Cancer
    Sulfo-SPDB-DGN462 is a drug-linker conjugate for ADC. Sulfo-SPDB-DGN462 consists a toxin DGN462 (HY-101150) conjugated to the cleavable Sulfo-SPDB linker. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML).
  • HY-W008859
    Tetrac

    Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid

    		 Integrin Endogenous Metabolite Cancer
    Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities.
  • HY-N0192
    Arbutin

    β-Arbutin

    		 Tyrosinase Endogenous Metabolite Cancer
    Arbutin (β-Arbutin) is a competitive inhibitor of tyrosinase, with Ki app values of 1.42 mM for monophenolase; 0.9 mM for diphenolase. Arbutin is also used as depigmenting agents. Arbutin is a natural polyphenol isolated from the bearberry plant Arctostaphylos uvaursi, possesses with anti-oxidant, anti-inflammatory and anti-tumor properties.
  • HY-B1334A
    Perhexiline maleate

    		Mitochondrial Metabolism Apoptosis Cancer Cardiovascular Disease
    Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina.
  • HY-145687
    HDAC-IN-32

    		HDAC Cancer
    HDAC-IN-32 is a potent HDAC inhibitor with IC50s of 5.2, 11, and 28 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-32 possesses potent antiproliferation activities against tumor cells. HDAC-IN-32 shows potent antitumor efficacy in vivo That trigger antitumor immunity.
  • HY-148088
    M1069

    		Adenosine Receptor Cancer
    M1069 is a selective and orall active, dual A2A/A2B adenosine receptor antagonist with a selectivity of >100 fold against the A1 and A3 receptors. M1069 counteracts immune-suppressive mechanisms of adenosine, and exhibits anti-tumor activity.
  • HY-15045
    INO-1001

    		PARP Cancer
    INO-1001 is a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor. INO-1001 is a potent enhancer of radiation sensitivity and enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death. INO-1001 has anti-tumor effects.
  • HY-112698
    CA-5f

    		Autophagy Apoptosis Cancer
    CA-5f is a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II (a marker to monitor autophagy) and SQSTM1 protein, and also increases ROS production. Anti-tumor activity.
  • HY-B0109S
    Dorzolamide-d5

    		Carbonic Anhydrase Cancer
    Dorzolamide-d5 (L671152-d5) is the deuterium labeled Dorzolamide. Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
  • HY-144366
    P-gp inhibitor 3

    		P-glycoprotein Cancer
    P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel.
  • HY-N0047
    Polyphyllin I

    		JNK mTOR Akt PDK-1 Autophagy Apoptosis Cancer
    Polyphyllin I is a bioactive constituent extracted from Paris polyphylla, has strong anti-tumor activity. Polyphyllin I is an activator of the JNK signaling pathway and is an inhibitor of PDK1/Akt/mTOR signaling. Polyphyllin I induces autophagy, G2/M phase arrest and apoptosis.
  • HY-145688
    HDAC-IN-33

    		HDAC Cancer
    HDAC-IN-33 is a potent HDAC inhibitor with IC50s of 24, 46, and 47 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-33 possesses potent antiproliferation activities against tumor cells. HDAC-IN-33 shows potent antitumor efficacy in vivo That trigger antitumor immunity.
  • HY-150072
    DS89002333

    		PKA Cancer
    DS89002333 is an orally active and potent PRKACA inhibitor, with an IC50 of 0.3 nM. DS89002333 shows good anti-tumor activity in an FL-HCC patient-derived xenograft model (expressing the DNAJB1-PRKACA fusion gene). DS89002333 can be used in study of fibrolamellar hepatocellular carcinoma (FL-HCC).
  • HY-119347
    Cirsilineol

    		IFNAR STAT Cancer Inflammation/Immunology
    Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4 + T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice.
  • HY-17565
    Bleomycin sulfate

    		DNA/RNA Synthesis Antibiotic Cancer
    Bleomycin sulfate is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin sulfate is an antitumor antibiotic.
  • HY-117253
    PHA-782584

    		Drug Metabolite Cancer
    PHA-782584 is a metabolite of sunitinib. Sunitinib is an oral multitargeted tyrosine kinase inhibitor with antitumor activities.
  • HY-101007A
    (+)-Tyrphostin B44

    Tyrphostin AG 835; Tyrphostin B 50

    		 EGFR Cancer
    (+)-Tyrphostin B44 (Tyrphostin AG 835) (Compound B50) is an EGRF inhibitor with antitumor activities.
  • HY-139877
    OXS007417

    		Others Cancer
    OXS007417 induces differentiation of acute myeloid leukemia cells (EC50 = 48 nM) in vitro and shows antitumor effects in vivo.
  • HY-133571A
    Aminohexylgeldanamycin hydrochloride

    AHGDM hydrochloride

    		 HSP ADC Cytotoxin Cancer
    Aminohexylgeldanamycin (AHGDM) hydrochloride, a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin hydrochloride shows antiangiogenic and antitumor activities.
  • HY-107549
    KD 5170

    		HDAC Cancer
    KD 5170 is a pan inhibitor of histone deacetylases (HDACs) and exhibits broad spectrum antitumor activity in vitro and in vivo.
  • HY-N0421
    Cinobufagin

    Cinobufagine

    		 Autophagy Apoptosis Cancer
    Cinobufagin, a kind of Chinese materia medica with antitumor effect, is widely used in clinical practice, especially in anti-liver cancer.
  • HY-130115
    IACS-8803

    		STING Cancer
    IACS-8803 is a highly potent cyclic dinucleotide STING agonist with robust systemic antitumor efficacy.
  • HY-133571
    Aminohexylgeldanamycin

    AHGDM

    		 HSP ADC Cytotoxin Cancer
    Aminohexylgeldanamycin (AHGDM), a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin shows antiangiogenic and antitumor activities.
  • HY-N6015
    Bacopasaponin C

    		Parasite Cancer
    Bacopasaponin C is an indigenous glycoside isolated from Bacopa monniera, with antitumor and anti-leishmanial activities.
  • HY-U00155
    NCI172112

    NSC172112; NSC268497

    		 DNA Alkylator/Crosslinker Cancer
    NCI172112 is a classical bifunctional alkylating agent synthesized in an effort to develop antitumor agents effective against CNS tumors.
  • HY-107769
    Duocarmycin TM

    CBI-TMI

    		 ADC Cytotoxin DNA Alkylator/Crosslinker Antibiotic Cancer
    Duocarmycin TM (CBI-TMI) is a potent antitumor antibiotic. Duocarmycin TM induces a sequence-selective alkylation of duplex DNA.
  • HY-70003
    Carboxypeptidase G2 (CPG2) Inhibitor

    CPG2 Inhibitor

    		 Carboxypeptidase Cancer
    Carboxypeptidase G2 (CPG2) Inhibitor is a novel Carboxypeptidase G2 (CPG2) Inhibitor, Antitumor agents.
  • HY-145737
    PROTAC SOS1 degrader-1

    		PROTACs Ras Cancer
    PROTAC SOS1 degrader-1 is a potent PROTAC SOS1 agonist with an DC50 of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity.
  • HY-N0108
    Physcion

    Parietin; Rheochrysidin

    		 Bacterial Cancer Infection Inflammation/Immunology
    Physcion (Parietin) is an anthraquinone isolated from traditional Chinese medicine Radix et Rhizoma Rhei, acts as an inhibitor of 6-phosphogluconate dehydrogenase, with an IC50 and a Kd of 38.5 μM and 26.0 μM, respectively. Physcion (Parietin) exhibits laxative, hepatoprotective, anti-inflammatory, anti-microbial, anti-proliferative and anti-tumor effects.
  • HY-113314
    AFMK

    		Endogenous Metabolite Cancer
    AFMK, antioxidant metabolite of Melatonin, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. AFMK is a poorer scavenger. The pKa of AFMK at physiological pH is 8.7. Antioxidant capacity. AFMK improves the anti-tumor effect of Gemcitabine in PANC-1 cells through the modulation of apoptotic pathway.
  • HY-119198
    NSC745885

    		Apoptosis Histone Methyltransferase Cancer
    NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers.
  • HY-129189
    RAS GTPase inhibitor 1

    		Ras Cancer
    RAS GTPase inhibitor 1 (example 51) is a RAS GTPase inhibitor with anti-tumor activity, extracted from patent WO2018212774A1. RAS GTPase inhibitor 1 (example 51) exhibits an EC50 less than 1 μM for at least one nucleotide exchange and an IC50 less than 1 μM in H727 cells.
  • HY-103665
    STING agonist-3

    		STING Cancer
    STING agonist-3, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pIC50 of 7.5 and 9.5, respectively. STING agonist-3 has durable anti-tumor effect and tremendous potential to improve treatment of cancer.
  • HY-N5112B
    β,β-Dimethylacrylshikonin

    Isoarnebin I

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    β,β-Dimethylacrylshikonin (Isoarnebin I) is a naphthoquinone derivative isolated from Lithospermum erythrorhizon Sieb. et Zucc. , promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway.β,β-Dimethylacrylshikonin has anti-tumor activity.
  • HY-114302
    CCB02

    		Microtubule/Tubulin Cancer
    CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC50 of 689 nM, and shows potent anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1.
  • HY-103665A
    STING agonist-3 trihydrochloride

    		STING Cancer
    STING agonist-3 trihydrochloride, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pEC50 of 7.5 and 9.5, respectively. STING agonist-3 trihydrochloride has durable anti-tumor effect and tremendous potential to improve treatment of cancer.
  • HY-130116
    IACS-8779

    		STING Cancer
    IACS-8779 is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy.
  • HY-B0063
    Gimatecan

    ST1481

    		 Topoisomerase Cancer
    Gimatecan (ST1481) is a potent topoisomerase I inhibitor. Gimatecan is an orally bioavailable camptothecin analogue with antitumor activity.
  • HY-N3741
    Didrovaltrate

    Didrovaltratum

    		 Others Cancer
    Didrovaltrate (Didrovaltratum) can be isolated from the roots of Valeriana wallichii D.C. Didrovaltrate is an antitumor agent with cytotoxicity.
  • HY-N2623
    Alloimperatorin

    Prangenidin

    		 Others Cancer
    Alloimperatorin (Prangenidin), a coumarin compound, is extracted from Angelica dahurica. Alloimperatorin (Prangenidin) has antitumor activity.
  • HY-19609
    Calicheamicin

    Calicheamicin γ1

    		 DNA Alkylator/Crosslinker ADC Cytotoxin Bacterial Apoptosis Antibiotic Cancer Infection
    Calicheamicin, an antitumor antibiotic, is a cytotoxic agent that causes double-strand DNA breaks. Calicheamicin is a DNA synthesis inhibitor.
  • HY-N2322
    Khasianine

    		Others Cancer
    Khasianine is a steroidal glycoalkaloid which is obtained from black nightshade (Solanum Nigrum L.), which displays antitumor activity.
  • HY-105529
    Indicine N-oxide

    (+)-Indicine N-oxide; NSC 132319

    		 Others Cancer
    Indicine N-oxide (NSC 132319), a pyrrolizidine alkaloid, is an antitumor agent for pediatric cancer and solid tumors research.
  • HY-101773
    c-Met-IN-2

    		c-Met/HGFR Cancer
    c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC50 of 0.6 nM, with antitumor activity.
  • HY-N0863
    Methyl protodioscin

    NSC-698790; Smilax saponin B

    		 Apoptosis Cancer
    Methyl protodioscin(NSC-698790) is a furostanol bisglycoside with antitumor properties; shows to reduce proliferation, cause cell cycle arrest.
  • HY-145237
    BM213

    		Others Cancer
    BM213, a potent and selective agonist for C5aR1, shows antitumor activity in a mouse model of mammary carcinoma.
  • HY-15491
    AG-024322

    		COX Apoptosis Cancer
    AG-024322 is a potent ATP-competitive pan-CDK inhibitor against cell cycle kinases CDK1, CDK2, and CDK4 with Ki values in the 1-3 nM range. AG-024322 displays broad-spectrum anti-tumor activity and clear target modulation in vivo. AG-024322 induces cell apoptosis.
  • HY-139782
    SKLB325

    		Histone Demethylase Apoptosis Cancer
    SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (KD) value of 0.755 μM, and the IC50 value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis. SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) .
  • HY-N0587
    Demethylzeylasteral

    		Apoptosis Cancer Inflammation/Immunology
    Demethylzeylasteral is a triterpene compound isolated from Tripterygium wilfordii Hook F, with anti-inflammatory, immunosuppressive and anti-tumor activities. Demethylzeylasteral can significantly alleviates atherosclerosis (AS). Demethylzeylasteral inhibits triple-negative breast cancer invasion by blocking the canonical and non-canonical TGF-β signaling pathways.
  • HY-N6246
    Asperulosidic Acid

    		NF-κB ERK Cancer Inflammation/Immunology
    Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities. ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways.
  • HY-143439
    LX-039

    		Estrogen Receptor/ERR Cancer
    LX-039 is a highly potent, selective and orally active estrogen receptor degrader with EC50 value of 2.29 nM. LX-039 has indole C-3 chlorine atom. LX-039 exhibits excellent mouse pharmacokinetics, low clearance, high Cmax and oral exposure. LX-039 has anti-tumor activity.
  • HY-126147
    J22352

    		HDAC Cancer
    J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM. J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1.
  • HY-131970
    LSD1/HDAC6-IN-1

    		Histone Demethylase HDAC Cancer
    LSD1/HDAC6-IN-1 is an orally active dual inhibitor of lysine specific demethylase 1(LSD1)/Histone deacetylase 6 (HDAC6), with anti-tumor activity. LSD1/HDAC6-IN-1 can be used for the research of multiple myeloma (MM).
  • HY-101597
    NVX-207

    		Apoptosis Cancer
    NVX-207, a Betulinic acid-derived anti-cancer compound, shows anti-tumor activity (mean IC50=3.5 μM) against various human and canine cell lines. NVX-207-induced apoptosis is associated with activation of the intrinsic apoptotic pathway via cleavage of caspases -9, -3, -7 and of PARP.
  • HY-14621
    Zingerone

    Vanillylacetone; Gingerone

    		 NF-κB Cancer Metabolic Disease Inflammation/Immunology
    Zingerone (Vanillylacetone) is a nontoxic methoxyphenol isolated from Zingiber officinale, with potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, antispasmodic and anti-tumor properties. Zingerone alleviates oxidative stress and inflammation, down-regulates NF-κB mediated signaling pathways. Zingerone acts as an anti-mitotic agent, and inhibits the growth of neuroblastoma cells.
  • HY-13737
    R1530

    		VEGFR FGFR Apoptosis Cancer
    R1530 is a highly potent, orally active, dual-acting mitosis/angiogenesis inhibitor, with anti-tumor and anti-angiogenic activities. R1530 is a multikinase inhibitor which binds to 31 kinases with Kd values of <500 nM. R1530 inhibits VGFR2 and FGFR1 with IC50 of 10 nM and 28 nM, respectively. R1530 triggers apoptosis (mitotic catastrophe) or senescence.
  • HY-103223
    Phortress

    NSC 710305

    		 Cytochrome P450 Cancer
    Phortress is a high affinity AhR ligand that elicits antitumor activity by inducing transcription of CYP1A1.
  • HY-139106
    N-Demethylansamitocin P-3

    		Others Others
    N-Demethylansamitocin P-3 can be prepared from Ansamitocin (an antitumor ansamycin antibiotic) by Streptomyces minutiscleroticus IFO 13361.
  • HY-112588
    dBET6

    		PROTACs Epigenetic Reader Domain Apoptosis Cancer
    dBET6 is a highly potent, selective and cell-permeable PROTAC connected by ligands for Cereblon and BET, with an IC50 of 14 nM, and has antitumor activity.
  • HY-U00248
    LMP744

    MJ-III65; NSC706744

    		 Topoisomerase Cancer
    LMP744 (MJ-III65) is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity.
  • HY-10447
    Terameprocol

    EM-1421

    		 Lipoxygenase Cancer Infection
    Terameprocol is a synthetic derivative of Nordihydroguaiaretic acid and a non-selective lipoxygenase inhibitor. Terameprocol has antiviral and antitumor effects.
  • HY-101486
    LF3

    		β-catenin Cancer
    LF3 is an antagonist of the β-Catenin/TCF4 interaction with antitumor activity; has an IC50 of 1.65 μM.
  • HY-128798
    Menin-MLL inhibitor 20

    		Epigenetic Reader Domain Cancer
    Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, Intermediate 6).
  • HY-107363
    FT-1518

    		mTOR Cancer
    FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.
  • HY-N2283
    Deltonin

    		ERK Akt Endogenous Metabolite Cancer
    Deltonin, a steroidal saponin, isolated from Dioscorea zingiberensis, with antitumor activity; Deltonin inhibits ERK1/2 and AKT activation.
  • HY-N0114
    Evodiamine

    (+)-Evodiamine; d-Evodiamine

    		 Others Cancer
    Evodiamine is an alkaloid isolated from the fruit of Evodia rutaecarpa Bentham with diverse biological activities including anti-inflammatory, anti-obesity, and antitumor.
  • HY-142678
    EGFR-IN-21

    		EGFR Cancer
    EGFR-IN-21 is a potent EGFR inhibtior with an IC50 of 0.38 nM. EGFR-IN-21 has antitumor activity.
  • HY-112167A
    GDC-0575 dihydrochloride

    ARRY-575 dihydrochloride; RG7741 dihydrochloride

    		 Checkpoint Kinase (Chk) Cancer
    GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is an orally bioavailable CHK1 inhibitor, with an IC50 of 1.2 nM, and has antitumor activity.
  • HY-142458
    KRAS G12C inhibitor 27

    		Ras Cancer
    KRAS G12C inhibitor 27 is a KRAS G12C inhibitor with antitumor effects (WO2021109737).
  • HY-U00248A
    LMP744 hydrochloride

    MJ-III65 hydrochloride; NSC706744 hydrochloride

    		 Topoisomerase Cancer
    LMP744 hydrochloride (MJ-III65 hydrochloride) is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity.
  • HY-114313
    Microtubule inhibitor 1

    		Microtubule/Tubulin Cancer
    Microtubule inhibitor 1 is an antitumor agent with microtubule polymerization inhibitory activity, with an IC50 value of 9-16 nM in cancer cells.
  • HY-142457
    KRAS G12C inhibitor 26

    		Ras Cancer
    KRAS G12C inhibitor 26 is a KRAS G12C inhibitor with antitumor effects (WO2021109737).
  • HY-142967
    TGFβ-IN-1

    		TGF-β Receptor Cancer
    TGFβ-IN-1 is an antitumor growth and metastasis agent through inhibiting the transforming growth factor‑β signaling pathway.
  • HY-145963
    DRB18

    		GLUT Cancer
    DRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity.
  • HY-105416
    Calphostin C

    UCN-1028C

    		 Antibiotic PKC Apoptosis Cancer Infection
    Calphostin C is a potent and specific inhibitor of protein kinase C. Calphostin C is an antitumor antibiotic. Calphostin C has 1000 times more inhibitory to protein kinase C with an IC50 of 0.05 μM than other protein kinases. Calphostin C induces apoptosis in some tumor cell lines. Calphostin C has potent cytotoxic activity and antitumor activity.
  • HY-B0091A
    Adapalene sodium salt

    CD 271 sodium salt

    		 RAR/RXR Autophagy Apoptosis Cancer Inflammation/Immunology Neurological Disease
    Adapalene (CD271) sodium salt, a third-generation synthetic retinoid, is widely used for the research of acne. Adapalene sodium salt is a potent RAR agonist, with AC50s of 2.3 nM, 9.3 nM, and 22 nM for RARβ, RARγ, RARα, respectively. Adapalene sodium salt also inhibits the enzymatic activity of GOT1 in a non-competitive manner. Adapalene sodium salt exhibits anti-tumor activity.
  • HY-121508
    (E/Z)-IT-603

    		NF-κB Cancer Inflammation/Immunology
    (E/Z)-IT-603 is a mixture of E-IT-603 and Z-IT-603 (IT-603). IT-603 is a c-Rel inhibitor with an IC50 of 3 μM. IT-603 has anti-tumor activity. (E/Z)-IT-603 is a promising modulator of T-cell responses in the context of graft-versus-host disease (GVHD) and malignant diseases.
  • HY-144497
    HE-S2

    		PD-1/PD-L1 Toll-like Receptor (TLR) Drug-Linker Conjugates for ADC Cancer Infection
    HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the PD-1/PD-L1 interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity.
  • HY-B0091
    Adapalene

    CD271

    		 RAR/RXR Autophagy Apoptosis Cancer Inflammation/Immunology Neurological Disease
    Adapalene (CD271), a third-generation synthetic retinoid, is widely used for the research of acne. Adapalene is a potent RAR agonist, with AC50s of 2.3 nM, 9.3 nM, and 22 nM for RARβ, RARγ, RARα, respectively. Adapalene also inhibits the enzymatic activity of GOT1 in a non-competitive manner. Adapalene exhibits anti-tumor activity.
  • HY-N1440
    Koumine

    		Bcl-2 Family Cancer Inflammation/Immunology
    Koumine is an alkaloid separated from Gelsemium elegans, shows potent anti-tumor activity. Koumine up-regulates the Bax/Bcl-2 ratio and caspase-3 expression in human breast cancer cells. Koumine has anxiolytic, antistress, antipsoriatic, and analgesic activities, protects against the development of arthritis in Rheumatoid arthritis (RA) animal models.
  • HY-148012
    SOP1812

    		G-quadruplex Cancer
    SOP1812 is a naphthalene diimide (ND) derivative with anti-tumor activity. SOP1812 binds to quadruplex arrangements (G4s), and down-regulates several cancer gene pathways. SOP1812 shows great affinity to hTERT G4 and HuTel21 G4 with KD values of 4.9 and 28.4 nM, respectively. SOP1812 can be used for the research of cancer.
  • HY-135691
    hnRNPK-IN-1

    		c-Myc Apoptosis Cancer
    hnRNPK-IN-1 is a heterogeneous nuclear ribonucleoprotein K (hnRNPK) binding ligand with Kd values of 4.6 μM and 2.6 μM measured with SPR and MST, respectively. hnRNPK-IN-1 inhibits c-myc transcription by disrupting the binding of hnRNPK and c-myc promoter. hnRNPK-IN-1 induces Hela cells apoptosis and has strongly anti-tumor activities.
  • HY-125858
    MI-1061

    		MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity.
  • HY-N10504
    Galactofucan

    Fucogalactan

    		 HSV Cancer Inflammation/Immunology
    Galactofucan (Fucogalactan) is a sulfated polysaccharide. Galactofucan can be extracted from brown seaweed Saccharina longicruris with anticoagulant, anti-tumor, anti-thrombosis, anti-inflammatory and antiviral properties. Galactofucan shows antiviral activities to HSV-1 and HSV-2 with IC50s of 0.76 and 1.34 µg/mL, respectively. Galactofucan can be used for the research of cancer and inflammation.
  • HY-N2389
    Formosanin C

    		Apoptosis Cancer
    Formosanin C is a diosgenin saponin isolated from Paris polyphylla and an immunomodulator with antitumor activity. Formosanin C induces apoptosis.
  • HY-101031
    c-Met-IN-1

    		c-Met/HGFR Cancer
    c-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC50 of 1.1 nM, with antitumor activity..
  • HY-15184
    Elaiophylin

    Azalomycin B; Gopalamicin; Efomycin E

    		 Autophagy Antibiotic Cancer
    Elaiophylin (Azalomycin B; Gopalamicin; Efomycin E) is an autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells.
  • HY-15739
    Ansamitocin P-3

    antibiotic C 15003P3; Maytansinol isobutyrate

    		 Microtubule/Tubulin ADC Cytotoxin Bacterial Antibiotic Cancer Infection
    Ansamitocin P-3 (Antibiotic C 15003P3) is a microtubule inhibitor. Ansamitocin P-3 is a macrocyclic antitumor antibiotic.
  • HY-145852
    Top/HDAC-IN-2

    		HDAC Topoisomerase Apoptosis Cancer
    Top/HDAC-IN-2 (45b), a Top and HDAC dual inhibitor, exhibits potent antitumor activities and induces apoptosis.
  • HY-144102
    HDAC-IN-29

    		HDAC Cancer
    HDAC-IN-29 (compound 13b) is a potent pan-HDAC inhibitor. HDAC-IN-29 shows antitumor activity.
  • HY-109104
    Telratolimod

    MEDI9197; 3M-052

    		 Toll-like Receptor (TLR) Cancer
    Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity.
  • HY-132001
    Ziftomenib

    KO-539

    		 Epigenetic Reader Domain Cancer
    Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151).
  • HY-124584
    Minnelide

    		Apoptosis Cancer
    Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide promotes apoptosis.
  • HY-15096
    MKT-077

    FJ-776

    		 HSP Cancer
    MKT-077 is a rhodacyanine dye and also a heat shock protein 70 (Hsp70) inhibitor which exhibits significant antitumor activity.
  • HY-121076
    Berteroin

    		Bacterial Cancer Infection Inflammation/Immunology
    Berteroin, a naturally occurring Sulforaphane analog, ia an antimetastatic agent. Berteroin has anti-inflammatory, antitumor and bactericidal effects.
  • HY-18174A
    Prexasertib dihydrochloride

    LY2606368 dihydrochloride

    		 Checkpoint Kinase (Chk) Apoptosis Cancer
    Prexasertib dihydrochloride (LY2606368 dihydrochloride) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib dihydrochloride inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib dihydrochloride causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dihydrochloride shows potent anti-tumor activity.
  • HY-117273
    AZ304

    		Raf Autophagy Cancer
    AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC50, 6 nM), CSF1R (IC50, 35 nM). Anti-tumor activity.
  • HY-19827
    Aeroplysinin 1

    (+)-Aeroplysinin-1

    		 Bacterial HIV Apoptosis Cancer Infection
    Aeroplysinin 1 ((+)-Aeroplysinin-1), a secondary metabolite isolated from marine sponges, shows potent antibiotic effects on Gram-positive bacteria and exerts antiviral activity against HIV-1 (IC50=14.6 μM). Aeroplysinin 1 has anti-inflammatory, anti-angiogenic and anti-tumor activities. Aeroplysinin 1 induces apoptosis in endothelial cells.
  • HY-N0192S
    Arbutin-d4

    β-Arbutin-d4

    		 Tyrosinase Endogenous Metabolite Cancer
    Arbutin-d4 is deuterium labeled Arbutin. Arbutin (β-Arbutin) is a competitive inhibitor of tyrosinase in melanocytes, with Kiapp values of 1.42 mM for monophenolase; 0.9 mM for diphenolase. Arbutin is also used as depigmenting agents. Arbutin is a natural polyphenol isolated from the bearberry plant Arctostaphylos uvaursi, possesses with anti-oxidant, anti-inflammatory and anti-tumor properties.
  • HY-125858A
    MI-1061 TFA

    		MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    MI-1061 TFA is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 TFA potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity.
  • HY-N2259
    Curcumenol

    (+)-Curcumenol

    		 Cytochrome P450 Cancer Inflammation/Immunology Neurological Disease
    Curcumenol ((+)-Curcumenol) is a potent CYP3A4 inhibitor with an IC50 of 12.6 μM, which is one of constituents in the plants of medicinally important genus of Curcuma zedoaria, with neuroprotection, anti-inflammatory, anti-tumor and hepatoprotective activities. Curcumenol ((+)-Curcumenol) suppresses Akt-mediated NF-κB activation and p38 MAPK signaling pathway in LPS-stimulated BV-2 microglial cells.
  • HY-18174B
    Prexasertib Mesylate Hydrate

    LY2606368 Mesylate Hydrate; LY2940930

    		 Checkpoint Kinase (Chk) Apoptosis Cancer
    Prexasertib Mesylate Hydrate (LY2606368 Mesylate Hydrate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib Mesylate Hydrate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib Mesylate Hydrate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib Mesylate Hydrate shows potent anti-tumor activity.
  • HY-18174C
    Prexasertib mesylate

    LY2606368 mesylate

    		 Checkpoint Kinase (Chk) DNA/RNA Synthesis Apoptosis Cancer
    Prexasertib mesylate (LY2606368 mesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib mesylate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib mesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib mesylate shows potent anti-tumor activity.
  • HY-18174
    Prexasertib

    LY2606368

    		 Checkpoint Kinase (Chk) Apoptosis Cancer
    Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib shows potent anti-tumor activity.
  • HY-138696
    XL092

    		TAM Receptor c-Met/HGFR VEGFR Cancer
    XL092 is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. XL092 exhibits anti-tumor activity. XL092 has the potential for kinase-dependent diseases and conditions research.
  • HY-128580
    FAK inhibitor 2

    		FAK Cancer
    FAK inhibitor 2 is a potent focal adhesion kinase (FAK) inhibitor with an IC50  of 0.07 nM, with antitumor and anti-angiogenesis activities.
  • HY-N2909
    Aurantiamide

    		Others Inflammation/Immunology
    Aurantiamide is an orally active constituent of Portulaca oleracea L and has various biological activities, including antioxidant, antiplatelet, anti-inflammatory, and antitumor activities.
  • HY-13468
    KW-2478

    		HSP Cancer
    KW-2478 is an inhibitor of Hsp90α, with an IC50 of 3.8 nM, and has antitumor activity against various human hematological tumor cells.
  • HY-N0580
    Fraxetin

    		Apoptosis Cancer Inflammation/Immunology
    Fraxetin is isolated from Cortex Fraxini. Fraxetin has antitumor, anti-oxidation effects and anti-inflammory effects. Fraxetin induces apoptosis.
  • HY-12045
    HMN-214

    IVX-214

    		 Polo-like Kinase (PLK) Cancer
    HMN-214, an orally bioavailable prodrug of HMN-176, is an inhibitor of polo-like kinase-1 (plk1), with antitumor activity.
  • HY-Y0247
    6-Chloropurine

    6-Chloro-9H-purine

    		 Others Cancer
    6-Chloropurine is a building block in chemical synthesis. Intermediate in the preparation of 9-alkylpurines and 6-rnercaptopurine. Antitumor activities.
  • HY-15359
    Episilvestrol

    		Eukaryotic Initiation Factor (eIF) Autophagy Cancer
    Episilvestrol is a derivative of silvestrol, isolated from the fruits and twigs of Aglaia perviridis, and is a specific eIF4A-targeting translation inhibitor, with antitumor activity.
  • HY-111999A
    E7766 diammonium salt

    		STING Cancer
    E7766 diammonium salt is a macrocycle-bridged STING agonist with a Kd of 40 nM. E7766 diammonium salt shows potent pan-genotypic and antitumor activities.
  • HY-18931A
    (Rac)-NSC305787 hydrochloride

    		Others Cancer
    NSC305787 hydrochloride is an inhibitor of ezrin with a Kd of 5.85 μM, inhibits the phosphorylation of ezrin caused by PKCΙ with an IC50 of 8.3 μM, has antitumor activity.
  • HY-U00097
    L-4-Oxalysine hydrochloride

    		Fungal Cancer Infection
    L-4-Oxalysine hydrochloride is a natural product isolated from the culture media of Streptomyces roseovirdofuscus in China which has shown antitumor activities.
  • HY-N144684
    Himastatin

    		Bacterial Cancer Infection
    Himastatin is a antitumor antibiotic produced by a strain of S. hygroscopicus sp. Himastatin is a dimeric cyclohexadepsipeptide containing piperazic acid and a unique central aromatic core.
  • HY-12395
    Ecteinascidin-Analog-1

    		Others Cancer
    Ecteinascidin-Analog-1 is a useful intermediate for chemical sythesis of Ecteinascidin analogues; Ecteinascidins is a family of tetrahydroisoquinoline alkaloids with wide range of antitumor and antimicrobial activities.
  • HY-132179
    Fucoidan

    		Glucosidase Cancer Metabolic Disease Cardiovascular Disease
    Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities.
  • HY-13585S
    Carmustine-d8

    		DNA Alkylator/Crosslinker Cancer
    Carmustine-d8 is the deuterium labeled Carmustine. Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA.
  • HY-N1166
    Tephrosin

    Deguelinol I; Hydroxydeguelin

    		 EGFR Cancer
    Tephrosin is a natural rotenoid which has potent antitumor activities. Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors.
  • HY-144121
    Ph-Ph+

    		Bacterial Fungal Apoptosis Cancer Infection
    Ph-Ph+ is a hemiprotonic compound, which is produced from phenanthroline (ph) dimerization. Ph-Ph+ has antitumor, antibacterial and antifungal activities.
  • HY-111999B
    E7766 disodium

    		STING Cancer
    E7766 disodium is a macrocycle-bridged STING agonist with a Kd of 40 nM. E7766 disodium shows potent pan-genotypic and antitumor activities.
  • HY-18931
    (Rac)-NSC305787

    		Others Cancer
    NSC305787 is an inhibitor of ezrin with a Kd of 5.85 μM, inhibits the phosphorylation of ezrin caused by PKCΙ with an IC50 of 8.3 μM, has antitumor activity.
  • HY-129651
    SHMT-IN-1

    		Others Cancer
    SHMT-IN-1 (compound (±)-46) is a potent inhibitor of plasmodial serine hydroxymethyltransferase (SHMT). SHMT-IN-1 has antitumor activity.
  • HY-B1793
    Tetraethylammonium chloride

    		Potassium Channel Cancer Neurological Disease
    Tetraethylammonium chloride is a non-selective potassium channel blocker. Tetraethylammonium chloride is a good substrate for organic cation transporter (OCTN1). Tetraethylammonium chloride antitumor properties.
  • HY-136327
    Phenylacetic acid mustard

    		DNA Alkylator/Crosslinker Cancer
    Phenylacetic acid mustard is the major metabolite of the cancer chemotherapeutic agent Chlorambucil (HY-13593). Chlorambucil is an alkylating agent with antitumor activity.
  • HY-13550
    Ametantrone

    NSC 196473; NSC 290813

    		 DNA/RNA Synthesis Cancer
    Ametantrone (NSC 196473) is an antitumor agent that intercalates into DNA and induces topoisomerase II (TOP2)-mediated DNA break.
  • HY-15149
    Romidepsin

    FK 228; FR 901228; NSC 630176

    		 HDAC Apoptosis Cancer
    Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC50s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively. Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis.
  • HY-132229
    LPM4870108

    		Trk Receptor Cancer
    LPM4870108 is a potent and orally active pan-Trk (WT and MT) inhibitor, with IC50s of 0.2 nM, 2.4 nM, 3.5 nM and 2.3 nM for TrkC, TrkA, TrkA G595R and TrkA G667C, respectively. LPM4870108 shows selectivity for Trk over ALK (IC50=182 nM). LPM4870108 exhibits anti-tumor activity.
  • HY-124586
    Streptonigrin

    Bruneomycin

    		 Protein Arginine Deiminase Antibiotic Cancer Infection
    Streptonigrin (Bruneomycin), a natural product produced by Streptomyces flocculus, possesses both anti-tumor and anti-bacterial activity. Streptonigrin acts as a pan-PAD inhibitor with IC50s of 48.3±34.2 µM, 26.1±0.3 µM, 0.43±0.03 µM, and 2.5±0.4 µM for PAD1, PAD2, PAD3, and PAD4, respectively.
  • HY-108790
    Peginterferon beta-1a

    Peginterferon β-1a

    		 Apoptosis Cancer Neurological Disease
    Peginterferon beta-1a (Peginterferon β-1a) is the first pegylated interferon beta-1a molecule. Peginterferon beta-1a induces cancer cells apoptosis and shows anti-tumor activities in nude mice models. Peginterferon beta-1a can be used for the research of cancer and multiple sclerosis (RMS).
  • HY-100237
    SZL P1-41

    		E1/E2/E3 Enzyme Apoptosis Cancer
    SZL P1-41 is a specific Skp2 inhibitor, binds to the F-box domain of Skp2 to prevent Skp1 association and Skp2 SCF complex formation. SZL P1-41, like Skp2 deficiency, augments p27-mediated apoptosis/senescence, while it impairs Akt-driven glycolysis. Anti-tumor activities.
  • HY-143325
    A2AAR/HDAC-IN-2

    		HDAC Adenosine Receptor Cancer
    A2AAR/HDAC-IN-2 is a potent A2AAR/HDAC dual inhibitor, with good binding affinity for A2AAR (Ki=10.3 nM) and good inhibitory activity against HDAC1 (IC50=18.5 nM). A2AAR/HDAC-IN-2 can be used in study of antitumor.
  • HY-148059
    B-Raf IN 10

    		Raf Cancer
    B-Raf IN 10 (Compound C09) is a BRAF inhibitor with an IC50 between 50 and 100 nM. B-Raf IN 10 shows antitumor activity.
  • HY-W015490
    1,4-Naphthoquinone

    		Monoamine Oxidase Cancer
    1,4-Naphthoquinone is a potential pharmacophore for inhibition of both MAO (monoamine oxidase) and DNA topoisomerase activities, this latter associated with antitumor activity.
  • HY-N0174
    Cryptotanshinone

    Cryptotanshinon; Tanshinone c

    		 STAT Autophagy Cancer
    Cryptotanshinone is a natural compound extracted from the root of Salvia miltiorrhiza Bunge that shows antitumor activities. Cryptotanshinone inhibits STAT3 with an IC50 of 4.6 μM.
  • HY-D0803
    Thymoquinone

    		Others Inflammation/Immunology
    Thymoquinone is a nature product isolated from N. sativa. Thymoquinone possess antioxidant, anti-inflammatory, anti-cancer, antitumor activities and hepatoprotective properties.
  • HY-14573
    SJG-136

    NSC-694501

    		 DNA Alkylator/Crosslinker ADC Cytotoxin Cancer
    SJG-136 is a DNA cross-linking agent, with an XL50 of 45 nM for pBR322 DNA. SJG-136 has potent antitumor activity.
  • HY-147894
    PCAF-IN-1

    		Others Cancer
    PCAF-IN-1 is a highly selective PCAF inhibitor. PCAF-IN-1 is a antitumor agents, which can be used in tumor treatment research.
  • HY-145483
    PROTAC IRAK4 degrader-7

    		PROTACs IRAK Cancer
    PROTAC IRAK4 degrader-7 (Compound I-417) is an orally active PROTAC IRAK4 degrader with antitumor activities.
  • HY-10824B
    Talotrexin ammonium

    PT523 ammonium

    		 Others Cancer
    Talotrexin ammonium is a nonpolyglutamatable antifolate. Talotrexin ammonium improves antitumor activity in a broad spectrum of cancer models by targeting DHFR to inhibit tumor growth.
  • HY-N0488
    Vincristine sulfate

    Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate

    		 Microtubule/Tubulin Apoptosis Cancer
    Vincristine sulfate is an antitumor vinca alkaloid which inhibits microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. It binds to microtubule with a Ki of 85 nM.
  • HY-N10391
    (-)-Cleistenolide

    Cleistenolide

    		 Others Cancer Infection
    (-)-Cleistenolide is a α,β-unsaturated δ-lactone isolated from Cleistochlamys kirkii Oliver. (-)-Cleistenolide has antibacterial and antitumor activity.
  • HY-112897
    IITZ-01

    		Autophagy PI3K Apoptosis Cancer
    IITZ-01 is a potent lysosomotropic autophagy inhibitor with single-agent antitumor activity, with an IC50 of 2.62 μM for PI3Kγ.
  • HY-N0021
    Verbascoside

    Acteoside; Kusaginin; TJC160

    		 PKC Apoptosis Bacterial HSV Cancer Inflammation/Immunology Neurological Disease
    Verbascoside is isolated from Acanthus mollis, acts as an ATP-competitive inhibitor of PKC, with an IC50 of 25 µM, and has antitumor, anti-inflammatory and antineuropathic pain activity.
  • HY-146646
    Bleomycin A2

    		Antibiotic Cancer Infection
    Bleomycin A2, an antitumor antibiotic promoting DNA-degradation, is an aspartate/asparagine-β-hydroxylase (AspH) inhibitor with an IC50 of 1.47 μM.
  • HY-136718
    CLEFMA

    		Apoptosis Cancer
    CLEFMA is a curcuminoid with antitumor activity. CLEFMA inhibits tumor growth is associated with NF-κB-regulated anti-inflammatory and anti-metastatic effects.
  • HY-145827
    KIF18A-IN-4

    		Microtubule/Tubulin Cancer
    KIF18A-IN-4 is a moderately potent ATP and microtubule (MT) noncompetitive KIF18A inhibitor (IC50=6.16 μM). KIF18A-IN-4 has selectivity against a large panel of mitotic kinesins and kinases, and does not show any direct effects on tubulin assembly. KIF18A-IN-4 exhibits anti-tumor activity.
  • HY-N2205
    Esculentoside H

    		NF-κB JNK Cancer
    Esculentoside H (EsH) is a saponin isolated from the root extract of perennial plant Phytolacca esculenta. Esculentoside H (EH) has anti-tumor activity, the mechanism is related to the capacity for TNFrelease. Esculentoside H (EsH) suppresses colon cancer cell migration through blockage of the JNK1/2 and NF-κB signaling-mediated matrix metalloproteinases-9 (MMP-9) expression.
  • HY-13440
    AMG 511

    		PI3K Cancer
    AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks, with Kis of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively. AMG 511 significantly suppresses PI3K signaling that is indicated by p-Akt (Ser473) decrease. AMG 511 exhibits anti-tumor activity in mouse glioblastoma xenograft model.
  • HY-137478A
    KB-0742 dihydrochloride

    		CDK Cancer
    KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity.
  • HY-139326
    NHS-MMAF

    		Others Cancer
    NHS-MMAF is a modified MMAF extracted from patent WO2012143499, intermediat 219. MMAF is a potent tubulin polymerization inhibitor and is used as a antitumor agent
  • HY-13745
    Sabarubicin

    MEN 10755

    		 Topoisomerase Cancer
    Sabarubicin is a doxorubicin disaccharide analogue with striking antitumor activity. Sabarubicin is more effective than doxorubicin as a topoisomerase II poison and stimulated DNA fragmentation at lower intracellular concentrations.
  • HY-N1931
    Epifriedelanol

    		Others Cancer
    Epifriedelanol is a triterpenoid isolated from the root bark of Ulmus davidiana, with antitumor activity. Epifriedelanol inhibits cellular senescence in human primary cells.
  • HY-N7153
    10-Hydroxycanthin-6-one

    		Others Cancer
    10-Hydroxycanthin-6-one is an antileukemic canthin-6-one alkaloid from Brucea antidysenterica. Antitumor agent.
  • HY-128959
    MCC-Modified Daunorubicinol

    		Drug-Linker Conjugates for ADC Cancer
    Daunorubicinol is a drug-linker conjugate for ADC with potent antitumor activity by using Aur0101 (DNA Topoisomerase II inhibitor), linked via the ADC linker.
  • HY-126532
    Fmoc-Val-Cit-PAB-Duocarmycin TM

    		Drug-Linker Conjugates for ADC Cancer
    Fmoc-Val-Cit-PAB-Duocarmycin TM is a drug-linker conjugate for ADC by using the antitumor antibiotic, Duocarmycin TM, linked via Fmoc-Val-Cit-PAB.
  • HY-130115A
    IACS-8803 disodium

    		STING Cancer
    IACS-8803 disodium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 disodium has a robust systemic antitumor efficacy.
  • HY-110215
    XD14

    		Epigenetic Reader Domain Cancer
    XD14 is a potent BET inhibitor with antitumor effect. It binds to BRD2, BRD3, and BRD4 with Kds of 170, 380, and 160 nM, respectively.
  • HY-146141
    EphA2 agonist 2

    		Ephrin Receptor Cancer
    EphA2 agonist 2 (Lead compound) is a selective EphA2 agonist with antitumor activities. EphA2 agonist 2 can cross the BBB.
  • HY-19402
    Spiruchostatin A

    OBP801; YM753

    		 HDAC Cancer
    Spiruchostatin A is a potent HDAC inhibitor with an IC50 value of 2 nM. Spiruchostatin A can induce apoptosis, has antitumor activity and may be used in leukemia studies.
  • HY-147426
    Zifcasiran

    		HIF/HIF Prolyl-Hydroxylase Cancer
    Zifcasiran is a hypoxia-inducible factor (HIF) synthesis reducer. Zifcasiran shows antitumor activities and can be used in advanced renal cell carcinoma research.
  • HY-130115B
    IACS-8803 diammonium

    		STING Cancer
    IACS-8803 diammonium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 diammonium has a robust systemic antitumor efficacy.
  • HY-111381
    BI-3812

    		Bcl-2 Family Cancer
    BI-3812 is potent and efficacious BCL6 inhibitor, inhibiting the BTB domain of BCL6, with an IC50 of ≤3 nM; BI-3812 has antitumor activity.
  • HY-16438
    RRx-001

    		Apoptosis Parasite Cancer Infection Inflammation/Immunology
    RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes drug resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity.
  • HY-126249
    AAPK-25

    		Aurora Kinase Polo-like Kinase (PLK) Apoptosis Cancer
    AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3 Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with Kd values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with Kd values ranging from 55-456 nM.
  • HY-10201
    Sorafenib

    Bay 43-9006

    		 Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis Cancer
    Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator.
  • HY-B0091S
    Adapalene-d3

    		RAR/RXR Autophagy Apoptosis Cancer Inflammation/Immunology Neurological Disease
    Adapalene-d3 is the deuterium labeled Adapalene. Adapalene (CD271), a third-generation synthetic retinoid, is widely used for the research of acne. Adapalene is a potent RAR agonist, with AC50s of 2.3 nM, 9.3 nM, and 22 nM for RARβ, RARγ, RARα, respectively. Adapalene also inhibits the enzymatic activity of GOT1 in a non-competitive manner. Adapalene exhibits anti-tumor activity.
  • HY-143869
    HPK1-IN-28

    		MAP4K Cancer
    HPK1-IN-28 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-28 enhances the body's anti-tumor immunity. HPK1-IN-28 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 1).
  • HY-143870
    HPK1-IN-29

    		MAP4K Cancer
    HPK1-IN-29 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-29 enhances the body's anti-tumor immunity. HPK1-IN-29 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 38).
  • HY-16478
    Trifluridine/tipiracil hydrochloride mixture

    TAS-102

    		 Nucleoside Antimetabolite/Analog Thymidylate Synthase Cancer
    Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a potent and orally active nucleoside antitumor agent. The composition of Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a 1:0.5 mixture (on a molar basis) of alpha,alpha,alpha-tri-fluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI). Trifluridine/tipiracil hydrochloride mixture (TAS-102) shows the antitumor activity mainly via the inhibition of thymidylate synthase (TS) and incorporation into DNA.
  • HY-18174E
    Prexasertib dimesylate

    LY2606368 dimesylate

    		 Checkpoint Kinase (Chk) Apoptosis Cancer
    Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib dimesylate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib dimesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dimesylate shows potent anti-tumor activity.
  • HY-112610
    CF53

    		Epigenetic Reader Domain Histone Acetyltransferase Cancer
    CF53 is a highly potent, selective and orally active inhibitor of BET protein, with a Ki of <1 nM, Kd of 2.2 nM and an IC50 of 2 nM for BRD4 BD1. CF53 binds to both the BD1 and BD2 domains of BRD2, BRD3, BRD4, and BRDT BET proteins with high affinities, very selective over non-BET bromodomain-containing proteins. CF53 shows potent anti-tumor activity both in vitro and in vivo.
  • HY-119940
    MC180295

    (rel)-MC180295

    		 CDK Cancer
    MC180295 ((rel)-MC180295) is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC50 of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. MC180295 also inhibits GSK-3α and GSK-3β. MC180295 ((rel)-MC180295) has potent anti-tumor effect.
  • HY-B0091S1
    Adapalene-d6 Methyl Ester

    		RAR/RXR Autophagy Apoptosis Cancer Inflammation/Immunology Neurological Disease
    Adapalene-d6 Methyl Ester is the deuterium labeled Adapalene. Adapalene (CD271), a third-generation synthetic retinoid, is widely used for the research of acne. Adapalene is a potent RAR agonist, with AC50s of 2.3 nM, 9.3 nM, and 22 nM for RARβ, RARγ, RARα, respectively. Adapalene also inhibits the enzymatic activity of GOT1 in a non-competitive manner. Adapalene exhibits anti-tumor activity.
  • HY-10201A
    Sorafenib Tosylate

    Bay 43-9006 Tosylate

    		 Raf VEGFR FLT3 Autophagy Ferroptosis Apoptosis Cancer
    Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator.
  • HY-146511
    Anticancer agent 41

    		Others Cancer
    Anticancer agent 41 is a potent anticancer agent, shows a potent antitumor activity against MDA-MB-231 cell with an IC50 of 3.99 μM[1].
  • HY-13772
    Valrubicin

    AD-32

    		 PKC Antibiotic Cancer Inflammation/Immunology
    Valrubicin is a chemotherapy agent, inhibits TPA- and PDBu-induced PKC activation with IC50s of 0.85 and 1.25 μM, respectively, and has antitumor and antiinflammatory activity.
  • HY-136582
    Androgen receptor-IN-2

    		Androgen Receptor Cancer
    Androgen receptor-IN-2 is a potent and orally active androgen receptor inhibitor. Androgen receptor-IN-2 has antitumor activity against prostate cancer.
  • HY-N7611
    7-Prenyloxyaromadendrin

    		Others Cancer
    7-Prenyloxyaromadendrin is a flavonoid from Pterocaulon alopecuroides with antitumor activity. 7-Prenyloxyaromadendrin shows good antiproliferative activity in tumor cell lines.
  • HY-101414
    L-DABA

    L-2,4-Diaminobutyric acid

    		 GABA Receptor Endogenous Metabolite Neurological Disease Cancer
    L-DABA (L-2,4-Diaminobutyric acid) is a week GABA transaminase inhibitor with an IC50 of larger than 500 μM; exhibits antitumor activity in vivo and in vitro.
  • HY-126804
    Safracin B

    		Antibiotic Cancer Infection
    Safracin B, a tetrahydroisoquinoline (THIQ) alkaloid, is a naturally occurring antibiotic from Pseudomonas fluorescens. Safracin B exhibits broad spectrum antimicrobial and strong antitumor activities.
  • HY-107578
    Macbecin

    Macbecin I; NSC 330499

    		 HSP Cancer
    Macbecin is a stable HSP90 inhibitor by binding to the ATP-binding site with an IC50 of 2 μM and a Kd of 0.24 μM. Macbecin exhibits antitumor and cytocidal activities.
  • HY-133117A
    (Rac)-BAY-985

    		IKK Cancer
    (Rac)-BAY-985 (Compound Example 100.01) is a potent, ATP-competitive and selective TBK1 inhibitor with an IC50 of 1.5 nM. Antitumor efficacy.
  • HY-N1318S
    Salvigenin-d9

    		Autophagy Cancer Inflammation/Immunology Neurological Disease
    Salvigenin-d9 is the deuterium labeled Salvigenin. Salvigenin is a natural polyphenolic compound, with neuroprotective effect. Salvigenin has antitumor cytotoxic and immunomodulatory properties.
  • HY-112805
    FCHFHS-ST7612AA1

    		Drug-Linker Conjugates for ADC Cancer
    FCHFHS-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity.
  • HY-136293
    Mechercharmycin A

    		Apoptosis Cancer
    Mechercharmycin A is a cytotoxic substance isolated from marine-derived Thermoactinomyces sp. YM3-251. Mechercharmycin A exhibits relatively strong antitumor activity.
  • HY-118474
    GW 610

    NSC 721648

    		 Others Cancer
    GW 610 (NSC 721648), an antitumor agent, shows potent and selective anticancer activity against lung, colon, and breast cancer cell lines.
  • HY-N9470
    λ-Carrageenan

    		Others Cancer Inflammation/Immunology
    λ-Carrageenan is a seaweed polysaccharide which has been generally used as proinflammatory agent in the basic research. λ-Carrageenan is a potent antitumor agent.
  • HY-111502
    Y06036

    		Epigenetic Reader Domain Cancer
    Y06036 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with Kd value of 82 nM. Antitumor activity.
  • HY-N9460
    Sibiromycin

    		DNA Alkylator/Crosslinker Antibiotic Cancer
    Sibiromycin is a naturally produced glycosylated pyrrolobenzodiazepines (PBDs). Sibiromycin is also a potent antitumor antibiotic that binds covalently to DNA in the minor groove at the NH2 of guanine.
  • HY-144817
    Tubulin inhibitor 27

    		Microtubule/Tubulin Cancer
    Tubulin inhibitor 27 (DYT-1) is a tubulin polymerisation inhibitor with an IC50 of 25.6 µM. Tubulin inhibitor 27 shows anti-angiogenesis and antitumor activities.
  • HY-111783
    AZD-7648

    		DNA-PK ATM/ATR PI3K Apoptosis Cancer
    AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity.
  • HY-144744
    NF-κB-IN-3

    		NF-κB Cancer
    NF-κB-IN-3 (Compound 2) is a NF-κB inhibitor with an IC50 of 0.70 µM. NF-κB-IN-3 can be used as an antitumor agent.
  • HY-100510
    RAF709

    		Raf Cancer
    RAF709 is a potent, selective, and efficacious RAF inhibitor with IC50s of 0.4 nM and 0.5 nM for BRAF and CRAF, respectively. Antitumor efficacy.
  • HY-17503
    Metoprolol

    		Adrenergic Receptor Apoptosis Cancer Infection Endocrinology Cardiovascular Disease
    Metoprolol is an orally active, selective β1-adrenoceptor antagonist. Metoprolol shows anti-inflammation, antitumor and anti-angiogenic properties.
  • HY-115568
    BETd-246

    		PROTACs Epigenetic Reader Domain Cancer
    BETd-246 is a second-generation and PROTAC-based BET bromodomain (BRD) inhibitor connected by ligands for Cereblon and BET, exhibiting superior selectivity, potency and antitumor activity.
  • HY-N0017
    Bergenin

    Cuscutin

    		 Autophagy Apoptosis Bacterial Fungal Virus Protease Cancer Infection Inflammation/Immunology
    Bergenin is a cytoprotective and antioxidative polyphenol found in many medicinal plants. Bergenin has a wide spectrum activities such as hepatoprotective, antiinflammatory, immunomodulatory, antitumor, antiviral, and antifungal properties.
  • HY-116786
    11-Hydroxycanthin-6-one

    		Others Cancer
    11-Hydroxycanthin-6-one, a canthin-6-one alkaloid, is an antitumor agent which shows potent cytotoxic activity.
  • HY-129071
    Vindesine sulfate

    		Microtubule/Tubulin Cancer
    Vindesine sulfate is a potent tubulin inhibitor with an Ki of 0.110 µM. Vindesine sulfate shows anti-proliferation effect in vitro. Vindesine sulfate shows antitumor effect in vivo.
  • HY-102087
    JPM-OEt

    		Cathepsin Cancer
    JPM-OEt is a broad spectrum cysteine cathepsin inhibitor. JPM-OEt binds covalently in the active site, and irreversibly inhibits the cysteine cathepsin family. Antitumor activity.
  • HY-120448
    QTX125

    		HDAC Apoptosis Cancer
    QTX125 is a potent and highly selective HDAC6 inhibitor. QTX125 exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects.
  • HY-126218
    HSV-TK substrate

    		HSV Cancer
    HSV-TK substrate is a substrate for HSV-TK, and induces multi-log cytotoxicity in HSV-TK-expressing and bystander cells. HSV-TK substrate shows antitumor activity.
  • HY-101978
    CPI-444

    V81444; ciforadenant

    		 Adenosine Receptor Cancer
    CPI-444 (V81444) is a potent, orally active and selective adenosine A2A receptor (A2AR) antagonist, which induces antitumor responses.
  • HY-128896
    Nitro-PDS-Tubulysin M

    		Drug-Linker Conjugates for ADC Cancer
    Nitro-PDS-Tubulysin M is a drug-linker conjugate for ADC with potent antitumor activity by using Tubulysin M (a tubulin polymerization inhibitor), linked via the ADC linker Nitro-PDS.
  • HY-N4111
    Wushanicaritin

    		Others Cancer Inflammation/Immunology
    Wushanicaritin exhibits significant antioxidant activity (IC50=35.3 μM) in DPPH radical scavenging activity tests. Antitumor effects and anti-inflammatory property.
  • HY-111899
    7-Ethoxyrosmanol

    		Others Cancer
    7-Ethoxyrosmanol is a phenolic diterpene that is isolated from Salvia chamelaeagnea. 7-Ethoxyrosmanol has antioxidant activity in vitro and antitumor effects on neuroblastoma cells.
  • HY-15582
    Auristatin E

    		Microtubule/Tubulin ADC Cytotoxin Cancer
    Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates. Auristatin E inhibits cell division by blocking the polymerisation of tubulin.
  • HY-101568
    Roblitinib

    FGF-401

    		 FGFR Cancer
    Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC50 of 1.9 nM. Roblitinib has antitumor activity.
  • HY-N10540
    Aplyronine A

    		Autophagy Apoptosis Cancer
    Aplyronine A is a specific actin-depolymerizing agent. Aplyronine A has antitumor and apoptosis effect. Aplyronine A can be used for the research of cancer and muscle contraction, cell motility and cell division.
  • HY-136499
    DI-82

    		Others Cancer
    DI-82 is a potent deoxycytidine kinase (dCK) inhibitor with an IC50 app of 27.8 nM and Ki app of 9.2 nM. DI-82 has antitumor activity.
  • HY-124944
    APS6-45

    		Ras Cancer
    APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity.
  • HY-131065
    MET kinase-IN-2

    		c-Met/HGFR Cancer
    MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM. MET kinase-IN-2 has antitumor activity.
  • HY-149029
    TH-6

    		HDAC Apoptosis Reactive Oxygen Species Cancer
    TH-6 is a potent HDAC inhibitor with IC50s of 0.115, 0.135, 0.242, 0.138, 2.120 µM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively. TH-6 inhibits cell migration and invasion. TH-6 induces apoptosis and cell cycle arrest at G2/M phase. TH-6 shows anti-tumor activity.
  • HY-125102
    AZ12253801

    		IGF-1R Cancer
    AZ12253801 is an ATP-competitive IGF-1R tyrosine kinase inhibitor that shows ∼10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R–driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC50 of 17 nmol/L. The IC50 for epidermal growth factor receptor (EGFR)–driven proliferation is 440 nmol/L. Anti-tumor activity.
  • HY-N6924
    Zingibroside R1

    		HIV Infection Metabolic Disease
    Zingibroside R1 is dammaranae-type triterpenoid saponin, isolated from rhizomes, taproots, and lateral roots of Panax japonicas C. A. Meyer, shows excellent anti-tumor effects as well as anti-angiogenic activity. Zingibroside R1 possesses some anti-HIV-1 activity. Zingibroside R1 has inhibitory effects on the 2-deoxy-D-glucose (2-DG) uptake by EAT cells (IC50=91.3 μM).
  • HY-128769
    M2N12

    		CDK Cancer
    M2N12 is a potent and highly selective cell division cycle 25C protein phosphatase (Cdc25C) inhibitor with an IC50 value of 0.09  μM. M2N12 also has promising activity against Cdc25A and Cdc25B with IC50 values of  0.53  μM and 1.39 μM, respectively. M2N12 has anti-tumor activity and can be used for cancer research.
  • HY-N0166
    Gramine

    Donaxine

    		 Adiponectin Receptor Adrenergic Receptor Reverse Transcriptase Cancer Infection Metabolic Disease Endocrinology
    Gramine (Donaxine) is a natural alkaloid isolated from giant reed, acts as an active adiponectin receptor (AdipoR) agonist, with IC50s of 3.2 and 4.2 µM for AdipoR2 and AdipoR1, respectively. Gramine is also a human and mouse β2-Adrenergic receptor (β2-AR) agonist. Gramine (Donaxine) has anti-tumor, anti-viral and anti-inflammatory properties.
  • HY-W011762
    VK3-OCH3

    		Others Cancer
    VK3-OCH3 is a potent antitumor agent. VK3-OCH3 shows cytotoxicity for neuroblastoma cell lines and low cytotoxicity for normal cell lines. VK3-OCH3 induces apoptosis and cell cycle arrest at G2/M phase in IMR-32 cells. VK3-OCH3 shows antitumor activity.
  • HY-114263
    NXT629

    		PPAR Cancer
    NXT629 is a potent, selective, and competitive PPAR-α antagonist, with an IC50 of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC50s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively. NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models.
  • HY-16749
    Pexidartinib

    PLX-3397

    		 c-Fms c-Kit Apoptosis Cancer
    Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity.
  • HY-W048303
    L-Azatyrosine

    		Antibiotic Cancer Infection
    L-Azatyrosine is an antitumor antibiotic isolated from Streptomyces chibaensis. L-Azatyrosine can restore normal phenotypic behavior to transformed cells bearing oncogenic Ras genes.
  • HY-101162
    SGD-1910

    		Drug-Linker Conjugates for ADC Cancer
    SGD-1910 is a drug-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala.
  • HY-149011
    CA IX-IN-1

    		Carbonic Anhydrase Cancer
    CA IX-IN-1 (compound 12g) is an effective and selective inhibitor of hCA IX with IC50 value of 7 nM. CA IX-IN-1 exhibits antitumor activity.
  • HY-B0431A
    Phenoxybenzamine hydrochloride

    		Adrenergic Receptor Cancer Endocrinology Cardiovascular Disease
    Phenoxybenzamine hydrochloride is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine hydrochloride also shows antitumor activity.
  • HY-107366
    SGN-2FF

    		Others Cancer
    SGN-2FF is a potent and orally active inhibitor of fucosylation, directly inhibits fucosyltransferase activity. SGN-2FF possesses antitumor activity.
  • HY-N0114A
    (±)-Evodiamine

    		Topoisomerase Apoptosis Cancer Inflammation/Immunology Cardiovascular Disease
    (±)-Evodiamine, a quinazolinocarboline alkaloid, is a Top1 inhibitor. Evodiamine exhibits anti-inflammatory, antiobesity, and antitumor effects. (±)-Evodiamine inhibits the proliferation of a wide variety of tumor cells by inducing their apoptosis.
  • HY-112806
    MAC-VC-PABC-ST7612AA1

    		Drug-Linker Conjugates for ADC Cancer
    MAC-VC-PABC-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity.
  • HY-139105
    20-O-Demethyl-AP3

    		Microtubule/Tubulin Cancer Infection
    20-O-Demethyl-AP3 is a minor metabolite of Ansamitocin P-3. Ansamitocin P-3, a microtubule inhibitor, is a macrocyclic antitumor antibiotic.
  • HY-136317
    MC-betaglucuronide-MMAE-1

    		Drug-Linker Conjugates for ADC Cancer
    MC-betaglucuronide-MMAE-1 is a drug-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide.
  • HY-146153
    HDAC-IN-40

    		HDAC Cancer
    HDAC-IN-40 is a potent alkoxyamide-based HDAC inhibitor with Ki values of 60 nM and 30 nM for HDAC2 and HDAC6, respectively. HDAC-IN-40 had antitumor effects.
  • HY-138645A
    5-Iminodaunorubicin hydrochloride

    		DNA/RNA Synthesis Cancer
    5-Iminodaunorubicin hydrochloride is a quinone-modified anthracycline that retains antitumor activity. 5-Iminodaunorubicin hydrochloride produces protein-concealed DNA strand breaks in cancer cells.
  • HY-136321
    MC-betaglucuronide-MMAE-2

    		Drug-Linker Conjugates for ADC Cancer
    MC-betaglucuronide-MMAE-2 is a drug-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide.
  • HY-138645
    5-Iminodaunorubicin

    		DNA/RNA Synthesis Cancer
    5-Iminodaunorubicin is a quinone-modified anthracycline that retains antitumor activity. 5-Iminodaunorubicin produces protein-concealed DNA strand breaks in cancer cells.
  • HY-136350
    BRD9500

    		Phosphodiesterase (PDE) Cancer
    BRD9500 is an orally active phosphodiesterases 3 (PDE3) inhibitor with IC50s of 10 and 27 nM for PDE3A and PDE3B, respectively. Antitumor activity.
  • HY-129156
    HS-1793

    		Apoptosis Cancer
    HS-1793 is a Resveratrol (HY-16561) analogue with antitumor activities in a variety of cancer cell lines. HS-1793 induces cell apoptosis.
  • HY-126685
    Mal-PEG4-VA-PBD

    		Drug-Linker Conjugates for ADC Cancer
    Mal-PEG4-VA-PBD is a drug-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via Mal-PEG4-VA.
  • HY-15579S
    MMAF-d8

    Monomethylauristatin F D8

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    D8-MMAF hydrochloride is a deuterated form of MMAF hydrochloride. MMAF Hydrochloride, a potent tubulin polymerization inhibitor, is used as a antitumor agent and a cytotoxic component of antibody-drug conjugates (ADCs).
  • HY-14429
    (-)-Irofulven

    MGI 114; 6-Hydroxymethylacylfulvene; NSC 683863

    		 DNA Alkylator/Crosslinker Apoptosis Cancer
    (-)-Irofulven (MGI 114), an Illudin S analog, is a DNA alkylating agent. (-)-Irofulven inhibits the replication of DNA, induces tumor cells apoptosis, and has potent antitumor activity.
  • HY-131994
    STING agonist-16

    		STING Cancer Infection
    STING agonist-16 (1a) is a specific stimulator of interferon genes (STING) agonist. STING agonist-16 (1a) can be used as a potential antiviral and antitumor tool.
  • HY-N7022
    Eclalbasaponin I

    		Others Cancer
    Eclalbasaponin I is isolated from Eclipta prostrata L with antitumor activity. Eclalbasaponin I inhibits the proliferation of hepatoma cell smmc-7721 with an IC50 value of 111.1703 μg/ml.
  • HY-126494
    DM4-SMCC

    		Drug-Linker Conjugates for ADC Cancer
    DM4-SMCC is a drug-linker conjugate for ADC with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker.
  • HY-123291
    SM-276001

    		Toll-like Receptor (TLR) IFNAR Cancer Inflammation/Immunology
    SM-276001 is a potent selective TLR7 agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer.
  • HY-N6656
    6-Hydroxycoumarin

    		Fungal Bacterial Cancer Inflammation/Immunology
    6-Hydroxycoumarin is a coumarin which has anti-inflammatory, anti-pyretic, anti-oxidant, vasodilator, anti-amoebic, anti-bacterial, anti-fungal, bacteriostatic and antitumor activity.
  • HY-N8253
    Spiraeoside

    Quercetin 4′-O-glucoside

    		 Reactive Oxygen Species Cancer Inflammation/Immunology
    Spiraeoside, an orally active natural compound, exerts antioxidant activity, inhibits reactive oxygen species (ROS) and malondialdehyde production. Spiraeoside possesses antiallergic, anti-inflammatory and antitumor activities.
  • HY-126692
    Mal-VC-PAB-ABAEP-Azonafide

    		Drug-Linker Conjugates for ADC Cancer
    Mal-VC-PAB-ABAEP-Azonafide is a drug-linker conjugate for ADC with with potent antitumor activity by using Azonafide (a cytotoxin), linked via the ADC linker Mal-VC-PAB.
  • HY-N7449
    Neamine

    		Bacterial Cancer Infection Neurological Disease Cardiovascular Disease
    Neamine, a degradation product of Neomycin, is a broad-spectrum aminoglycoside antibiotic. Neamine is an anti-angiogenesis agent targeting angiogenin. Neamine has potent antibacterial, antitumor and neuroprotective activities.
  • HY-106689
    Dihydro-5-azacytidine

    DHAC; NSC 264880

    		 Nucleoside Antimetabolite/Analog DNA Methyltransferase Cancer
    Dihydro-5-azacytidine (DHAC), the nucleoside analog, is incorporated into DNA and inhibits DNA methylation. Dihydro-5-azacytidine has an antitumor activity.
  • HY-138799
    KA2507

    		HDAC Cancer
    KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models.
  • HY-107324
    β-Elemene

    (-)-β-Elemene; Levo-β-elemene

    		 Apoptosis Cancer
    β-Elemene ((-)-β-Elemene; Levo-β-elemene) is isolated from natural plant Curcuma aromatica with an antitumor activity. β-Elemene can induce cell apoptosis.
  • HY-B0431
    Phenoxybenzamine

    		Adrenergic Receptor Cancer Endocrinology Cardiovascular Disease
    Phenoxybenzamine is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine also shows antitumor activity.
  • HY-N0622
    Morusin

    Mulberrochromene

    		 NF-κB STAT Bacterial Cancer Infection Inflammation/Immunology
    Morusin is a prenylated flavonoid isolated from Morus alba Linn. with various biological activities, such as antitumor, antioxidant, and anti-bacteria property. Morusin could inhibit NF-κB and STAT3 activity.
  • HY-137450
    Senaparib

    IMP4297

    		 PARP Cancer
    Senaparib (IMP4297) is a highly potent, selective and orally active PARP1/2 inhibitor. Senaparib (IMP4297) exhibits strong antitumor activity in animal models.
  • HY-135152
    CYPMPO

    		Reactive Oxygen Species Cancer
    CYPMPO is a spin-trapping reagent. CYPMPO, a cyclic DEPMPO-type nitrone, is evaluated for spin-trapping capabilities toward hydroxyl and superoxide radicals. anti-oxidant and anti-tumor activity.
  • HY-128906
    MC-Val-Cit-PAB-Retapamulin

    		Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-Retapamulin is a drug-linker conjugate for ADC with potent antitumor activity by using Retapamulin (a ribosome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-108488
    KB SRC 4

    		Src Cancer
    KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.
  • HY-122818
    bpV(phen) trihydrate

    		PTEN Phosphatase Parasite Apoptosis Cancer Infection Metabolic Disease Inflammation/Immunology
    bpV(phen) trihydrate, a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC50s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) trihydrate inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) trihydrate strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) trihydrate can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity.
  • HY-132832
    Sirpiglenastat

    DRP-104

    		 Others Cancer
    Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.
  • HY-149015
    FTase-IN-1

    		Farnesyl Transferase Cancer
    FTase-IN-1 (compound 17a) is a potent and specific inhibitor of fanesyl transferase (FTase) with an IC50 of 0.35 μM. FTase-IN-1 displays cytotoxicity potential and antitumor activity.
  • HY-13810
    PF-04880594

    		Raf Cancer
    PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity.
  • HY-150507
    JNJ-4355

    		Bcl-2 Family Cancer
    JNJ-4355 is a highly potent MCL-1 (myeloid cell leukemia-1) inhibitor, with KI of 18 pM. JNJ-4355 shows antitumor activity.
  • HY-144804
    VEGFR-2-IN-17

    		VEGFR Cancer
    VEGFR-2-IN-17 (Compound 15a) is a potent VEGFR-2 inhibitor with an IC50 of 67.25 nM. VEGFR-2-IN-17 shows antitumor activities.
  • HY-P9905
    Cetuximab

    C225

    		 EGFR Cancer
    Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.
  • HY-146014
    Multi-kinase-IN-1

    		Apoptosis c-Met/HGFR PDGFR Src TAM Receptor Cancer
    Multi-kinase-IN-1 (Compound 11k) is a potent kinase inhibitor with antitumor activity. Multi-kinase-IN-1 induces cell apoptosis, and can be studied for colorectal cancer.
  • HY-148091
    Duocarmycin analog-2

    		DNA Alkylator/Crosslinker Cancer
    Duocarmycin analog-2 is a potent DNA alkylating agent. Duocarmycin analog-2 can be used of synthetic immunoconjugate. Duocarmycin analog-2 has antitumor activity.
  • HY-19599
    Vorozole

    (+)-Vorozole; R83842

    		 Aromatase Cancer
    Vorozole is a potent and selective, orally active non-steroidal aromatase inhibitor. Vorozole shows antitumor activity in vivo. Vorozole has the potential for the research of mammary cancer.
  • HY-130233
    S516

    		Microtubule/Tubulin Cancer
    S516 (Compound 22) is an active metabolite of CKD-516 and a potent tubulin polymerization inhibitor with an IC50 of 4.29 μM. S516 has marked antitumor activity.
  • HY-145859
    Topo I-IN-1

    		Topoisomerase Apoptosis Reactive Oxygen Species Cancer
    Topo I-IN-1 (Compound 14d) is a potent Topo I inhibitor with antitumor activity and DNA intercalative capability. Topo I-IN-1 induces cell apoptosis.
  • HY-124584S
    Minnelide-d3

    		Apoptosis Cancer
    Minnelide-d3 is the deuterium labeled Minnelide. Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide promotes apoptosis.
  • HY-145330
    NSC639828

    		DNA/RNA Synthesis Cancer
    NSC639828 is a potent inhibitor of DNA polymerase α with an IC50 of 70 μM. NSC639828 has high antitumor activity. NSC639828 has the potential for researching cancer disease.
  • HY-B1714A
    NSC 601980

    		Others Cancer
    NSC601980 shows antitumor activity in the yeast screening experiment, which can inhibit cell proliferation in the COLO 205 and HT29 with Log GI 50 of -6.6 and -6.9 respectively.
  • HY-147993
    Aurora kinase inhibitor-10

    		Aurora Kinase Cancer
    Aurora kinase inhibitor-10 (Compound 6c) is an orally active Aurora B inhibitor with an IC50 of 8 nM. Aurora kinase inhibitor-10 shows antitumor activity.
  • HY-120448A
    QTX125 TFA

    		HDAC Apoptosis Cancer
    QTX125 TFA is a potent and highly selective HDAC6 inhibitor. QTX125 TFA exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects.
  • HY-128907
    MC-Val-Cit-PAB-clindamycin

    		Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-clindamycin is a drug-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-N7591
    Millepachine

    		Apoptosis Cancer
    Millepachine is a bioactive natural chalcone from Chinese herbal medicine Millettia pachycarpa Benth, exhibits strong antitumor effects against numerous human cancer cells both in vitro and in vivo.
  • HY-N0878
    Bufotalin

    		Apoptosis Reactive Oxygen Species Cancer
    Bufotalin is a steroid lactone isolated from Venenum Bufonis with potently antitumor activities. Bufotalin induces cancer cell apoptosis and also induces endoplasmic reticulum (ER) stress activation.
  • HY-128957
    Vc-seco-DUBA

    SYD985

    		 Drug-Linker Conjugates for ADC Cancer
    Vc-seco-DUBA (SYD985) is a drug-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco.
  • HY-N7271
    Solanidine

    		Others Cancer
    Solanidine is a cholestane alkaloid isolated from several potato species including Solanum demissum, Solanum acaule, and Solanum tuberosum. Solanidine can inhibit proliferation and exhibit obvious antitumor effect.
  • HY-145828
    Microtubule inhibitor 2

    		Microtubule/Tubulin Ferroptosis Cancer
    Microtubule inhibitor 2 is a potent and selective, orally active microtubule inhibitor. Microtubule inhibitor 2 triggers cell death through ferroptosis . Microtubule inhibitor 2 shows antitumor activity.
  • HY-128968
    PEG4-aminooxy-MMAF

    		Microtubule/Tubulin Drug-Linker Conjugates for ADC Cancer Inflammation/Immunology
    PEG4-aminooxy-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4.
  • HY-10231
    PX-478

    		HIF/HIF Prolyl-Hydroxylase Autophagy Cancer
    PX-478 is an orally active HIF-1α inhibitor with potent antitumor activities. PX-478 can cross the blood-brain barrier.
  • HY-138799A
    KA2507 monohydrochloride

    		HDAC Cancer Inflammation/Immunology
    KA2507 hydrochloride is a potent and highly selective inhibitor of HDAC6 (IC50=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects.
  • HY-128902
    MC-Val-Cit-PAB-vinblastine

    		Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-vinblastine is a drug-linker conjugate for ADC with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-17503B
    Metoprolol tartrate

    		Adrenergic Receptor Apoptosis Cancer Infection Endocrinology Cardiovascular Disease
    Metoprolol tartrate is an orally active, selective β1-adrenoceptor antagonist. Metoprolol tartrate shows anti-inflammation, antitumor and anti-angiogenic properties.
  • HY-120350
    BI-1347

    		CDK Cancer
    BI-1347 is an orally active, selective and potent CDK8 inhibitor (IC50=1.1 nM). BI-1347 shows anti-tumoral activity.
  • HY-136684
    BrBzGCp2

    S-p-Bromobenzylglutathione cyclopentyl diester

    		 Glyoxalase (GLO) Cancer Neurological Disease
    BrBzGCp2 is a Glyoxalase 1 (GLO1) inhibitor, with a GC50 of 4.23 μM in HL-60 cells. BrBzGCp2 possesses antitumor and neuroprotective activity.
  • HY-126491
    SPP-DM1

    		Drug-Linker Conjugates for ADC Cancer
    SPP-DM1 is a drug-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker SPP.
  • HY-100760
    Toxoflavin

    Xanthothricin; Toxoflavine; PKF-118-310

    		 β-catenin Bacterial Antibiotic Cancer Infection
    Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor activity. Antibiotic properties.
  • HY-147327
    N-Formylsarcolysine

    		Others Cancer
    N-Formylsarcolysine has antitumor activity, and inhibits leukemia by increasing the Hb and erythrocyte levels and decreasing the number of leukocytes. N-Formylsarcolysine also involves in glioblastoma and other diseases research.
  • HY-12823
    BLU9931

    		FGFR Cancer
    BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 3 nM and a Kd of 6 nM. BLU9931 has significant antitumor activity.
  • HY-128961
    MC-Alkyl-Hydrazine Modified MMAF

    		Drug-Linker Conjugates for ADC Cancer
    MC-Alkyl-Hydrazine Modified MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the Modified MMAF (a tubulin inhibitor), linked via the noncleavable MC-Alkyl-Hydrazine.
  • HY-17503A
    Metoprolol succinate

    		Adrenergic Receptor Apoptosis Cardiovascular Disease Endocrinology Cancer
    Metoprolol succinate is an orally active, selective β1-adrenoceptor antagonist. Metoprolol succinate shows anti-inflammation, antitumor and anti-angiogenic properties.
  • HY-N10387
    Glucodichotomine B

    		Others Cancer
    Glucodichotomine B (Compound 13) is a natural product which can be isolated from the roots of Chinese medicinal plant Stellaria dichotoma L. var. lanceolata. Glucodichotomine B shows antitumor activity.
  • HY-16961
    Sitravatinib

    MGCD516; MG-516

    		 VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor Cancer Inflammation/Immunology
    Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.
  • HY-W009732
    Sinapinic acid

    Sinapic acid

    		 HDAC Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species Apoptosis Cancer Metabolic Disease
    Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of HDAC, with an IC50 of 2.27 mM, and also inhibits ACE-I activity. Sinapinic acid posssess potent anti-tumor activity, induces apoptosis of tumor cells. Sinapinic acid shows antioxidant and antidiabetic activities. Sinapinic acid reduces total cholesterol, triglyceride, and HOMA-IR index, and also normalizes some serum parameters of antioxidative abilities and oxidative damage in ovariectomized rats.
  • HY-146755
    TIY-7

    		Trk Receptor Cancer
    TIY-7 is a selective and orally active tropomyosin receptor kinase (TRK) inhibitor. TIY-7 shows enzyme inhibitory activity with IC50s of 2.9, 1.1, 0.7, 0.8, 0.8, 0.2 nM for TRKA, TRKA G595R, TRKA G667C, TRKA F589L, TRKC G623R, TRKC G696A, respectively. TIY-7 shows anti-tumor potency in mouse xenograft model.
  • HY-145102
    NCT-58

    		HSP Apoptosis Cancer
    NCT-58 is a potent inhibitor of C-terminal HSP90. NCT-58 does not induce the heat shock response (HSR) due to its targeting of the C-terminal region and elicits anti-tumor activity via the simultaneous downregulation of HER family members as well as inhibition of Akt phosphorylation. NCT-58 kills Trastuzumab-resistant breast cancer stem-like cells. NCT-58 induces apoptosis in HER2-positive breast cancer cells.
  • HY-151453
    Topoisomerase IIα-IN-4

    		Topoisomerase Apoptosis Cancer
    Topoisomerase IIα-IN-4 (F2) is a non-intercalative ATP-competitive human DNA topoisomerase II inhibitor with an IC50 value of 3.8 and 10.1 μM for TopoIIα and TopoIIβ, respectively. Topoisomerase IIα-IN-4 shows potent potency in apoptosis induction and cell cycle arrest in HepG2 cells. Topoisomerase IIα-IN-4 exhibits strong antitumor activities against human cancer cell lines, it can be used for the research of cancer.
  • HY-17503C
    Metoprolol fumarate

    CGP 2175C; Lopressor OROS

    		 Adrenergic Receptor Apoptosis Cancer Infection Endocrinology Cardiovascular Disease
    Metoprolol fumarate (CGP 2175C) is an orally active, selective β1-adrenoceptor antagonist. Metoprolol fumarate shows anti-inflammation, antitumor and anti-angiogenic properties.
  • HY-136645
    EP4 receptor antagonist 2

    		Prostaglandin Receptor Cancer
    EP4 receptor antagonist 2 (compound 2-13) is a potent EP4 receptor antagonist with an IC50 of 7.8 nM. EP4 receptor antagonist 2 shows antitumor activity.
  • HY-150036
    Anthramycin

    		Antibiotic Cholecystokinin Receptor Cancer
    Anthramycin, a member of the pyrolobenzodiazepine (PBD) family, is a potent antibiotic. Anthramycin has potent antitumor activity. Anthramycin can act as an potent antagonist of cholecystokinin in the central nervous system in mice.
  • HY-136289
    MB-VC-MGBA

    		Drug-Linker Conjugates for ADC Cancer
    MB-VC-MGBA is a drug-linker conjugate for ADC with potent antitumor activity by using MGBA (minor-groove-binding DNA-alkylating agent), linked via the ADC linker MB-VC.
  • HY-128903
    MC-Val-Cit-PAB-carfilzomib iodide

    		Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-carfilzomib iodide is a drug-linker conjugate for ADC with potent antitumor activity by using carfilzomib (an irreversible proteasome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-133433
    DBCO-PEG4-VA-PBD

    		Drug-Linker Conjugates for ADC Cancer
    DBCO-PEG4-VA-PBD is a drug-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via DBCO-PEG4-VA.
  • HY-136316
    MC-VC-PAB-MMAD

    		Microtubule/Tubulin Drug-Linker Conjugates for ADC Cancer
    MC-VC-PAB-MMAD is a drug-linker conjugate for ADC with potent antitumor activity by using MMAD (a potent tubulin inhibitor), linked via the cleavable ADC linker MC-VC-PAB.
  • HY-59208
    4-Quinolinol

    Kynurine

    		 Endogenous Metabolite Cancer Neurological Disease
    4-Quinolone (Kynurine) is a quinoline derivative. Kynurine pathway modulates tryptophan metabolism and involves in neuroprotective effect. Kynurine promotes tumor cell survival and motility by suppressing antitumor immune.
  • HY-143302
    Anticancer agent 31

    		Others Cancer
    Anticancer agent 31 is a 1,3-diphenylurea quinoxaline derivative, and a anticancer agent. Anticancer agent 31 exhibits antitumor acitvity by arresting cell cycle at S phase and inducing apoptosis.
  • HY-144697
    p38 MAPK-IN-3

    		p38 MAPK Apoptosis Reactive Oxygen Species Cancer
    p38 MAPK-IN-3 (Compound 2c) is a p38α MAPK inhibitor. p38 MAPK-IN-3 has antitumor activities and induces apoptosis and ROS.
  • HY-147057A
    FAP-2286 acetate

    		Others Cancer
    FAP-2286 acetate is the conjugate of a fibroblast activation protein (FAP)-binding peptide. FAP-2286 acetate can be labeled with radionuclides for theranostic applications. FAP-2286 acetate has antitumor activity.
  • HY-147136
    MYF-03-176

    		Others Cancer
    MYF-03-176 is an orally active and potent anticancer agent. MYF-03-176 shows strong antitumor efficacy in MPM mouse xenograft model via oral administration.
  • HY-14949
    Cevipabulin

    TTI-237

    		 Microtubule/Tubulin Cancer
    Cevipabulin (TTI-237) is an oral, microtubule-active antitumor compound and inhibits the binding of [ 3H] vinblastine to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line.
  • HY-136315
    OSu-Glu-VC-PAB-MMAD

    		Microtubule/Tubulin Drug-Linker Conjugates for ADC Cancer
    OSu-Glu-VC-PAB-MMAD is a drug-linker conjugate for ADC with potent antitumor activity by using MMAD (a potent tubulin inhibitor), linked via the cleavable ADC linker OSu-Glu-VC-PAB.
  • HY-128955
    MC-VC-PABC-Aur0101

    		Drug-Linker Conjugates for ADC Cancer
    MC-VC-PABC-Aur0101 is a drug-linker conjugate for ADC with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC.
  • HY-100875A
    Bisantrene dihydrochloride

    CL-216942 dihydrochloride

    		 Topoisomerase Cancer
    Bisantrene dihydrochloride is a highly effective antitumor agent, it exerts its cytotoxicity by affecting DNA intercalation. Bisantrene dihydrochloride targets eukaryotic type II topoisomerases. Bisantrene dihydrochloride is a substrate of MDR1.
  • HY-N0351S
    p-Coumaric acid-13C3

    		Endogenous Metabolite Cancer
    p-Coumaric acid-13C3 is the 13C-labeled p-Coumaric acid. p-Coumaric acid is the abundant isomer of cinnamic acid which has antitumor and anti-mutagenic activities.
  • HY-100875
    Bisantrene

    CL216942

    		 Topoisomerase Cancer
    Bisantrene is a highly effective antitumor agent, it exerts its cytotoxicity by affecting DNA intercalation. Bisantrene targets eukaryotic type II topoisomerases. Bisantrene is a substrate of MDR1.
  • HY-144803
    VEGFR-2-IN-16

    		VEGFR Cancer
    VEGFR-2-IN-16 (Compound 15b) is a potent VEGFR-2 inhibitor with an IC50 of 86.36 nM. VEGFR-2-IN-16 shows antitumor activities.
  • HY-128893
    MC-Sq-Cit-PAB-Gefitinib

    		Drug-Linker Conjugates for ADC Cancer
    MC-Sq-Cit-PAB-Gefitinib is a drug-linker conjugate for ADC with potent antitumor activity by using Gefitinib (an EGFR tyrosine kinase inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.
  • HY-19095
    TNP-351

    		Antifolate Cancer
    TNP-351 is an antifolate. TNP-351, a dihydrofolate reductase (DHFR) inhibitor, has potent antitumor activity against not only leukemia cells but also solid tumor cells in vitro and in vivo.
  • HY-N9488
    Girinimbine

    Girinimbin

    		 Apoptosis Bacterial Parasite Cancer Infection Inflammation/Immunology
    Girinimbine (Girinimbin) is a carbazole alkaloid with a variety of biological effects. Girinimbine can induce apoptosis, and has antitrypanosomal, antiplatelet activity, antibacterial activity, anti-inflammatory, antioxidant and antitumor activities.
  • HY-133492
    DBCO-PEG4-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    DBCO-PEG4-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4.
  • HY-115937
    c-Met-IN-9

    		c-Met/HGFR Apoptosis Cancer
    c-Met-IN-9, a 4-phenoxypyridine derivative, is a c-Met kinas inhibitor with an IC50 of 12 nM. c-Met-IN-9 induces cells apoptosis, and has antitumor activities.
  • HY-128908
    MC-Val-Cit-PAB-Indibulin

    		Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-Indibulin is a drug-linker conjugate for ADC with potent antitumor activity by using Indibulin (an orally applicable inhibitor of tubulin assembly), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-128899
    MC-Val-Cit-PAB-Auristatin E

    		Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-Auristatin E is a drug-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-115349
    Neamine tetrahydrochloride

    		Bacterial Cancer Infection Neurological Disease
    Neamine tetrahydrochloride, a degradation product of Neomycin, is a broad-spectrum aminoglycoside antibiotic. Neamine tetrahydrochloride is an anti-angiogenesis agent targeting angiogenin. Neamine tetrahydrochloride has potent antibacterial, antitumor and neuroprotective activities.
  • HY-126492
    Vat-Cit-PAB-Monomethyl Dolastatin 10

    		Drug-Linker Conjugates for ADC Cancer
    Vat-Cit-PAB-Monomethyl Dolastatin 10 is a drug-linker conjugate for ADC with potent antitumor activity by using Monomethyl Dolastatin 10 (a potent tubulin inhibitor), linked via the ADC linker Vat-Cit-PAB.
  • HY-117288A
    S55746 hydrochloride

    BCL201 hydrochloride

    		 Bcl-2 Family Cancer
    S55746 hydrochloride (BCL201 hydrochloride) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 hydrochloride (BCL201 hydrochloride) has antitumor activity with low toxicity.
  • HY-147981
    Tubulin polymerization-IN-31

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-31 (Compound 4c) is a tubulin polymerization inhibitor with an IC50 of 3.64 μM. Tubulin polymerization-IN-31 induces cancer cell apoptosis and shows antitumor activity.
  • HY-128897
    MC-VC-PABC-DNA31

    		Drug-Linker Conjugates for ADC Cancer
    MC-VC-PABC-DNA31 is a drug-linker conjugate for ADC with potent antitumor activity by using DNA31 (a potent RNA polymerase inhibitor), linked via the ADC linker MC-VC-PABC.
  • HY-16200
    Ethynylcytidine

    ECyD; TAS-106; 3'-C-Ethynylcytidine

    		 DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Cancer
    Ethynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis, inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancer.
  • HY-106662
    Chloroquinoxaline sulfonamide

    Chloroquinoxaline; NSC-339004

    		 Topoisomerase Parasite Cancer Infection
    Chloroquinoxaline sulfonamide (Chloroquinoxaline), a structural analogue of sulfaquinoxaline, is a topoisomerase II alpha/beta poison. Chloroquinoxaline sulfonamide is used to control coccidiosis in poultry, rabbit, sheep, and cattle. Antitumor activity.
  • HY-107777
    LLY-283

    		Histone Methyltransferase Cancer
    LLY-283 is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM and a Kd of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity.
  • HY-102026
    Formycin A

    NSC 102811

    		 HIV Nucleoside Antimetabolite/Analog Antibiotic Cancer Infection
    Formycin A (NSC 102811), a purine nucleoside antibiotic, is a potent human immunodeficiency virus type 1 (HIV-1) inhibitor with an EC50 of 10 μM. Formycin A shows antitumor and antiviral activities.
  • HY-145989
    Aminobenzenesulfonic auristatin E

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic.
  • HY-15717
    Kobe2602

    		Ras Cancer
    Kobe2602 is a Ras-Raf interaction inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki of 149 μM. Kobe2602 has antitumor activity.
  • HY-N2380
    N-Benzoyl-(2R,3S)-3-phenylisoserine

    		Others Cancer
    N-Benzoyl-(2R,3S)-3-phenylisoserine is a Taxol C-13 Side Chain and crucial for the strong antitumor activity of Taxol.
  • HY-117288
    S55746

    BCL201

    		 Bcl-2 Family Cancer
    S55746 (BCL201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BCL201) has antitumor activity with low toxicity.
  • HY-128909
    MC-Val-Cit-PAB-rifabutin

    		Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-rifabutin is a drug-linker conjugate for ADC with potent antitumor activity by using rifabutin (an DNA-dependent RNA polymerase inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-147337
    MeTC7

    		VD/VDR Cancer
    MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC50 value of 2.9 μM. MeTC7 shows good antitumor effects.
  • HY-129545
    DS-1001b

    		Isocitrate Dehydrogenase (IDH) Cancer
    DS-1001b is a mutant IDH-1 (Isocitrate Dehydrogenase-1) inhibitor extracted from patent WO2016052697A1, Example 168, and has antitumor activity.
  • HY-137552
    MKI-1

    MASTL Kinase Inhibitor-1

    		 Others Cancer
    MKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer.
  • HY-136320
    MC-VC-PABC-SP 141

    		Drug-Linker Conjugates for ADC MDM-2/p53 Cancer
    MC-VC-PABC-SP 141 is a drug-linker conjugate for ADC with potent antitumor activity by using SP 141 (a potent MDM2 inhibitor), linked via the cleavable ADC linker MC-VC-PABC.
  • HY-16961A
    Sitravatinib malate

    MGCD516 malate; MG-516 malate

    		 VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor Cancer Inflammation/Immunology
    Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively. Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.
  • HY-10201S2
    Sorafenib-13C,d3

    		Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis Cancer
    Sorafenib-13C,d3 is the 13C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator.
  • HY-10981A
    Lenvatinib mesylate

    E7080 mesylate

    		 VEGFR FGFR PDGFR RET c-Kit Cancer
    Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
  • HY-N8533
    Sodium Camptothecin

    		DNA/RNA Synthesis Cancer Infection
    Sodium Camptothecin is a plant alkaloid, with antitumor activity. Sodium Camptothecin is a reversible inhibitor of RNA synthesis. Sodium Camptothecin is an effective inhibitor of adenovirus replication. Sodium Camptothecin inhibits DNA synthesis and causes breaks in intracellular preformed viral DNA.
  • HY-125506
    NP-G2-044

    		Others Cancer
    NP-G2-044 is a potent, orally active fascin inhibitor, with an IC50 of ~2 μM. NP-G2-044 blocks tumor metastasis and increases antitumor immune response.
  • HY-116446
    Pironetin

    		Microtubule/Tubulin Cancer
    Pironetin is an α/β unsaturated lactone isolated from Streptomyces species. Pironetin binds to α-tubulin and is a potent inhibitor of microtubule polymerization, and has cell cycle arrest and antitumor activity.
  • HY-148127
    TAM558

    		Drug-Linker Conjugates for ADC Cancer
    TAM558 is a payload molecule used for the synthesis of OMTX705. OMTX705 is a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470 (HY-148128), with antitumor activity.
  • HY-142460
    KRAS G12C inhibitor 28

    		Ras Cancer
    KRAS G12C inhibitor 28 is a KRAS G12C inhibitor with an IC50 of 57 nM. KRAS G12C inhibitor 28 has antitumor effects (WO2021113595A1; Example 1).
  • HY-126682
    Mal-VC-PAB-DM1

    		Drug-Linker Conjugates for ADC Cancer
    Mal-VC-PAB-DM1 is a drug-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB .
  • HY-125916
    Pseurotin A

    		Others Cancer
    Pseurotin A, a secondary metabolite of Aspergillus and other fungi, is a competitive inhibitor of chitin synthase and a neuritogenic agent. Pseurotin A inhibits IgE production (IC50=3.6 μM). Antitumor activity.
  • HY-126693
    SC-VC-PAB-DM1

    		Drug-Linker Conjugates for ADC Cancer
    SC-VC-PAB-DM1 is a drug-linker conjugate for ADC with with potent antitumor activity by using DM1 (Mertansine, a tubulin inhibitor) , linked via the ADC linker SC-VC-PAB.
  • HY-136327S
    Phenylacetic acid mustard-d8

    		DNA Alkylator/Crosslinker Cancer
    Phenylacetic Mustard-d8 is the deuterium labeled Phenylacetic acid mustard. Phenylacetic acid mustard is the major metabolite of the cancer chemotherapeutic agent Chlorambucil (HY-13593). Chlorambucil is an alkylating agent with antitumor activity.
  • HY-10981
    Lenvatinib

    E7080

    		 VEGFR FGFR PDGFR c-Kit RET Cancer
    Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
  • HY-N2113
    Glaucocalyxin B

    		Autophagy Cancer
    Glaucocalyxin B is an ent kaurane diterpenoid isolated from the Chinese traditional medicine Rabdosia japonica with anticancer and antitumor activity; decreases the growth of HL-60 cells with an IC50 of approximately 5.86 μM at 24 h.
  • HY-12019
    SGX-523

    		c-Met/HGFR Cancer
    SGX523 is a exquisitely selective and ATP-competitive MET inhibitor. SGX523 potently inhibits MET with an IC50 of 4 nM and is >1,000-fold selective versus other protein kinases. Antitumor activity.
  • HY-147812
    POLA1 inhibitor 1

    		Others Cancer
    POLA1 inhibitor 1 (Compound 12) is an orally active POLA1 inhibitor. POLA1 inhibitor 1 shows antitumor activity against several tumor histotypes and Adarotene-resistant cell line.
  • HY-139612
    JDQ-443

    NVP-JDQ443

    		 Ras PERK Cancer
    JDQ-443 is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). JDQ-443 shows antitumor activity.
  • HY-128904
    MC-Val-Cit-PAB-duocarmycin chloride

    		Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-duocarmycin chloride is a drug-linker conjugate for ADC with potent antitumor activity by using Duocarmycin (a DNA minor groove binding alkylating agent), linked via the ADC linker MC-Val-Cit-PAB.
  • HY-N4210
    Yadanziolide A

    		TMV Cancer Infection
    Yadanziolide A, isolated from the cultivated dry seeds of Brucea javanica, has strong antiviral activities with IC50 of 5.5 μM against tobacco mosaic virus. Yadanziolide A shows significant antitumor effects.
  • HY-128894
    MC-Sq-Cit-PAB-Dolastatin10

    		Drug-Linker Conjugates for ADC Cancer
    MC-Sq-Cit-PAB-Dolastatin10 is a drug-linker conjugate for ADC with potent antitumor activity by using Dolastatin10 (a tubulin polymerization inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.
  • HY-N0936
    Coixol

    6-Methoxy-2-benzoxazolinone; 6-MBOA

    		 Bacterial Cancer Infection
    Coixol (6-Methoxy-2-benzoxazolinone;6-MBOA) is a polyphenol extracted from coix (Coix lachryma-jobi L.var.ma-yuen Stapf) with antimicrobial and antitumor activities.
  • HY-111407
    MK-8353

    SCH900353

    		 ERK Cancer
    MK-8353 (SCH900353) is a potent, selective and orally available ERK1/2 inhibitor, with IC50s of 23.0 nM and 8.8 nM, respectively; MK-8353 has antitumor activity.
  • HY-115880
    KRAS G12D inhibitor 3

    		Ras Cancer
    KRAS G12D inhibitor 3 is a KRAS G12D inhibitor with an IC50 of <500 nM. KRAS G12D inhibitor 3 has antitumor effects (WO2022002102A1; compound 146).
  • HY-N1318
    Salvigenin

    		Autophagy Apoptosis ROS Kinase Cancer Inflammation/Immunology Neurological Disease
    Salvigenin is a natural polyphenolic compound, with neuroprotective effect. Salvigenin has antitumor cytotoxic and immunomodulatory properties. Salvigenin inhibits H2O2-induced cell apoptosis.
  • HY-139784
    Idroxioleic acid

    (R)-2-Hydroxyoleic acid; (R)-2-OHOA

    		 Others Cancer
    Idroxioleic acid ((R)-2-Hydroxyoleic acid; (R)-2-OHOA), the R enantiomer of (Rac)-Idroxioleic acid, is an orally active fatty acid that modulates the lipid composition and structure of the membranes. Idroxioleic acid has antitumor activities.
  • HY-14949C
    Cevipabulin fumarate

    TTI-237 fumarate

    		 Microtubule/Tubulin Cancer
    Cevipabulin fumarate (TTI-237 fumarate) is an oral, microtubule-active, antitumor compound and inhibits the binding of [ 3H]NSC 49842 to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line.
  • HY-N1373
    Sophoridine

    		Apoptosis Cancer
    Sophoridine is a quinolizidine alkaloid isolated from Leguminous plant Sophora flavescens. Sophoridine induces apoptosis. Sophoridine has the potential to be a novel, potent and selective antitumor drug candidate for pancreatic cancer with well-tolerated toxicity.
  • HY-P9956
    Siltuximab

    CNTO-328

    		 Interleukin Related Cancer
    Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research.
  • HY-143460
    CAXII-IN-1

    		Carbonic Anhydrase Cancer
    CAXII-IN-1 (Compound 17) is a selective CA XII inhibitor with Ki values of 3.8 nM and 56.0 nM against hCA XII and hCA IX, respectively. CAXII-IN-1 shows antitumor activity.
  • HY-19825
    Rebeccamycin

    		Topoisomerase ADC Cytotoxin Antibiotic Cancer
    Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I and has negligible effect on protein kinase C and topoisomerase II.
  • HY-133141
    DI-87

    		Others Cancer
    DI-87 is an orally active and selective deoxycytidine kinase (dCK) inhibitor with an EC50 of 10.2 nM. DI-87 has antitumor activity and is used in combination therapy against tumors expressing dCK.
  • HY-147630
    KRAS G12C inhibitor 49

    		Ras Cancer
    KRAS G12C inhibitor 49 (Compound 3-2M) is an orally active KRAS G12C inhibitor. KRAS G12C inhibitor 49 shows antitumor activity.
  • HY-13598
    Valecobulin

    CKD-516

    		 Microtubule/Tubulin Cancer
    Valecobulin (CKD516) is a valine prodrug of (S516) and a vascular disrupting agent (VDA). Valecobulin is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors.
  • HY-146465
    Anticancer agent 60

    		Microtubule/Tubulin Cancer
    Anticancer agent 60 (compound 3h) has antiproliferative activity against human HepG2 cells (IC50 = 4.13 μM) and presents antitumor efficacy in a human HepG2 xenograft mouse model.
  • HY-126562
    Piperlonguminine

    		Bacterial Fungal Antibiotic Cancer Infection Inflammation/Immunology Neurological Disease Cardiovascular Disease
    Piperlonguminine is an alkaloid amide isolated from the Piper species. Piperlonguminine shows various biological properties, including anti-inflammatory, antitumor, neuroprotective, anti-platelet, anti-melanogenic, antifungal and antibacterial activities.
  • HY-N10542
    Aplyronine C

    		Others Cancer
    Aplyronine C is an active compound. Aplyronine C shows potent antitumor activity and has cytotoxicity against HeLa-S3 cells with an IC50 values of 22 nM. Aplyronine C can be used for the research of cancer.
  • HY-15579A
    MMAF hydrochloride

    Monomethylauristatin F hydrochloride

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    MMAF (Monomethylauristatin F) hydrochloride is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A.
  • HY-16475
    TAK-441

    		Hedgehog Cancer
    TAK-441 is a highly potent and orally active hedgehog (Hh) signaling inhibitor with an IC50value of 4.4 nM. TAK-441 has strong antitumor activity in solid tumors.
  • HY-144232
    Anticancer agent 28

    		Others Cancer
    Anticancer agent 28 showed good antitumor activity in H22 allogeneic mice in vivo. Its potency in K562 cells was 50 times that of oridonin, and its < b > IC < sub > 50 < / sub > < / b > value was 0.09 μ M。
  • HY-N2108
    7-Ethylcamptothecin

    		Others Cancer
    7-Ethylcamptothecin is one of camptothecin analogues. camptothecin (CPT), a cytotoxic alkaloid isolated from Camptotheca acuminata, is shown to have strong antitumor activity against L1210 leukemia and Walker 256 carcinosarcoma models.
  • HY-105019A
    Melflufen hydrochloride

    Melphalan flufenamide hydrochloride

    		 DNA Alkylator/Crosslinker Apoptosis Cancer
    Melflufen (Melphalan flufenamide) hydrochloride, a dipeptide prodrug of Melphalan, is an alkylating agent. Melflufen hydrochloride shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen hydrochloride induces irreversible DNA damage and cytotoxicity in MM cells.
  • HY-111207
    CA224

    		CDK Apoptosis Cancer
    CA224 (Compound 1) is a selective and orally active Cdk4–cyclin D1 inhibitor with an IC50 of 6.2 µM. CA224 induces cell apoptosis and shows antitumor activity.
  • HY-145989A
    Aminobenzenesulfonic auristatin E TFA

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E TFA is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E TFA has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic.
  • HY-105019
    Melflufen

    Melphalan flufenamide

    		 DNA Alkylator/Crosslinker Apoptosis Cancer
    Melflufen (Melphalan flufenamide), a dipeptide prodrug of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells.
  • HY-137193
    5,6-Dihydroabiraterone

    		Drug Metabolite Cancer
    5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer).
  • HY-129167
    Menin-MLL inhibitor 4

    		Epigenetic Reader Domain Cancer
    Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction extracted from patent WO2017214367, compound example 1. Menin-MLL inhibitor 4 has antitumor activity.
  • HY-128759
    DYRKs-IN-2

    		DYRK Cancer
    DYRKs-IN-2 (Example 132) is a potent DYRKs inhibitor with IC50s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively. DYRKs-IN-2 has antitumor activity.
  • HY-N2000
    Bellidifolin

    		HIV Cancer Infection Inflammation/Immunology
    Bellidifolin is a xanthone isolated from the stems of Swertia punicea, with hepatoprotective, hypoglycemic, anti-oxidation, anti-inflammatory and antitumor activities. Bellidifolin also acts as a viral protein R (Vpr) inhibitor.
  • HY-145856
    VEGFR-2-IN-11

    		VEGFR Apoptosis Cancer
    VEGFR-2-IN-11 (Compound 8h) is a potent VEGFR-2 inhibitor with an IC50 of 60.27 nM. VEGFR-2-IN-11 shows antitumor activity and induces cell apoptosis.
  • HY-113612
    Cytostatin

    		Phosphatase Apoptosis Cancer
    Cytostatin is a potent and selective inhibitor of PP2A with promising antitumor activity. Cytostatin is also an inhibitor of cell adhesion to extracellular matrix and induces cell apoptosis. Cytostatin belongs to the fostriecin family of natural products.
  • HY-N10538
    Shishijimicin B

    		Others Cancer
    Shishijimicin B is an active compound of the enediyne class. Shishijimicin B shows extremely potent cytotoxicity with IC50 values of 2.0-3.3 nM. Shishijimicin B has antitumor activity and can be used for the research of cancer.
  • HY-15514A
    Merestinib dihydrochloride

    LY2801653 dihydrochloride

    		 c-Met/HGFR FLT3 ROS Kinase Discoidin Domain Receptor Cancer
    Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM).
  • HY-15514
    Merestinib

    LY2801653

    		 c-Met/HGFR FLT3 ROS Kinase Discoidin Domain Receptor Cancer
    Merestinib (LY2801653) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib (LY2801653) also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM).
  • HY-112614
    ATM Inhibitor-1

    		ATM/ATR Cancer
    ATM Inhibitor-1 is a highly potent, selective and orally active ATM inhibitor, with an IC50 of 0.7 nM, shows weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM) and PI3Kδ (IC50, 0.73 μM). ATM Inhibitor-1 exhibits anti-tumor activity.
  • HY-146267
    ERα degrader 5

    		Estrogen Receptor/ERR Cancer
    ERα degrader 5 (Compound 40) is a selective, orally bioavailable estrogen receptor (ER) degrader (SERD) with an EC50 of 1.1 nM against ERα. ERα degrader 5 shows antitumor effect in vivo.
  • HY-N10541
    Aplyronine B

    		Others Cancer
    Aplyronine B is an active compound. Aplyronine B shows potent antitumor activity and has cytotoxicity against HeLa-S3 cells with an IC50 values of 2.9 nM. Aplyronine B can be used for the research of cancer.
  • HY-142740
    Rha-PEG3-SMCC

    		Drug-Linker Conjugates for ADC Cancer
    Rha-PEG3-SMCC (compound 13) is a drug-linker conjugate for ADC with potent antitumor activity by using SMCC (a protein crosslinker), linked via the noncleavable ADC linker Rha-PEG3.
  • HY-10991
    MGCD-265 analog

    		c-Met/HGFR VEGFR Apoptosis Cancer
    MGCD-265 analog is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity.
  • HY-12442
    LY5

    		STAT Apoptosis Cancer
    LY5 is a STAT3 inhibitor with an IC50 value of 0.5 μM. LY5 induces apoptosis and inhibits STAT3 phosphorylation. LY5 shows antitumor activity in vivo, it can be used for the research of cancer.
  • HY-147834
    STING agonist-9

    		STING Cancer
    STING agonist-9 (Compound 45) is a potent STING agonist with an EC50 of 1.2 nM and 32.82 μM against h-STING and m-STING, respectively. STING agonist-9 shows antitumor activity.
  • HY-145729
    Danvatirsen

    AZD9150

    		 STAT Apoptosis Cancer
    Danvatirsen is an antisense oligonucleotide targeting STAT3 with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth.
  • HY-115941
    HDAC-IN-9

    		HDAC Microtubule/Tubulin Apoptosis Cancer
    HDAC-IN-9 is a potent and selective tubulin and HDAC dual inhibitor. HDAC-IN-9 inhibits the invasion and migration of A549 cells. HDAC-IN-9 shows potent antitumor and antiangiogenic effect in vitro and in vivo.
  • HY-126681
    SC-VC-PAB-MMAE

    		Drug-Linker Conjugates for ADC Cancer
    SC-VC-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB.
  • HY-111792
    GSK1795091

    CRX-601

    		 Toll-like Receptor (TLR) Cancer Inflammation/Immunology
    GSK1795091 (CRX-601), an immunologic stimulator, is a synthetic TLR4 agonist. Antitumor activity. GSK1795091 can be used as a vaccine adjuvant to enhance both mucosal and systemic immunity to influenza virus vaccines.
  • HY-126683
    Mal-C6-α-Amanitin

    		Drug-Linker Conjugates for ADC Cancer
    Mal-C6-α-Amanitin is a drug-linker conjugate for ADC with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6.
  • HY-123794
    MP07-66

    		Phosphatase Cancer
    MP07-66, a FTY720 analogue, is devoid of immunosuppressive effects and shows promising antitumor effects in chronic lymphocytic leukemia by disruption of the SET-PP2A complex leading to PP2A reactivation.
  • HY-108477
    TMPyP4 tosylate

    TMP 1363

    		 G-quadruplex Telomerase Cancer
    TMPyP4 tosylate (TMP 1363) is a quadruplex-specific ligand, which inhibits the interaction between G-quadruplexes and IGF-1. TMPyP4 tosylate (TMP 1363) is a telomerase inhibitor with antitumor effects in osteosarcoma cell lines.
  • HY-124012
    PCNA-I1

    		DNA/RNA Synthesis Cancer
    PCNA-I1 is a potent PCNA (proliferating cell nuclear antigen) inhibitor. PCNA-I1 directly binds PCNA trimers with a Kd of 0.41 μM and exhibits antitumor activity both in vitro and in vivo.
  • HY-N1376
    (20R)-Ginsenoside Rg3

    (20R)-Propanaxadiol; R-ginsenoside Rg3

    		 Others Cancer
    (20R)-ginsenoside Rg3 ((20R)-Propanaxadiol), one of the active compounds present in ginseng root, inhibits vascular endothelial growth factor (VEGF)(IC50=10 nM) and antitumor activities.
  • HY-108441
    CCT031374 hydrobromide

    		β-catenin Cancer
    CCT 031374 hydrobromid is a potent inhibitor of β-catenin/transcription factor (TCF) complex signaling. CCT031374 inhibits TCF-dependent transcription of genes of Wnt signaling pathway. CCT 031374 has antitumor activity.
  • HY-144217
    SKLB-197

    		ATM/ATR Cancer
    SKLB-197 showed an IC50 value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficent tumors both in vitro and in vivo.
  • HY-115880A
    KRAS G12D inhibitor 3 TFA

    		Ras Cancer
    KRAS G12D inhibitor 3 TFA is a KRAS G12D inhibitor with an IC50 of <500 nM. KRAS G12D inhibitor 3 TFA has antitumor effects (WO2022002102A1; compound 146).
  • HY-15575
    VcMMAE

    MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    VcMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
  • HY-N7765
    Oenothein B

    		HCV Bacterial Apoptosis Fungal Cancer Infection Inflammation/Immunology
    Oenothein B is a dimeric macrocyclic ellagitannin and has widely pharmacological activities, including antioxidant, anti-inflammatory, antifungal, anti-HCV, and antitumor properties. Oenothein B is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase.
  • HY-151462
    RP-6685

    		DNA/RNA Synthesis Cancer
    RP-6685 is a potent, selective and orally active DNA polymerase theta (Polθ) inhibitor with an IC50 value of 5.8 nM (PicoGreen assay). RP-6685 shows antitumor efficacy in mouse tumor xenograft model.
  • HY-13744
    Rubitecan

    RFS 2000; 9-Nitrocamptothecin

    		 Topoisomerase Cancer
    Rubitecan (RFS 2000), a Camptothecin derivative, is an orally active topoisomerase I inhibitor with broad antitumor activity, and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells.
  • HY-15579B
    MMAF sodium

    Monomethylauristatin F sodium

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A.
  • HY-148128
    TAM470

    		Microtubule/Tubulin ADC Cytotoxin Cancer
    TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity.
  • HY-148131
    MC-Val-Cit-PABA-amide-PEG4-COOH

    		ADC Linker Cancer
    MC-Val-Cit-PABA-amide-PEG4-COOH is a cleavable ADC linker used in the synthesis of OMTX705. OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs), and shows antitumor activity.
  • HY-N6961
    Lapachol

    		Bacterial Fungal Influenza Virus Parasite Cancer Infection Inflammation/Immunology
    Lapachol is a naphthoquinone that was first isolated from Tabebuia avellanedae (Bignoniaceae). Lapachol shows anti-abscess, anti-ulcer, antileishmanial, anticarcinomic, antiedemic, anti-inflammatory, antimalarial, antiseptic, antitumor, antiviral, antibacterial, antifungal and pesticidal activities.
  • HY-123979
    ζ-Stat

    NSC37044

    		 PKC Apoptosis Cancer
    ζ-Stat (NSC37044) is a specific and atypical PKC-ζ inhibitor, with an IC50 of 5 μM. ζ-Stat can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro.
  • HY-N6036
    Ganoderic acid F

    		Others Cancer
    Ganoderic acid F is a ganoderic acid. Ganoderic acid F exhibits antitumor and antimetastatic activities through inhibition of angiogenesis and alteration of proteins involving cell proliferation and/or cell death, carcinogenesis, oxidative stress, calcium signaling, and endoplasmic reticulum stress.
  • HY-19986
    AAL993

    		VEGFR Cancer Cardiovascular Disease
    IC50s of 130 nM, 23 nM, and 18 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. AAL993 shows less potently inhibits other tyrosine kinases. AAL993 possesses potent antiangiogenic and antitumor properties.
  • HY-P99250
    Onartuzumab

    MetMAb

    		 c-Met/HGFR Cancer
    Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity.
  • HY-122306
    Ansatrienin B

    Mycotrienin II

    		 Antibiotic Bacterial Cancer Infection
    Ansatrienin B (Mycotrienin II) is an ansamycin antibiotic isolated from Streptomyces. Ansatrienin B is active against fungi and yeasts, but inactive against bacteria.Ansatrienin B displays antitumor antibiotic activity and can be used as an ADC Toxin.
  • HY-N10131
    Biatractylolide

    (+)-Biatractylolide

    		 Apoptosis Cancer Neurological Disease
    Biatractylolide is a compound isolated from the ethyl acetate extract of Atractylodes macrocephala. Biatractylolide has antitumor and antioxidant activities. Biatractylolide improves cell viability, inhibits the apoptosis of cells induced by glutamate, and reduces the activity of LDH. Biatractylolide has neuroprotective effects.
  • HY-17503AS
    Metoprolol-d7 hydrochloride

    		Adrenergic Receptor Cancer Infection Endocrinology Cardiovascular Disease
    Metoprolol-d7 hydrochloride is the deuterium labeled Metoprolol. Metoprolol is an orally active, selective β1-adrenoceptor antagonist. Metoprolol shows anti-inflammation, antitumor and anti-angiogenic properties.
  • HY-B1714
    NSC 601980 (analog)

    		Others Cancer
    NSC 601980 analog is the analog of the NSC601980, NSC601980 shows antitumor activity in the yeast screening experiment, which can inhibit cell proliferation in the COLO 205 and HT29 with Log GI 50 of -6.6 and -6.9 respectively.
  • HY-15579
    MMAF

    Monomethylauristatin F

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A.
  • HY-15528
    kb NB 142-70

    		PKD Cancer
    kb NB 142-70 is a potent PKD inhibitor, with IC50s of 28.3, 58.7 and 53.2 nM for PKD1, PKD2, and PKD3, respectively. kb NB 142-70 also has antitumor activity.
  • HY-N6011
    9-Methoxycamptothecin

    		Topoisomerase Apoptosis Cancer
    9-Methoxycamptothecin (MCPT), isolated from Camptotheca acuminata, has antitumor activities through topoisomerase inhibition. 9-Methoxycamptothecin (MCPT) induces strong G2/M arrest and apoptosis in cancer.
  • HY-130812
    Gemcitabine-O-Si(di-iso)-O-Mc

    		Drug-Linker Conjugates for ADC Cancer
    Gemcitabine-O-Si(di-iso)-O-Mc is a drug-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker.
  • HY-126684
    Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA

    		Drug-Linker Conjugates for ADC Cancer
    Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is a drug-linker conjugate for ADC by using the antitumor antibiotic, Duocarmycin SA, linked via Mal-PEG4-VC-PAB-DMEA-Seco.
  • HY-108230
    ALK-IN-12

    		Anaplastic lymphoma kinase (ALK) Cancer
    ALK-IN-12 is a potent and orally active ALK inhibitor with an IC50 of 0.18 nM. ALK-IN-12 also inhibits IGF1R and InsR (IC50=20.3 and 90.6 nM). Antitumor activities.
  • HY-111237
    Butyrolactone I

    Olomoucin

    		 CDK Cancer
    Butyrolactone I is an ATP-competitive inhibitor of CDK1 as a secondary metabolite from A. terreus. Butyrolactone I has antitumor effects in non-small cell lung, small cell lung, and prostate cancer cell lines.
  • HY-100513A
    Dehydroaltenusin

    		Apoptosis DNA/RNA Synthesis Antibiotic Cancer
    Dehydroaltenusin is a small molecule selective inhibitor of eukaryotic DNA polymerase α, a type of antibiotic produced by a fungus with an IC50 value of 0.68 μM. The inhibitory mode of action of dehydroaltenusin against mammalian pol α activity is competitive with respect to the DNA template primer (Ki=0.23 µM) and non-competitive with respect to the 2'-deoxyribonucleoside 5'-triphosphate substrate (Ki=0.18 µM). Dehydroaltenusin arrests the cancer cell cycle at the S-phase and triggers apoptosis. Dehydroaltenusin possesses anti-tumor activity against human adenocarcinoma tumor in vivo.
  • HY-128860
    Mutated EGFR-IN-2

    		EGFR Cancer
    Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=＜1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity.
  • HY-129602
    SD-36

    		PROTACs STAT Apoptosis Cancer
    SD-36 is a potent and efficacious STAT3 PROTAC degrader (Kd=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC50=10 nM). SD-36 exerts robust anti-tumor activity, and achieves complete and long-lasting tumor regression in mouse tumor models. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of Cereblon ligand Lenalidomide for E3 ubiquitin ligase.
  • HY-B0421
    Mycophenolic acid

    Mycophenolate

    		 Apoptosis Bacterial Fungal Endogenous Metabolite Antibiotic Cancer Infection Inflammation/Immunology
    Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 µM. Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects.
  • HY-B0421A
    Mycophenolic acid sodium

    Mycophenolate sodium

    		 Apoptosis Bacterial Fungal Antibiotic Endogenous Metabolite Cancer Infection Inflammation/Immunology
    Mycophenolic acid sodium is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 µM. Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid sodium is an immunosuppressive agent. Antiangiogenic and antitumor effects.
  • HY-145574
    Iruplinalkib

    WX-0593

    		 Anaplastic lymphoma kinase (ALK) ROS Kinase Cancer
    Iruplinalkib (WX-0593) is a potent, selective, and orally active inhibitor of ALK and ROS1 tyrosine kinase. Iruplinalkib (WX-0593) shows favorable safety and promising antitumor activity in advanced NSCLC with ALK or ROS1 rearrangement.
  • HY-101291
    Iberdomide

    CC-220

    		 Ligands for E3 Ligase Apoptosis Inflammation/Immunology Cancer
    Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC50 of ~150 nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities.
  • HY-100506
    GLPG0187

    		Integrin Cancer
    GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits αvβ1-integrin with an IC50 of 1.3 nM. GLPG0187 inhibits migrasome biogenesis without cytotoxicity.
  • HY-146397
    TD-802

    		PROTACs Androgen Receptor Cancer
    TD-802 (Compound 33c) is an androgen receptor (AR) PROTAC degrader with good microsomal stability. TD-802 has good antitumor efficacy in vivo and can be used for metastatic castration-resistant prostate cancer research.
  • HY-B0431AS
    Phenoxybenzamine-d5 hydrochloride

    		Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Phenoxybenzamine-d5 hydrochloride is the deuterium labeled Phenoxybenzamine hydrochloride. Phenoxybenzamine hydrochloride is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine hydrochloride also shows antitumor activity.
  • HY-15337
    Hesperidin

    Hesperetin 7-rutinoside

    		 Apoptosis Autophagy Reactive Oxygen Species Endogenous Metabolite Cancer
    Hesperidin (Hesperetin 7-rutinoside), a flavanone glycoside, is isolated from citrus fruits. Hesperidin has numerous biological properties, such as decreasing inflammatory mediators and exerting significant antioxidant effects. Hesperidin also exhibits antitumor and antiallergic activities.
  • HY-W011102
    S-Trityl-L-cysteine

    NSC 83265; S-Tritylcysteine; 3-Tritylthio-L-alanine

    		 Kinesin Apoptosis Cancer
    S-Trityl-L-cysteine (NSC 83265) is a selective and allosteric kinesin Eg5 inhibitor with an IC50 of 1 μM for the inhibition of basal ATPase activity and 140 nM for the microtubule-activated ATPase activity. S-Trityl-L-cysteine has antitumor activities.
  • HY-128758
    DYRKs-IN-1

    		DYRK Cancer
    DYRKs-IN-1 is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC50s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 has antitumor activity.
  • HY-119339
    SX-682

    		CXCR Cancer Inflammation/Immunology Endocrinology
    SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity.
  • HY-128758A
    DYRKs-IN-1 hydrochloride

    		DYRK Cancer
    DYRKs-IN-1 hydrochloride is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC50s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity.
  • HY-109019
    Vorolanib

    CM082; X-82

    		 VEGFR PDGFR Cancer Cardiovascular Disease
    Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895).
  • HY-17422B
    Acyclovir monophosphate

    		HSV Antibiotic Cancer Infection
    Acyclovir monophosphate is a potent anti-herpes simplex virus (HSV) agent. Acyclovir monophosphate blocks DNA synthesis through the inhibition of the viral DNA polymerase and terminates the chain elongation of the viral DNA. Acyclovir monophosphate shows antitumor activity.
  • HY-75161
    (-)-Menthol

    		TRP Channel Endogenous Metabolite Cancer
    (-)-Menthol is a key component of peppermint oil that binds and activates transient receptor potential melastatin 8 (TRPM8), a Ca 2+-permeable nonselective cation channel, to increase [Ca 2+]i. Antitumor activity.
  • HY-10080
    Teglarinad chloride

    GMX1777; EB-1627

    		 NAMPT Cancer
    Teglarinad chloride (GMX1777) is a prodrug of GMX1778 (a nicotinamide phosphoribosyl transferase inhibitor). Teglarinad chloride exhibits antitumor activity in mice can be attributed to inhibition of NAMPT. Teglarinad chloride also enhances radiation efficacy, mediated by interference with DNA repair and antiangiogenesis.
  • HY-13598A
    Valecobulin hydrochloride

    CKD-516 hydrochloride

    		 Microtubule/Tubulin Cancer
    Valecobulin hydrochloride (CKD-516 hydrochloride) is a valine prodrug of S516 (HY-130233) and a vascular disrupting agent (VDA). Valecobulin hydrochloride is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors.
  • HY-16106
    Talazoparib

    BMN-673; LT-673

    		 PARP Cancer
    Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity.
  • HY-111554
    AcLys-PABC-VC-Aur0101

    		Microtubule/Tubulin Drug-Linker Conjugates for ADC Cancer
    AcLys-PABC-VC-Aur0101 is a drug-linker conjugate for ADC (anti-CXCR4 ADC) with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the cleavable linker AcLys-PABC-VC.
  • HY-17503BS
    Metoprolol-d6 tartrate

    		Adrenergic Receptor Cancer Infection Endocrinology Cardiovascular Disease
    Metoprolol-d6 tartrate is the deuterium labeled Metoprolol tartrate. Metoprolol is an orally active, selective β1-adrenoceptor antagonist. Metoprolol shows anti-inflammation, antitumor and anti-angiogenic properties.
  • HY-144805
    VEGFR-2-IN-18

    		VEGFR Apoptosis Cancer
    VEGFR-2-IN-18 (Compound 15d) is a potent VEGFR-2 inhibitor with an IC50 of 60 nM. VEGFR-2-IN-18 induces cell apoptosis. VEGFR-2-IN-18 shows antitumor activities.
  • HY-113041
    Prostaglandin A2

    PGA2; Medullin

    		 Endogenous Metabolite Apoptosis Cancer Infection
    Prostaglandin A2 (PGA2), a human endogenous metabolite of PGE2, is an antitumor agent. Prostaglandin A2 induces p53-dependent apoptosis. Prostaglandin A2 also has antiviral activity.
  • HY-115983
    DMUP

    		Apoptosis Cancer
    DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity.
  • HY-N0035
    Arctigenin

    (-)-Arctigenin

    		 MMP Influenza Virus Autophagy Apoptosis Cancer Infection Metabolic Disease Inflammation/Immunology Neurological Disease
    Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions.
  • HY-12803
    Fulvene-5

    		NADPH Oxidase Reactive Oxygen Species Cancer
    Fulvene-5 is a potent NADPH oxidase 4 (NOX4) inhibitor with antioxidant properties. Fulvene-5 is a reactive oxygen species (ROS) modifying agent and a potent radioprotector. Fulvene-5 has antitumor activity.
  • HY-N7698B
    Hexa-N-acetylchitohexaose

    		Others Cancer Inflammation/Immunology
    Hexa-N-acetylchitohexaose is an inducer of disease resistance in crop plants, which could elicit an increase of lignification-related and antioxidative enzymes in soybean plants. Hexa-N-acetylchitohexaose is a substrate of lysozyme. Hexa-N-acetylchitohexaose shows antitumor effect.
  • HY-N0488S2
    Vincristine-d6 sulfate

    Leurocristine-d6 sulfate; NSC-67574-d6 sulfate; 22-Oxovincaleukoblastine-d6 sulfate

    		 Microtubule/Tubulin Apoptosis Cancer
    Vincristine-d6 (Leurocristine-d6) sulfate is the deuterium labeled Vincristine sulfate. Vincristine sulfate is an antitumor vinca alkaloid which inhibits microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. It binds to microtubule with a Ki of 85 nM.
  • HY-W029411
    4-(Benzo[d]oxazol-2-yl)aniline

    		Others Cancer
    4-(Benzo[d]oxazol-2-yl)aniline is a potent antitumor agent. 4-(Benzo[d]oxazol-2-yl)aniline has inhibitory activity against mammary carcinoma cell lines.
  • HY-13563
    Batabulin

    T138067

    		 Microtubule/Tubulin Apoptosis Cancer
    Batabulin (T138067) is an antitumor agent, which binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Batabulin affects cell morphology and leads to cell-cycle arrest ultimately induces apoptotic cell death.
  • HY-N7504
    Isopsoralenoside

    		Bacterial Cancer Infection Metabolic Disease
    Isopsoralenoside is a benzofuran glycoside from Psoralea corylifolia. Isopsoralenoside can be quickly metabolized to Psoralen (HY-N0053) in digestive tract contents. Isopsoralenoside show estrogen-like activity, osteoblastic proliferation accelerating activity, antitumor effects and antibacterial activity.
  • HY-136270
    Gartisertib

    VX-803; M4344; ATR inhibitor 2

    		 ATM/ATR Cancer
    Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a Ki of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC50 of 8 nM. Antitumor activity.
  • HY-148391
    23-Oxa-OSW-1

    SBF-1

    		 DNA/RNA Synthesis Cancer
    23-Oxa-OSW-1 (SBF-1), a derivative of OSW 1 (HY-101213), is a potent osterol-binding protein (OSBP) inhibitor. 23-Oxa-OSW-1 has antitumor activity.
  • HY-129441
    Metoprine

    BW 197U

    		 Histone Methyltransferase Antifolate Cancer Neurological Disease
    Metoprine (BW 197U) is a potent histamine N-methyltransferase (HMT) inhibitor. Metoprine, a diaminopyrimidine derivative, can cross the blood-brain barrier and increase brain histamine levels by inhibiting HMT. Metoprine is an antifolate and antitumor agent.
  • HY-16399
    Pladienolide B

    		Apoptosis Cancer
    Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. Pladienolide B exerts antitumor activities mediated through the inhibition of pre-mRNA splicing. Pladienolide B induces apoptosis.
  • HY-112786
    MC-Val-Cit-PAB-MMAF

    Vc-MMAF

    		 Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF, linked via cathepsin cleavable MC-Val-Cit-PAB. MC-Val-Cit-PAB-MMAF shows antitumor activity.
  • HY-N1934
    Dihydroberberine

    		Potassium Channel HSP Cancer Inflammation/Immunology Cardiovascular Disease
    Dihydroberberine inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces heat shock protein 90 (Hsp90) expression and its interaction with hERG. Dihydroberberine has anti-inflammatory, anti-atherosclerotic, hypolipidemic and antitumor activities.
  • HY-100507
    Avadomide

    CC 122

    		 E1/E2/E3 Enzyme Apoptosis Cancer Inflammation/Immunology
    Avadomide (CC 122) is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity and induces apoptosis of diffuse large B-cell lymphoma (DLBCL) cell lines. Avadomide exhibits potent antitumor and immunomodulatory activities.
  • HY-146406
    Anticancer agent 52

    		Apoptosis Cancer
    Anticancer agent 52 is a potent anticancer agent. Anticancer agent 52 shows in vitro cytotoxicity. Anticancer agent 52 induces apoptosis. Anticancer agent 52 shows antitumor effect. Anticancer agent 52 has the potential for the research of bladder cancer.
  • HY-13563A
    Batabulin sodium

    T138067 sodium

    		 Microtubule/Tubulin Apoptosis Cancer
    Batabulin sodium (T138067 sodium) is an antitumor agent, which binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Batabulin sodium affects cell morphology and leads to cell-cycle arrest ultimately induces apoptotic cell death.
  • HY-108697
    PT2399

    		HIF/HIF Prolyl-Hydroxylase Cancer
    PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo.
  • HY-149016
    Tubulin polymerization-IN-25

    		Microtubule/Tubulin Farnesyl Transferase Cancer
    Tubulin polymerization-IN-25 (compound 17f) is a dual inhibitor of tubulin polymerization and farnesyl transferase (FTase) with IC50s of 1.11 μM and 0.39 μM, respectively. Tubulin polymerization-IN-25 displays cytotoxicity and excellent antitumor activity .
  • HY-13736A
    Quinagolide hydrochloride

    CV205-502 hydrochloride

    		 Dopamine Receptor Akt Cancer Neurological Disease
    Quinagolide hydrochloride (CV205-502 hydrochloride) is a selective and orally active dopamine D2 receptor agonist. Quinagolide hydrochloride is an inhibitor of prolactin. Quinagolide hydrochloride down-regulates AKT levels and its phosphorylation. Quinagolide hydrochloride shows antitumor effects, it can be used for the research of cancer.
  • HY-133117
    BAY-985

    		IKK Cancer
    BAY-985 is a highly potent, orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 (low/high ATP) and IKKε, respectively. Antitumor efficacy.
  • HY-131345
    PI3Kα-IN-4

    		PI3K Cancer
    PI3Kα-IN-4 is a potent, selective and orally active inhibitor of PI3Kα, with an IC50 of 1.8 nM. PI3Kα-IN-4 has antitumor activity.
  • HY-16261
    Aldoxorubicin

    INNO-206; DOXO-EMCH

    		 Topoisomerase ADC Cytotoxin Cancer
    Aldoxorubicin (INNO-206) is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
  • HY-146438
    PPARγ agonist 3

    		PPAR Cancer
    PPARγ agonist 3 (Compound 18a) is a potent and selective agonist of PPARγ. PPARγ agonist 3 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 3 exerts antitumor potency only in combination with Imatinib.
  • HY-B0180
    Imiquimod

    R 837

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Cancer Infection Inflammation/Immunology
    Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
  • HY-151592
    Anticancer agent 91

    		Others Cancer
    Anticancer agent 91 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor and antiviral activity. Anticancer agent 91 has high inhibition against the two cell line from CNS cancer (SF-539 and SNB-75).
  • HY-126534A
    Abemaciclib metabolite M18 hydrochloride

    LSN3106729 hydrochloride

    		 Ligands for Target Protein for PROTAC CDK Cancer
    Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.
  • HY-B0180A
    Imiquimod hydrochloride

    R 837 hydrochloride

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Cancer Infection Inflammation/Immunology
    Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo. Imiquimod hydrochloride can be used for the research of external genital, perianal warts, cancer and COVID-19.
  • HY-101030
    MBM-17

    		Apoptosis Cancer
    MBM-17 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 3 nM. It effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice.
  • HY-150752
    BTK-IN-15

    		Btk Pyroptosis Cancer
    BTK-IN-15 is a potent Bruton's tyrosine kinase (BTK) inhibitor with high oral absorption. BTK-IN-15 inhibits BTK with an IC50 value of 0.7 nM. BTK-IN-15 displays excellent kinase selectivity, antitumor activity, and induces apoptosis.
  • HY-N10188
    Nidurufin

    		Others Cancer
    Nidurufin is a potent cell cycle inhibitor with antitumor activity.Nidurufin induces in vitro cell cycle arrest at G2/M transition in the K562 cell line in a concentration and time dependent manner(IC50=12.6 μM).
  • HY-N6641
    Monascin

    		Others Cancer Inflammation/Immunology
    Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice). Monascin also exhibits anti-tumor-initiating activity and anti-inflammatory activity with oral administration. Monascin inhibits the activation of NOR 1 (an NO donor).
  • HY-110120
    DSR-6434

    		Toll-like Receptor (TLR) Cancer
    DSR-6434 is a potent and selective Toll-like receptor 7 (TLR7) agonist, with EC50s of 7.2 nM and 4.6 nM for human and mice TLR7, respectively. DSR-6434 has a strong antitumor effect.
  • HY-111388
    SEL120-34A

    		CDK Cancer
    SEL120-34A is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
  • HY-123979A
    ζ-Stat trisodium

    NSC37044 trisodium

    		 PKC Apoptosis Cancer
    ζ-Stat trisodium (NSC37044 trisodium) is a specific and atypical PKC-ζ inhibitor, with an IC50 of 5 μM. ζ-Stat trisodium can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro.
  • HY-B0180B
    Imiquimod maleate

    R 837 maleate

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Cancer Infection Inflammation/Immunology
    Imiquimod maleate (R 837 maleate), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod maleate exhibits antiviral and antitumor effects in vivo. Imiquimod maleate can be used for the research of external genital, perianal warts, cancer and COVID-19.
  • HY-12743A
    K-7174 dihydrochloride

    		Proteasome Apoptosis Cancer Inflammation/Immunology
    K-7174 dihydrochloride is an orally active proteasome and GATA inhibitor. K-7174 dihydrochloride is a cell adhesion inhibitor. K-7174 dihydrochloride induces cell apoptosis. K-7174 dihydrochloride shows antitumor activities, it can be used for the research of cancer.
  • HY-126534
    Abemaciclib metabolite M18

    LSN3106729

    		 Ligands for Target Protein for PROTAC CDK Cancer
    Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.
  • HY-142772
    Y08284

    		Epigenetic Reader Domain Cancer
    Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity.
  • HY-111388B
    SEL120-34A HCl

    		CDK Cancer
    SEL120-34A HCl is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
  • HY-12743
    K-7174

    		Proteasome Apoptosis Cancer Inflammation/Immunology
    K-7174 is an orally active proteasome and GATA inhibitor. K-7174 is a cell adhesion inhibitor. K-7174 induces cell apoptosis. K-7174 shows antitumor activities, it can be used for the research of cancer.
  • HY-12678
    Entrectinib

    NMS-E628; RXDX-101

    		 ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy Cancer
    Entrectinib (NMS-E628) is a potent, orally available, and CNS-active pan-Trk, ROS1, and ALK inhibitor. Entrectinib inhibits TrkA, TrkB, TrkC, ROS1 and ALK with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Antitumor activity.
  • HY-147656
    NAMPT degrader-1

    		NAMPT Autophagy Cancer
    NAMPT degrader-1 (Compound A3) is an nicotinamide phosphoribosyltransferase (NAMPT) degrader with an IC50 of 0.023 μM. NAMPT degrader-1 significantly induces the degradation of NAMPT through the autophagy-lysosomal pathway and shows excellent cellular antitumor potency.
  • HY-119182
    Mitonafide

    NSC 300288

    		 DNA/RNA Synthesis Cancer
    Mitonafide (NSC 300288) is a cytostatic agent. Mitonafide binds to double-stranded DNA through intercalation, and inhibits DNA and RNA synthesis. Mitonafide is an antitumor agent that can be used in the research of cancers, such as non-small cell lung cancer (NSCLC), leukemia.
  • HY-106364
    Peplomycin

    Bleomycin PEP; Pepleomycin

    		 Antibiotic Cancer
    Peplomycin (Bleomycin PEP; Pepleomycin) is an antibiotic analogue of Bleomycin (HY-108345), with high antitumor effect and less pulmonary toxicity. Peplomycin induce apoptosis in oral squamous carcinoma cell line SSCKN cells and pulmonary fibrosis in rats.
  • HY-134673A
    UZH1a

    		Apoptosis Cancer
    UZH1a is a potent and selective METTL3 inhibitor, with an IC50 of 280 nM. UZH1a can be used for epitranscriptomic modulation of cellular processes. UZH1a has antitumor activity. UZH1a also can be used as a chemical probe for studying METTL3.
  • HY-19829
    Sandramycin

    		ADC Cytotoxin Bacterial Antibiotic Cancer Infection
    Sandramycin ia a cyclic depsipeptide antibiotic isolated from cultured broth of a Nocardioides sp. Sandramycin is also a DNA intercalator that potently binds DNA and is an ADC cytotoxin. Sandramycin is active against Gram-positive bacteria and has potent antitumor activity.
  • HY-146439
    PPARγ agonist 4

    		PPAR Cancer
    PPARγ agonist 4 (Compound 18b) is a potent and selective agonist of PPARγ. PPARγ agonist 4 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 4 exerts antitumor potency only in combination with Imatinib.
  • HY-151588
    Anticancer agent 90

    		Virus Protease Cancer
    Anticancer agent 90 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor activity. Anticancer agent 90 has high inhibition against the two cell line from ovarian cancer (OVCAR-4), renal cancer (A498).
  • HY-N2306A
    Aclacinomycin A hydrochloride

    Aclarubicin hydrochloride

    		 Topoisomerase DNA/RNA Synthesis Proteasome Antibiotic Cancer
    Aclacinomycin A (Aclarubicin) hydrochloride is an orally active and potent anthracycline antitumor antibiotic. Aclacinomycin A hydrochloride is an inhibitor of topoisomerase I and II. Aclacinomycin A hydrochloride inhibits synthesis of nucleic acid, especially RNA. Aclacinomycin A hydrochloride might inhibit the 26S protease complex as well as the ubiquitin-ATP-dependent proteolysis.
  • HY-129393
    AB928

    		Adenosine Receptor Inflammation/Immunology
    AB928 is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist. AB928 relieves adenosine-mediated immune suppression. AB928 has immunomodulatory and antitumor activities.
  • HY-19356A
    Didesmethylrocaglamide

    		Eukaryotic Initiation Factor (eIF) Apoptosis Cancer
    Didesmethylrocaglamide, a derivative of Rocaglamide, is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. Didesmethylrocaglamide has potent growth-inhibitory activity with an IC50 of 5 nM. Didesmethylrocaglamide suppresses multiple growth-promoting signaling pathways and induces apoptosis in tumor cells. Antitumor activity.
  • HY-120356A
    T-1101 tosylate

    TAI-95 tosylate

    		 Apoptosis Cancer
    T-1101 tosylate (TAI-95 tosylate) is a Hec1/Nek2 (Highly expressed in cancer 1 / NIMA-related kinase 2) inhibitor with antitumor activity. T-1101 tosylate is inactive toward normal cells, kinases and hERG
  • HY-107367
    Epertinib

    S-22611

    		 EGFR Cancer
    Epertinib (S-22611) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib shows potent antitumor activity.
  • HY-103266
    TC-A 2317 hydrochloride

    		Aurora Kinase Cancer
    TC-A 2317 hydrochloride is an orally active Aurora A kinase inhibitor (Ki=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora B kinase (Ki=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity.
  • HY-17493
    MI-773

    		MDM-2/p53 E1/E2/E3 Enzyme Cancer
    MI-773 is a potent MDM2-p53 protein‐protein interaction (PPI) inhibitor with high binding affinity against MDM2 (Kd=8.2 nM). MI-773 has antitumor activity.
  • HY-114334
    Glutaminase-IN-1

    CB839 derivative

    		 Glutaminase Cancer
    Glutaminase-IN-1 (CB839 derivative), a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (KGA), with an IC50 of 1 nM. Glutaminase-IN-1 (CB839 derivative) shows improved cellular uptake and antitumor activity.
  • HY-147710
    PIN1 inhibitor 2

    		MicroRNA Cancer
    PIN1 inhibitor 2 (compound 12) is a potent PIN1 inhibitor. PIN1 inhibitor 2 shows antitumor activity with an IC50 of 9.55 µM for MCF7 cells. PIN1 inhibitor 2 has the potential for the research of breast cancer.
  • HY-10446
    Pralatrexate

    		Antifolate Apoptosis Cancer
    Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a Ki of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment.
  • HY-N0835
    (20S)-Protopanaxatriol

    20(S)-APPT; g-PPT

    		 Glucocorticoid Receptor Estrogen Receptor/ERR LXR Apoptosis Endocrinology Cardiovascular Disease
    (20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and oestrogen receptor (ER), and is also a LXRα inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects.
  • HY-N0158
    Oxymatrine

    		TGF-beta/Smad Apoptosis Cancer Infection Inflammation/Immunology
    Oxymatrine, an alkaloid from Sophora flavescens Alt. with anti-inflammatory, antifibrosis, and antitumor effects, inhibits the iNOS expression and TGF-β/Smad pathway. Oxymatrine inhibits bocavirus minute virus of canines (MVC) replication, reduces viral gene expression and decreases apoptosis induced by viral infection.
  • HY-A0210
    Cerulenin

    		Fatty Acid Synthase (FASN) Fungal Apoptosis Antibiotic Infection Metabolic Disease
    Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies.
  • HY-N2306
    Aclacinomycin A

    Aclarubicin

    		 Topoisomerase DNA/RNA Synthesis Proteasome Antibiotic Cancer
    Aclacinomycin A (Aclarubicin) is an orally active and potent anthracycline antitumor antibiotic. Aclacinomycin A is an inhibitor of topoisomerase I and II. Aclacinomycin A inhibits synthesis of nucleic acid, especially RNA. Aclacinomycin A might inhibit the 26S protease complex as well as the ubiquitin-ATP-dependent proteolysis.
  • HY-135299
    CH6953755

    		Src Cancer
    CH6953755 is a potent, orally active and selective YES1 kinase (a member of the SRC family) inhibitor with an IC50 of 1.8 nM. CH6953755 inhibits YES1 kinase, leading to antitumor activity against YES1 Gene -amplified cancers in vitro and in vivo.
  • HY-107367A
    Epertinib hydrochloride

    S-22611 hydrochloride

    		 EGFR Cancer
    Epertinib (S-22611) hydrochloride is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib hydrochloride shows potent antitumor activity.
  • HY-10008
    SNS-032

    BMS-387032

    		 CDK Apoptosis Cancer
    SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK2, CDK7, and CDK9 with IC50s of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect.
  • HY-111388A
    SEL120-34A monohydrochloride

    		CDK Cancer
    SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kd of 3 nM for CDK8. SEL120-34A monohydrochloride weakly inhibits CDK9 (calculated IC50=1070 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7. SEL120-34A monohydrochloride inhibits phosphorylation of STAT1 S727 and STAT5 S726. Has anti-tumor activity.
  • HY-11080A
    PKI-179 hydrochloride

    		PI3K mTOR Cancer
    PKI-179 hydrochloride is a potent and orally active dual PI3K/mTOR inhibitor, with IC50s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 hydrochloride also exhibits activity over E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 hydrochloride shows anti-tumor activity in vivo.
  • HY-11080
    PKI-179

    		PI3K mTOR Cancer
    PKI-179 is a potent and orally active dual PI3K/mTOR inhibitor, with IC50s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 also exhibits activity over E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo.
  • HY-138294
    RAS/RAS-RAF-IN-1

    		Ras Raf Cancer
    RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity.
  • HY-146574
    AKR1C3-IN-7

    		Others Cancer
    AKR1C3-IN-7 (Compound 13) is a potent, selective AKR1C3 inhibitor with an IC50 of 0.19 μM. AKR1C3-IN-7 shows antitumor activity.
  • HY-133980
    O-Demethyl Lenvatinib

    		Drug Metabolite Cancer
    O-Demethyl Lenvatinib is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
  • HY-13680
    Meisoindigo

    Dian III; N-Methylisoindigotin; Natura-α

    		 Apoptosis Cancer
    Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity.
  • HY-139642
    Mal-(CH2)5-Val-Cit-PAB-Eribulin

    		Drug-Linker Conjugates for ADC Cancer
    Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB.
  • HY-145762
    YM281

    		Apoptosis Histone Methyltransferase Cancer
    YM281 is a potent EZH2 inhibitor. YM281 induces cell apoptosis and cell cycle arrest at the G0/G1 phase. YM281 shows antitumor effects in vivo. YM281 has the potential for the research of lymphoma.
  • HY-103682A
    PF-06726304 acetate

    		Histone Methyltransferase Cancer
    PF-06726304 acetate is a potent and selective EZH2 inhibitor. PF-06726304 acetate inhibits wild-type and Y641N mutant EZH2 with Kis of 0.7 and 3.0 nM, respectively. PF-06726304 acetate displays robust antitumor growth activity.
  • HY-18619
    YL-109

    		Aryl Hydrocarbon Receptor Cancer
    YL-109 is an antitumor agent that can induce carboxyl terminus of Hsp70-interacting protein (CHIP) expression through aryl hydrocarbon receptor (AhR) signaling. YL-109 has ability to inhibit breast cancer cell growth and invasiveness.
  • HY-146575
    AKR1C3-IN-8

    		Others Cancer
    AKR1C3-IN-8 (Compound 5) is a potent, selective AKR1C3 inhibitor with an IC50 of 0.069 μM. AKR1C3-IN-8 shows antitumor activity.
  • HY-114311
    FGFR1/DDR2 inhibitor 1

    		FGFR Discoidin Domain Receptor Cancer
    FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM and 3.2 nM, respectively. Antitumor activity.
  • HY-12457
    Rachelmycin

    CC-1065; NSC 298223

    		 Antibiotic Cancer Infection
    Rachelmycin (CC-1065; NSC 298223) is a potent naturally antibiotic isolated from Streptomyces zelensis. Rachelmycin binds non-covalently and covalently (N-3 adenine adduct) in the minor groove of B-form DNA. Rachelmycin has exceptionally potent antitumor activity.
  • HY-14833
    Atiratecan

    TP300

    		 Topoisomerase Cancer
    Atiratecan (TP300) is a prodrug of camptothecin analog CH0793076 (HY-107096). Atiratecan does not inhibit acetylcholinesterase (AChE) activities. Atiratecan shows antitumor activity against both breast cancer resistance protein (BCRP)-positive and -negative xenografts in mouse xenograft models.
  • HY-U00279
    Nitracrine

    		DNA/RNA Synthesis Cancer
    Nitracrine inhibits RNA synthesis and covalently, reversibly binds to DNA but also forms covalent adducts with DNA in vivo. Nitracrine, a 1-nitroacridine derivative, is a potent hypoxia-selective agent in vitro and antitumor drug. Nitracrine has cytotoxicity towards most cells.
  • HY-125827
    13-Methylberberine chloride

    13-Methylberberinium chloride

    		 Interleukin Related Cancer Metabolic Disease
    13-Methylberberine chloride (13-Methylberberinium chloride), a berberine analogue, has anti-adipogenic and antitumor activities. 13-Methylberberine chloride (13-Methylberberinium chloride) increases production of IL-12 and inhibits the expression of iNOS at posttranscriptional level in macrophages activated with LPS.
  • HY-103682
    PF-06726304

    		Histone Methyltransferase Cancer
    PF-06726304 is a potent and selective EZH2 inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 with Kis of 0.7 and 3.0 nM, respectively. PF-06726304 displays robust antitumor growth activity.
  • HY-144656
    Steroid sulfatase-IN-1